US20050238538A1 - Analyte detection system with software download capabilities - Google Patents

Analyte detection system with software download capabilities Download PDF

Info

Publication number
US20050238538A1
US20050238538A1 US11/106,352 US10635205A US2005238538A1 US 20050238538 A1 US20050238538 A1 US 20050238538A1 US 10635205 A US10635205 A US 10635205A US 2005238538 A1 US2005238538 A1 US 2005238538A1
Authority
US
United States
Prior art keywords
detection system
analyte
analyte detection
sample
software
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/106,352
Inventor
James Braig
Gary Hewett
Michael Munrow
Julian Cortella
Kamrava Azizi
Daniel Goldberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/106,352 priority Critical patent/US20050238538A1/en
Publication of US20050238538A1 publication Critical patent/US20050238538A1/en
Assigned to HERCULES TECHNOLOGY II, L.P. reassignment HERCULES TECHNOLOGY II, L.P. SECURITY AGREEMENT Assignors: OPTISCAN BIOMEDICAL CORPORATION
Assigned to OPTISCAN BIOMEDICAL CORPORATION reassignment OPTISCAN BIOMEDICAL CORPORATION RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: HERCULES TECHNOLOGY II, L.P.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1495Calibrating or testing of in-vivo probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/40ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2560/00Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
    • A61B2560/02Operational features
    • A61B2560/0266Operational features for monitoring or limiting apparatus function
    • A61B2560/0271Operational features for monitoring or limiting apparatus function using a remote monitoring unit
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02Details of sensors specially adapted for in-vivo measurements
    • A61B2562/0295Strip shaped analyte sensors for apparatus classified in A61B5/145 or A61B5/157
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S707/00Data processing: database and file management or data structures
    • Y10S707/99941Database schema or data structure
    • Y10S707/99944Object-oriented database structure
    • Y10S707/99945Object-oriented database structure processing

Definitions

  • This invention pertains, in certain embodiments, to medical equipment for measuring blood analyte levels, and more particularly to a blood analyte measuring instrument having internet-based communication features.
  • a patient having been taught how to use an existing portable analyte monitor is generally required thereafter to independently conduct and record his or her own measurements. Furthermore, the patient typically is required to both record and assess the measurements without benefit from a practitioner or supervising authority. Numerous errors can arise from these unsupervised procedures that may result in serious health risks for patients which knowingly, or inadvertently, are not in compliance with medical directives.
  • patients using an analyte monitor are given a schedule of measurements they are required to take and a notebook in which to record the measurements. Patients often forget, or in some instances forego, conducting and correctly recording their analyte levels as measured by the instrument. If patients skip a measurement they may even elect to write down a “likely” number in the notebook as if such a measurement had been taken. Patient interaction with such a manual analyte monitoring instrument therefore provides no assurance of correct measurement and recordation. Furthermore, patients in a myriad of situations may require additional information and assistance with regard to the use and maintenance of their analyte measurement instrument.
  • a measuring instrument may require periodic calibration or software updates. Assuring calibration compliance on instruments or updating the instrument's software in the field is burdensome.
  • an analyte monitoring system that encourages patient compliance and facilitates equipment calibration and software updates.
  • the present invention in certain embodiments, satisfies those needs, as well as others, and overcomes deficiencies in current monitoring systems and procedures.
  • the present invention is an analyte measuring device with remote communications capabilities.
  • a data link is provided between the equipment and a centralized station, or server.
  • the centralized station can monitor important information, such as: equipment calibration, the diligence of a patient taking and recording measurements according to a schedule, whether a software update is needed and the actual measurements taken by the patient.
  • the centralized station is preferably capable of forwarding information to the patient's physician for evaluation.
  • the centralized station can have optional capability of locking out the patient if the patient has not paid his or her bills.
  • the information is communicated from the analyte measuring device directly to the physician.
  • the centralized station can determine an update status of the analyte measuring device's software and automatically send a software update to the analyte measuring device.
  • the preferred embodiments link the monitoring activities performed by the patient and the assessment of those activities by the physician while reducing the chance of human error introduced into the long-term monitoring and treatment process.
  • a non-invasive subsurface spectrophotometer instrument equipped with a communications link takes the analyte measurements and communicates them over a network, such as the internet.
  • the spectrophotometer instrument comprises data communication circuitry, such as dial-up circuitry, and additional session control protocols which integrate a number of the functions within the instrument for communication over a network connection.
  • a destination site, or sites, on the network are configured to receive information from the instrument and to transmit information and services.
  • an analyte concentration monitoring system comprises an analyte detection system having a processor that calculates analyte concentration in accordance with software executable by the processor.
  • the monitoring system further comprises a network interface that is configured to provide connectivity to a computer.
  • the analyte detection system is configured to receive an update to the software from the computer.
  • a method of automatically updating software on an analyte detection system comprises connecting an analyte detection system to a computer via a network, and checking, in the computer, an update status of software included in the analyte detection system. The method further comprises sending, when the update status indicates that a software update is needed, the software update to the analyte detection system via the network without intervention from a user. The method further comprises updating, in the analyte detection system, the software with the software update.
  • an analyte concentration monitoring system comprises an analyte detection system comprising a processor, a software, and a network interface.
  • the processor is configured to calculate analyte concentration in accordance to the software
  • the network interface is configured to provide connectivity to a computer.
  • the analyte detection system is configured to update the software according to instructions from the computer.
  • a method of automatically updating software on an analyte detection system comprises connecting an analyte detection system to a computer via a network.
  • the method further comprises checking, in the computer, an update status of software included in the analyte detection system.
  • the method further comprises encrypting, when the update status indicates that a software update is needed, the software update and sending the software update to the analyte detection system via the network.
  • the method further comprises updating, in the analyte detection system, the software with the software update.
  • FIG. 1 is a schematic view of a noninvasive optical detection system.
  • FIG. 2 is a perspective view of a window assembly for use with the noninvasive detection system.
  • FIG. 2A is a plan view of another embodiment of a window assembly for use with the noninvasive detection system.
  • FIG. 3 is an exploded schematic view of another embodiment of a window assembly for use with the noninvasive detection system.
  • FIG. 4 is a plan view of the window assembly connected to a cooling system.
  • FIG. 5 is a plan view of the window assembly connected to a cold reservoir.
  • FIG. 6 is a cutaway view of a heat sink for use with the noninvasive detection system.
  • FIG. 6A is a cutaway perspective view of a lower portion of the noninvasive detection system of FIG. 1 .
  • FIG. 6B is an exploded perspective view of a window mounting system for use with the noninvasive optical detection system.
  • FIG. 6C is a partial plan view of the window mounting system of FIG. 6B .
  • FIG. 6D is a sectional view of the window mounting system of FIG. 6C .
  • FIG. 7 is a schematic view of a control system for use with the noninvasive optical detection system.
  • FIG. 8 depicts a first methodology for determining the concentration of an analyte of interest.
  • FIG. 9 depicts a second methodology for determining the concentration of an analyte of interest.
  • FIG. 10 depicts a third methodology for determining the concentration of an analyte of interest.
  • FIG. 11 depicts a fourth methodology for determining the concentration of an analyte of interest.
  • FIG. 12 depicts a fifth methodology for determining the concentration of an analyte of interest.
  • FIG. 13 is a schematic view of a reagentless whole-blood detection system.
  • FIG. 14 is a perspective view of one embodiment of a cuvette for use with the reagentless whole-blood detection system.
  • FIG. 15 is a plan view of another embodiment of a cuvette for use with the reagentless whole-blood detection system.
  • FIG. 16 is a disassembled plan view of the cuvette shown in FIG. 15 .
  • FIG. 16A is an exploded perspective view of the cuvette of FIG. 15 .
  • FIG. 17 is a side view of the cuvette of FIG. 15 .
  • FIG. 18 is a functional block diagram showing an analyte monitoring system with network connectivity.
  • FIG. 19 is a block diagram of the electronic circuits within the analyte monitoring system of FIG. 18 .
  • FIG. 20 is a flowchart exemplifying calibration lockout according to one embodiment disclosed herein.
  • FIG. 21 is a block diagram of components of an analyte monitoring system having software update capabilities.
  • FIG. 22 is a flowchart exemplifying updating a analyte monitoring device's software according to another embodiment disclosed herein.
  • Part I contains a description of a number of analyte detection systems, including a noninvasive system and a whole-blood system, as well as associated methods of analyte detection.
  • Parts II and III includes a discussion of further systems and methods for, inter alia, updating software executed by analyte detection systems such as (but not limited to) those described in Part I. Accordingly, the systems and methods described in Parts II and III may (but need not) be employed by, within and/or in connection with those described in Part I.
  • analyte detection systems including a noninvasive system discussed largely in part A below and a whole-blood system discussed largely in part B below.
  • various methods including methods for detecting the concentration of an analyte in a material sample.
  • Both the noninvasive system/method and the whole-blood system/method can employ optical measurement.
  • optical is a broad term and is used in its ordinary sense and refers, without limitation, to identification of the presence or concentration of an analyte in a material sample without requiring a chemical reaction to take place.
  • the two approaches each can operate independently to perform an optical analysis of a material sample.
  • the two approaches can also be combined in an apparatus, or the two approaches can be used together to perform different steps of a method.
  • the two approaches are combined to perform calibration of an apparatus, e.g., of an apparatus that employs a noninvasive approach.
  • an advantageous combination of the two approaches performs an invasive measurement to achieve greater accuracy and a whole-blood measurement to minimize discomfort to the patient.
  • the whole-blood technique may be more accurate than the noninvasive technique at certain times of the day, e.g., at certain times after a meal has been consumed, or after a drug has been administered.
  • any of the disclosed devices may be operated in accordance with any suitable detection methodology, and that any disclosed method may be employed in the operation of any suitable device.
  • the disclosed devices and methods are applicable in a wide variety of situations or modes of operation, including but not limited to invasive, noninvasive, intermittent or continuous measurement, subcutaneous implantation, wearable detection systems, or any combination thereof.
  • FIG. 1 depicts a noninvasive optical detection system (hereinafter “noninvasive system”) 10 in a presently preferred configuration.
  • the depicted noninvasive system 10 is particularly suited for noninvasively detecting the concentration of an analyte in a material sample S, by observing the infrared energy emitted by the sample, as will be discussed in further detail below.
  • noninvasive is a broad term and is used in its ordinary sense and refers, without limitation, to analyte detection devices and methods which have the capability to determine the concentration of an analyte in in-vivo tissue samples or bodily fluids. It should be understood, however, that the noninvasive system 10 disclosed herein is not limited to noninvasive use, as the noninvasive system 10 may be employed to analyze an in-vitro fluid or tissue sample which has been obtained invasively or noninvasively.
  • invasive or, alternatively, “traditional” is a broad term and is used in its ordinary sense and refers, without limitation, to analyte detection methods which involve the removal of fluid samples through the skin.
  • the term “material sample” is a broad term and is used in its ordinary sense and refers, without limitation, to any collection of material which is suitable for analysis by the noninvasive system 10 .
  • the material sample S may comprise a tissue sample, such as a human forearm, placed against the noninvasive system 10 .
  • the material sample S may also comprise a volume of a bodily fluid, such as whole blood, blood component(s), interstitial fluid or intercellular fluid obtained invasively, or saliva or urine obtained noninvasively, or any collection of organic or inorganic material.
  • analyte is a broad term and is used in its ordinary sense and refers, without limitation, to any chemical species the presence or concentration of which is sought in the material sample S by the noninvasive system 10 .
  • the analyte(s) which may be detected by the noninvasive system 10 include but not are limited to glucose, ethanol, insulin, water, carbon dioxide, blood oxygen, cholesterol, bilirubin, ketones, fatty acids, lipoproteins, albumin, urea, creatinine, white blood cells, red blood cells, hemoglobin, oxygenated hemoglobin, carboxyhemoglobin, organic molecules, inorganic molecules, pharmaceuticals, cytochrome, various proteins and chromophores, microcalcifications, electrolytes, sodium, potassium, chloride, bicarbonate, and hormones.
  • the term “continuous” is a broad term and is used in its ordinary sense and refers, without limitation, to the taking of discrete measurements more frequently than about once every 10 minutes, and/or the taking of a stream or series of measurements or other data over any suitable time interval, for example, over an interval of one to several seconds, minutes, hours, days, or longer.
  • the term “intermittent” is a broad term and is used in its ordinary sense and refers, without limitation, to the taking of measurements less frequently than about once every 10 minutes.
  • the noninvasive system 10 preferably comprises a window assembly 12 , although in some embodiments the window assembly 12 may be omitted.
  • One function of the window assembly 12 is to permit infrared energy E to enter the noninvasive system 10 from the sample S when it is placed against an upper surface 12 a of the window assembly 12 .
  • the window assembly 12 includes a heater layer (see discussion below) which is employed to heat the material sample S and stimulate emission of infrared energy therefrom.
  • a cooling system 14 preferably comprising a Peltier-type thermoelectric device, is in thermally conductive relation to the window assembly 12 so that the temperature of the window assembly 12 and the material sample S can be manipulated in accordance with a detection methodology discussed in greater detail below.
  • the cooling system 14 includes a cold surface 14 a which is in thermally conductive relation to a cold reservoir 16 and the window assembly 12 , and a hot surface 14 b which is in thermally conductive relation to a heat sink 18 .
  • the infrared energy E As the infrared energy E enters the noninvasive system 10 , it first passes through the window assembly 12 , then through an optical mixer 20 , and then through a collimator 22 .
  • the optical mixer 20 preferably comprises a light pipe having highly reflective inner surfaces which randomize the directionality of the infrared energy E as it passes therethrough and reflects against the mixer walls.
  • the collimator 22 also comprises a light pipe having highly-reflective inner walls, but the walls diverge as they extend away from the mixer 20 . The divergent walls cause the infrared energy E to tend to straighten as it advances toward the wider end of the collimator 22 , due to the angle of incidence of the infrared energy when reflecting against the collimator walls.
  • each filter 24 is preferably in optical communication with a concentrator 26 and an infrared detector 28 .
  • the concentrators 26 have highly reflective, converging inner walls which concentrate the infrared energy as it advances toward the detectors 28 , increasing the density of the energy incident upon the detectors 28 .
  • the detectors 28 are in electrical communication with a control system 30 which receives electrical signals from the detectors 28 and computes the concentration of the analyte in the sample S.
  • the control system 30 is also in electrical communication with the window 12 and cooling system 14 , so as to monitor the temperature of the window 12 and/or cooling system 14 and control the delivery of electrical power to the window 12 and cooling system 14 .
  • the window assembly 12 generally comprises a main layer 32 formed of a highly infrared-transmissive material and a heater layer 34 affixed to the underside of the main layer 32 .
  • the main layer 32 is preferably formed from diamond, most preferably from chemical-vapor-deposited (“CVD”) diamond, with a preferred thickness of about 0.25 millimeters.
  • CVD chemical-vapor-deposited
  • alternative materials which are highly infrared-transmissive, such as silicon or germanium, may be used in forming the main layer 32 .
  • the heater layer 34 preferably comprises bus bars 36 located at opposing ends of an array of heater elements 38 .
  • the bus bars 36 are in electrical communication with the elements 38 so that, upon connection of the bus bars 36 to a suitable electrical power source (not shown) a current may be passed through the elements 38 to generate heat in the window assembly 12 .
  • the heater layer 34 may also include one or more temperature sensors (not shown), such as thermistors or resistance temperature devices (RTDs), to measure the temperature of the window assembly 12 and provide temperature feedback to the control system 30 (see FIG. 1 ).
  • the heater layer 34 preferably comprises a first adhesion layer of gold or platinum (hereinafter, referred to as the “gold” layer) deposited over an alloy layer which is applied to the main layer 32 .
  • the alloy layer comprises a material suitable for implementation of the heater layer 34 , such as, by way of example, 10/90 titanium/tungsten, titanium/platinum, nickel/chromium, or other similar material.
  • the gold layer preferably has a thickness of about 4000 ⁇ , and the alloy layer preferably has a thickness ranging between about 300 ⁇ and about 500 ⁇ .
  • the gold layer and/or the alloy layer may be deposited onto the main layer 32 by chemical deposition including, but not necessarily limited to, vapor deposition, liquid deposition, plating, laminating, casting, sintering, or other forming or deposition methodologies well known to those or ordinary skill in the art.
  • the heater layer 34 may be covered with an electrically insulating coating which also enhances adhesion to the main layer 32 .
  • One preferred coating material is aluminum oxide.
  • Other acceptable materials include, but are not limited to, titanium dioxide or zinc selenide.
  • the heater layer 34 may incorporate a variable pitch distance between centerlines of adjacent heater elements 38 to maintain a constant power density, and promote a uniform temperature, across the entire layer 34 . Where a constant pitch distance is employed, the preferred distance is at least about 50-100 microns. Although the heater elements 38 generally have a preferred width of about 25 microns, their width may also be varied as needed for the same reasons stated above.
  • heater layer 34 Alternative structures suitable for use as the heater layer 34 include, but are not limited to, thermoelectric heaters, radiofrequency (RF) heaters, infrared radiation heaters, optical heaters, heat exchangers, electrical resistance heating grids, wire bridge heating grids, or laser heaters. Whichever type of heater layer is employed, it is preferred that the heater layer obscures about 10% or less of the window assembly 12 .
  • RF radiofrequency
  • the window assembly 12 comprises substantially only the main layer 32 and the heater layer 34 .
  • the window assembly 12 when installed in an optical detection system such as the noninvasive system 10 shown in FIG. 1 , the window assembly 12 will facilitate a minimally obstructed optical path between a (preferably flat) upper surface 12 a of the window assembly 12 and the infrared detectors 28 of the noninvasive system 10 .
  • the optical path 32 in the preferred noninvasive system 10 proceeds only through the main layer 32 and heater layer 34 of the window assembly 12 (including any antireflective, index-matching, electrical insulating or protective coatings applied thereto or placed therein), through the optical mixer 20 and collimator 22 and to the detectors 28 .
  • FIG. 2A shows another embodiment of the window assembly 12 , that may be used in place of the window assembly 12 depicted in FIG. 2 .
  • the window assembly 12 shown in FIG. 2A may be similar to that shown in FIG. 2 , except as described below.
  • the main layer 32 has a preferred thickness of up to about 0.012′′ and more preferably about 0.010′′ or less.
  • the heater layer 34 may also include one or more resistance temperature devices (RTD's) 55 to measure the temperature of the window assembly 12 and provide temperature feedback to a control system 30 .
  • the RTDs 55 terminate in RTD connection pads 57 .
  • the heater elements 38 are typically provided with a width of about 25 microns.
  • the pitch distance separating centerlines of adjacent heater elements 38 may be reduced, and/or the width of the heater elements 38 may be increased, in the regions of the window assembly 12 near the point(s) of contact with the thermal diffuser 410 (see FIGS. 6B-6D and discussion below).
  • This arrangement advantageously promotes an isothermal temperature profile at the upper surface of the main layer 32 despite thermal contact with the thermal diffuser.
  • the embodiment shown in FIG. 2A includes a plurality of heater elements 38 of substantially equal width which are variably spaced across the width of the main layer 32 .
  • the centerlines of the heater elements 38 are spaced at a first pitch distance of about 0.0070′′ at peripheral portions 34 a of the heater layer 34 , and at a second pitch distance of about 0.015′′ at a central portion 34 b of the main layer 32 .
  • the heater elements 38 closest to the center are preferably sufficiently spaced to allow the RTDs 55 to extend therebetween.
  • the main layer 32 includes peripheral regions 32 a which extend about 0.053′′ from the outermost heater element on each side of the heater layer 34 to the adjacent edge of the main layer 32 .
  • the bus bars 36 are preferably configured and segmented to allow space for the RTDs 55 and the RTD connection pads 57 , in intermediate gaps 36 a.
  • the RTDs 55 preferably extend into the array of heater elements 38 by distance that is slightly longer than half of the length of an individual heater element 38 .
  • the RTDs 55 may be located at the edges of the main layer 32 , or at other locations as desired for a particular noninvasive system.
  • the peripheral regions of the main layer 32 may include metallized edge portions 35 for facilitating connection to the diffuser 410 (discussed below in connection with FIGS. 6B-6D ).
  • the metallized edge portions 35 may be formed by the same or similar processes used in forming the heater elements 38 and RTDs 55 .
  • the edge portions 35 are typically between about 0.040′′ and about 0.060′′ wide by about 0.450′′ and about 0.650′′ long, and in one embodiment, they are about 0.050′′ by about 0.550′′. Other dimensions may be appropriately used so long as the window assembly 12 may be joined in thermal communication with the diffuser 410 as needed.
  • the main layer 32 is about 0.690′′ long by about 0.571′′ wide, and the heater layer (excluding the metallized edge portions 35 ) is about 0.640′′ long by about 0.465′′ wide.
  • the main layer 32 is about 0.010′′-0.012′′ thick, and is advantageously thinner than about 0.010′′ where possible.
  • Each heater element 38 is about 0.570′′ long, and each peripheral region 34 a is about 0.280′′ wide.
  • FIG. 3 depicts an exploded side view of an alternative configuration for the window assembly 12 , which may be used in place of the configuration shown in FIG. 2 .
  • the window assembly 12 depicted in FIG. 3 includes near its upper surface (the surface intended for contact with the sample S) a highly infrared-transmissive, thermally conductive spreader layer 42 . Underlying the spreader layer 42 is a heater layer 44 .
  • a thin electrically insulating layer (not shown), such as layer of aluminum oxide, titanium dioxide or zinc selenide, may be disposed between the heater layer 44 and the spreader layer 42 .
  • Adjacent to the heater layer 44 is a thermal insulating and impedance matching layer 46 .
  • Adjacent to the thermal insulating layer 46 is a thermally conductive inner layer 48 .
  • the spreader layer 42 is coated on its top surface with a thin layer of protective coating 50 .
  • the bottom surface of the inner layer 48 is coated with a thin overcoat layer 52 .
  • the protective coating 50 and the overcoat layer 52 have antireflective properties.
  • the spreader layer 42 is preferably formed of a highly infrared-transmissive material having a high thermal conductivity sufficient to facilitate heat transfer from the heater layer 44 uniformly into the material sample S when it is placed against the window assembly 12 .
  • Other effective materials include, but are not limited to, CVD diamond, diamondlike carbon, gallium arsenide, germanium, and other infrared-transmissive materials having sufficiently high thermal conductivity.
  • Preferred dimensions for the spreader layer 42 are about one inch in diameter and about 0.010 inch thick. As shown in FIG. 3 , a preferred embodiment of the spreader layer 42 incorporates a beveled edge. Although not required, an approximate 45-degree bevel is preferred.
  • the protective layer 50 is intended to protect the top surface of the spreader layer 42 from damage.
  • the protective layer is highly infrared-transmissive and highly resistant to mechanical damage, such as scratching or abrasion. It is also preferred that the protective layer 50 and the overcoat layer 52 have high thermal conductivity and antireflective and/or index-matching properties.
  • a satisfactory material for use as the protective layer 50 and the overcoat layer 52 is the multi-layer Broad Band Anti-Reflective Coating produced by Deposition Research Laboratories, Inc. of St. Charles, Mo. Diamondlike carbon coatings are also suitable.
  • the heater layer 44 is generally similar to the heater layer 34 employed in the window assembly shown in FIG. 2 .
  • the heater layer 44 may comprise a doped infrared-transmissive material, such as a doped silicon layer, with regions of higher and lower resistivity.
  • the heater layer 44 preferably has a resistance of about 2 ohms and has a preferred thickness of about 1,500 angstroms.
  • a preferred material for forming the heater layer 44 is a gold alloy, but other acceptable materials include, but are not limited to, platinum, titanium, tungsten, copper, and nickel.
  • the thermal insulating layer 46 prevents the dissipation of heat from the heater element 44 while allowing the cooling system 14 to effectively cool the material sample S (see FIG. 1 ).
  • This layer 46 comprises a material having thermally insulative (e.g., lower thermal conductivity than the spreader layer 42 ) and infrared transmissive qualities.
  • a preferred material is a germanium-arsenic-selenium compound of the calcogenide glass family known as AMTIR-1 produced by Amorphous Materials, Inc. of Garland, Tex.
  • the pictured embodiment has a diameter of about 0.85 inches and a preferred thickness in the range of about 0.005 to about 0.010 inches. As heat generated by the heater layer 44 passes through the spreader layer 42 into the material sample S, the thermal insulating layer 46 insulates this heat.
  • the inner layer 48 is formed of thermally conductive material, preferably crystalline silicon formed using a conventional floatzone crystal growth method.
  • the purpose of the inner layer 48 is to serve as a cold-conducting mechanical base for the entire layered window assembly.
  • the overall optical transmission of the window assembly 12 shown in FIG. 3 is preferably at least 70%.
  • the window assembly 12 of FIG. 3 is preferably held together and secured to the noninvasive system 10 by a holding bracket (not shown).
  • the bracket is preferably formed of a glass-filled plastic, for example Ultem 2300, manufactured by General Electric. Ultem 2300 has low thermal conductivity which prevents heat transfer from the layered window assembly 12 .
  • the cooling system 14 (see FIG. 1 ) preferably comprises a Peltier-type thermoelectric device.
  • the cooling system 14 cools the window assembly 12 via the situation of the window assembly 12 in thermally conductive relation to the cold surface 14 a of the cooling system 14 .
  • the cooling system 14 , the heater layer 34 , or both can be operated to induce a desired time-varying temperature in the window assembly 12 to create an oscillating thermal gradient in the sample S, in accordance with various analyte-detection methodologies discussed herein.
  • the cold reservoir 16 is positioned between the cooling system 14 and the window assembly 12 , and functions as a thermal conductor between the system 14 and the window assembly 12 .
  • the cold reservoir 16 is formed from a suitable thermally conductive material, preferably brass.
  • the window assembly 12 can be situated in direct contact with the cold surface 14 a of the cooling system 14 .
  • the cooling system 14 may comprise a heat exchanger through which a coolant, such as air, nitrogen or chilled water, is pumped, or a passive conduction cooler such as a heat sink.
  • a gas coolant such as nitrogen may be circulated through the interior of the noninvasive system 10 so as to contact the underside of the window assembly 12 (see FIG. 1 ) and conduct heat therefrom.
  • FIG. 4 is a top schematic view of a preferred arrangement of the window assembly 12 (of the types shown in FIG. 2 or 2 A) and the cold reservoir 16
  • FIG. 5 is a top schematic view of an alternative arrangement in which the window assembly 12 directly contacts the cooling system 14
  • the cold reservoir 16 /cooling system 14 preferably contacts the underside of the window assembly 12 along opposing edges thereof, on either side of the heater layer 34 . With thermal conductivity thus established between the window assembly 12 and the cooling system 14 , the window assembly can be cooled as needed during operation of the noninvasive system 10 .
  • the pitch distance between centerlines of adjacent heater elements 38 may be made smaller (thereby increasing the density of heater elements 38 ) near the region(s) of contact between the window assembly 12 and the cold reservoir 16 /cooling system 14 .
  • the heater elements 38 themselves may be made wider near these regions of contact.
  • isothermal is a broad term and is used in its ordinary sense and refers, without limitation, to a condition in which, at a given point in time, the temperature of the window assembly 12 or other structure is substantially uniform across a surface intended for placement in thermally conductive relation to the material sample S.
  • the temperature of the structure or surface may fluctuate over time, at any given point in time the structure or surface may nonetheless be isothermal.
  • the heat sink 18 drains waste heat from the hot surface 14 b of the cooling system 16 and stabilizes the operational temperature of the noninvasive system 10 .
  • the preferred heat sink 18 (see FIG. 6 ) comprises a hollow structure formed from brass or any other suitable material having a relatively high specific heat and high heat conductivity.
  • the heat sink 18 has a conduction surface 18 a which, when the heat sink 18 is installed in the noninvasive system 18 , is in thermally conductive relation to the hot surface 14 b of the cooling system 14 (see FIG. 1 ).
  • a cavity 54 is formed in the heat sink 18 and preferably contains a phase-change material (not shown) to increase the capacity of the sink 18 .
  • a preferred phase change material is a hydrated salt, such as calciumchloride hexahydrate, available under the name TH29 from PCM Thermal Solutions, Inc., of Naperville, Ill.
  • the cavity 54 may be omitted to create a heat sink 18 comprising a solid, unitary mass.
  • the heat sink 18 also forms a number of fins 56 to further increase the conduction of heat from the sink 18 to surrounding air.
  • the heat sink 18 may be formed integrally with the optical mixer 20 and/or the collimator 22 as a unitary mass of rigid, heat-conductive material such as brass or aluminum.
  • the mixer 20 and/or collimator 22 extend axially through the heat sink 18 , and the heat sink defines the inner walls of the mixer 20 and/or collimator 22 .
  • These inner walls are coated and/or polished to have appropriate reflectivity and nonabsorbance in infrared wavelengths as will be further described below.
  • any suitable structure may be employed to heat and/or cool the material sample S, instead of or in addition to the window assembly 12 /cooling system 14 disclosed above, so long a proper degree of cycled heating and/or cooling are imparted to the material sample S.
  • other forms of energy such as but not limited to light, radiation, chemically induced heat, friction and vibration, may be employed to heat the material sample S.
  • heating of the sample can achieved by any suitable method, such as convection, conduction, radiation, etc.
  • FIG. 6B illustrates an exploded view of a window mounting system 400 which, in one embodiment, is employed as part of the noninvasive system 10 disclosed above.
  • the window mounting system 400 supplements or, where appropriate, replaces any of the window assembly 12 , cooling system 14 , cold reservoir 16 and heat sink 18 shown in FIG. 1 .
  • the window mounting system 400 is employed in conjunction with the window assembly 12 depicted in FIG. 2A ; in alternative embodiments, the window assemblies shown in FIGS. 2 and 3 and described above may also be used in conjunction with the window mounting system 400 illustrated in FIG. 6B .
  • the window assembly 12 is physically and electrically connected (typically by soldering) to a first printed circuit board (“first PCB”) 402 .
  • the window assembly 12 is also in thermally conductive relation (typically by contact) to a thermal diffuser 410 .
  • the window assembly may also be fixed to the diffuser 410 by soldering.
  • the thermal diffuser 410 generally comprises a heat spreader layer 412 which, as mentioned, preferably contacts the window assembly 12 , and a conductive layer 414 which is typically soldered to the heat spreader layer 412 .
  • the conductive layer 414 may then be placed in direct contact with a cold side 418 a of a thermoelectric cooler (TEC) 418 or other cooling device.
  • TEC 418 which in one embodiment comprises a 25 W TEC manufactured by MELCOR, is in electrical communication with a second PCB 403 , which includes TEC power leads 409 and TEC power terminals 411 for connection of the TEC 418 to an appropriate power source (not shown).
  • the second PCB 403 also includes contacts 408 for connection with RTD terminals 407 (see FIG.
  • a heat sink 419 which may take the form of the illustrated water jacket, the heat sink 18 shown in FIG. 6 , any other heat sink structures mentioned herein, or any other appropriate device, is in thermal communication with a hot side 418 b of the TEC 418 (or other cooling device), in order to remove any excess heat created by the TEC 418 .
  • FIG. 6C illustrates a plan view of the interconnection of the window assembly 12 , the first PCB 402 , the diffuser 410 and the thermoelectric cooler 418 .
  • the first PCB includes RTD bonding leads 406 and heater bonding pads 404 which permit attachment of the RTDs 55 and bus bars 36 , respectively, of the window assembly 12 to the first PCB 402 via soldering or other conventional techniques. Electrical communication is thus established between the heater elements 38 of the heater layer 34 , and heater terminals 405 formed in the heater bonding pads 404 . Similarly, electrical communication is established between the RTDs 55 and RTD terminals 407 formed at the ends of the RTD bonding leads 406 . Electrical connections can be established with the heater elements 38 and the RTDs 55 via simple connection to the terminals 405 , 407 of the first PCB 402 .
  • the heat spreader layer 412 of the thermal diffuser 410 contacts the underside of the main layer 32 of the window assembly 12 via a pair of rails 416 .
  • the rails 416 may contact the main layer 32 at the metallized edge portions 35 , or at any other appropriate location.
  • the physical and thermal connection between the rails 416 and the window main layer 32 may be achieved by soldering, as indicated above. Alternatively, the connection may be achieved by an adhesive such as epoxy, or any other appropriate method.
  • the material chosen for the window main layer 32 is preferably sufficiently thermally conductive that heat may be quickly removed from the main layer 32 through the rails 416 , the diffuser 410 , and the TEC 128 .
  • FIG. 6D shows a cross-sectional view of the assembly of FIG. 6C through line 22 - 22 .
  • the window assembly 12 contacts the rails 416 of the heat spreader layer 412 .
  • the conductive layer 414 underlies the spreader layer 412 and may comprise protrusions 426 configured to extend through openings 424 formed in the spreader layer 412 .
  • the openings 424 and protrusions 426 are sized to leave sufficient expansion space therebetween, to allow expansion and contraction of the conductive layer 414 without interference with, or causing deformation of, the window assembly 12 or the heat spreader layer 412 .
  • the protrusions 426 and openings 424 coact to prevent displacement of the spreader layer 412 with respect to the conductive layer 414 as the conductive layer 414 expands and contracts.
  • the thermal diffuser 410 provides a thermal impedance between the TEC 418 and the window assembly 12 , which impedance is selected to drain heat from the window assembly at a rate proportional to the power output of the heater layer 34 . In this way, the temperature of the main layer 32 can be rapidly cycled between a “hot” and a “cold” temperatures, thereby allowing a time-varying thermal gradient to be induced in a sample S placed against the window assembly 12 .
  • the heat spreader layer 412 is preferably made of a material which has substantially the same coefficient of thermal expansion as the material used to form the window assembly main layer 32 , within the expected operating temperature range.
  • both the material used to form the main layer 32 and the material used to form the heat spreader layer 412 have substantially the same, extremely low, coefficient of thermal expansion.
  • CVD diamond is preferred for the main layer 32 (as mentioned above); with a CVD diamond main layer 32 the preferred material for the heat spreader layer 412 is Invar.
  • Invar advantageously has an extremely low coefficient of thermal expansion and a relatively high thermal conductivity. Because Invar is a metal, the main layer 32 and the heat spreader layer 412 can be thermally bonded to one another with little difficulty.
  • other materials may be used for the heat spreader layer 412 ; for example, any of a number of glass and ceramic materials with low coefficients of thermal expansion may be employed.
  • the conductive layer 414 of the thermal diffuser 410 is typically a highly thermally conductive material such as copper (or, alternatively, other metals or non-metals exhibiting comparable thermal conductivities).
  • the conductive layer 414 is typically soldered or otherwise bonded to the underside of the heat spreader layer 412 .
  • the heat spreader layer 412 may be constructed according to the following dimensions, which are to be understood as exemplary; accordingly the dimensions may be varied as desired.
  • the heat spreader layer 412 has an overall length and width of about 1.170′′, with a central opening of about 0.590′′ long by 0.470′′ wide.
  • the heat spreader layer 412 is about 0.030′′ thick; however, the rails 416 extend a further 0.045′′ above the basic thickness of the heat spreader layer 412 .
  • Each rail 416 has an overall length of about 0.710′′; over the central 0.525′′ of this length each rail 416 is about 0.053′′ wide.
  • each rail 416 tapers, at a radius of about 0.6′′, down to a width of about 0.023′′.
  • Each opening 424 is about 0.360′′ long by about 0.085′′ wide, with comers rounded at a radius of about 0.033′′.
  • conductive layer 414 may be constructed according to the following dimensions, which are to be understood as exemplary; accordingly the dimensions may be varied as desired.
  • the conductive layer 414 has an overall length and width of about 1.170′′, with a central opening of about 0.590′′ long by 0.470′′ wide.
  • the conductive layer 412 is about 0.035′′ thick; however, the protrusions 426 extend a further 0.075′′-0.085′′ above the basic thickness of the conductive layer 414 .
  • Each protrusion 426 is about 0.343′′ long by about 0.076′′ wide, with corners rounded at a radius of about 0.035′′.
  • first and second clamping plates 450 and 452 may be used to clamp the portions of the window mounting system 400 to one another.
  • the second clamping plate 452 is configured to clamp the window assembly 12 and the first PCB 402 to the diffuser 410 with screws or other fasteners extending through the openings shown in the second clamping plate 452 , the heat spreader layer 412 and the conductive layer 414 .
  • the first clamping plate 450 is configured overlie the second clamping plate 452 and clamp the rest of the window mounting system 400 to the heat sink 419 , thus sandwiching the second clamping plate 452 , the window assembly 12 , the first PCB 402 , the diffuser 410 , the second PCB 403 , and the TEC 418 therebetween.
  • the first clamping plate 450 prevents undesired contact between the sample S and any portion of the window mounting system 400 , other than the window assembly 12 itself.
  • Other mounting plates and mechanisms may also be used as desired.
  • the optical mixer 20 comprises a light pipe with an inner surface coating which is highly reflective and minimally absorptive in infrared wavelengths, preferably a polished gold coating, although other suitable coatings may be used where other wavelengths of electromagnetic radiation are employed.
  • the pipe itself may be fabricated from a another rigid material such as aluminum or stainless steel, as long as the inner surfaces are coated or otherwise treated to be highly reflective.
  • the optical mixer 20 has a rectangular cross-section (as taken orthogonal to the longitudinal axis A-A of the mixer 20 and the collimator 22 ), although other cross-sectional shapes, such as other polygonal shapes or circular or elliptical shapes, may be employed in alternative embodiments.
  • the inner walls of the optical mixer 20 are substantially parallel to the longitudinal axis A-A of the mixer 20 and the collimator 22 .
  • the highly reflective and substantially parallel inner walls of the mixer 20 maximize the number of times the infrared energy E will be reflected between the walls of the mixer 20 , thoroughly mixing the infrared energy E as it propagates through the mixer 20 .
  • the mixer 20 is about 1.2 inches to 2.4 inches in length and its cross-section is a rectangle of about 0.4 inches by about 0.6 inches.
  • other dimensions may be employed in constructing the mixer 20 . In particular it is be advantageous to miniaturize the mixer or otherwise make it as small as possible
  • the collimator 22 comprises a tube with an inner surface coating which is highly reflective and minimally absorptive in infrared wavelengths, preferably a polished gold coating.
  • the tube itself may be fabricated from a another rigid material such as aluminum, nickel or stainless steel, as long as the inner surfaces are coated or otherwise treated to be highly reflective.
  • the collimator 22 has a rectangular cross-section, although other cross-sectional shapes, such as other polygonal shapes or circular, parabolic or elliptical shapes, may be employed in alternative embodiments.
  • the inner walls of the collimator 22 diverge as they extend away from the mixer 20 .
  • the inner walls of the collimator 22 are substantially straight and form an angle of about 7 degrees with respect to the longitudinal axis A-A.
  • the collimator 22 aligns the infrared energy E to propagate in a direction that is generally parallel to the longitudinal axis A-A of the mixer 20 and the collimator 22 , so that the infrared energy E will strike the surface of the filters 24 at an angle as close to 90 degrees as possible.
  • the collimator is about 7.5 inches in length.
  • the cross-section of the collimator 22 is a rectangle of about 0.4 inches by 0.6 inches.
  • the collimator 22 has a rectangular cross-section of about 1.8 inches by 2.6 inches.
  • the collimator 22 aligns the infrared energy E to an angle of incidence (with respect to the longitudinal axis A-A) of about 0-15 degrees before the energy E impinges upon the filters 24 .
  • angle of incidence with respect to the longitudinal axis A-A
  • other dimensions or incidence angles may be employed in constructing and operating the collimator 22 .
  • each concentrator 26 comprises a tapered surface oriented such that its wide end 26 a is adapted to receive the infrared energy exiting the corresponding filter 24 , and such that its narrow end 26 b is adjacent to the corresponding detector 28 .
  • the inward-facing surfaces of the concentrators 26 have an inner surface coating which is highly reflective and minimally absorptive in infrared wavelengths, preferably a polished gold coating.
  • the concentrators 26 themselves may be fabricated from a another rigid material such as aluminum, nickel or stainless steel, so long as their inner surfaces are coated or otherwise treated to be highly reflective.
  • the concentrators 26 have a rectangular cross-section (as taken orthogonal to the longitudinal axis A-A), although other cross-sectional shapes, such as other polygonal shapes or circular, parabolic or elliptical shapes, may be employed in alternative embodiments.
  • the inner walls of the concentrators converge as they extend toward the narrow end 26 b.
  • the inner walls of the collimators 26 are substantially straight and form an angle of about 8 degrees with respect to the longitudinal axis A-A.
  • Such a configuration is adapted to concentrate infrared energy as it passes through the concentrators 26 from the wide end 26 a to the narrow end 26 b, before reaching the detectors 28 .
  • each concentrator 26 is about 1.5 inches in length. At the wide end 26 a, the cross-section of each concentrator 26 is a rectangle of about 0.6 inches by 0.57 inches. At the narrow end 26 b, each concentrator 26 has a rectangular cross-section of about 0.177 inches by 0.177 inches. Of course, other dimensions or incidence angles may be employed in constructing the concentrators 26 .
  • the filters 24 preferably comprise standard interference-type infrared filters, widely available from manufacturers such as Optical Coating Laboratory, Inc. (“OCLI”) of Santa Rosa, Calif.
  • OCLI Optical Coating Laboratory, Inc.
  • a 3 ⁇ 4 array of filters 24 is positioned above a 3 ⁇ 4 array of detectors 28 and concentrators 26 .
  • the filters 24 are arranged in four groups of three filters having the same wavelength sensitivity. These four groups have bandpass center wavelengths of 7.15 ⁇ m ⁇ 0.03 ⁇ m, 8.40 ⁇ m ⁇ 0.03 ⁇ m, 9.48 ⁇ m ⁇ 0.04 ⁇ m, and 11.10 ⁇ m ⁇ 0.04 ⁇ m, respectively, which correspond to wavelengths around which water and glucose absorb electromagnetic radiation. Typical bandwidths for these filters range from 0.20 ⁇ m to 0.50 ⁇ m.
  • the array of wavelength-specific filters 24 may be replaced with a single Fabry-Perot interferometer, which can provide wavelength sensitivity which varies as a sample of infrared energy is taken from the material sample S.
  • this embodiment permits the use of only one detector 28 , the output signal of which varies in wavelength specificity over time.
  • the output signal can be de-multiplexed based on the wavelength sensitivities induced by the Fabry-Perot interferometer, to provide a multiple-wavelength profile of the infrared energy emitted by the material sample S.
  • the optical mixer 20 may be omitted, as only one detector 28 need be employed.
  • the array of filters 24 may comprise a filter wheel that rotates different filters with varying wavelength sensitivities over a single detector 24 .
  • an electronically tunable infrared filter may be employed in a manner similar to the Fabry-Perot interferometer discussed above, to provide wavelength sensitivity which varies during the detection process.
  • the optical mixer 20 may be omitted, as only one detector 28 need be employed.
  • the detectors 28 may comprise any detector type suitable for sensing infrared energy, preferably in the mid-infrared wavelengths.
  • the detectors 28 may comprise mercury-cadmium-telluride (MCT) detectors.
  • MCT mercury-cadmium-telluride
  • a detector such as a Fermionics (Simi Valley, Calif.) model PV-9.1 with a PVA481-1 pre-amplifier is acceptable. Similar units from other manufacturers such as Graseby (Tampa, Fla.) can be substituted.
  • Other suitable components for use as the detectors 28 include pyroelectric detectors, thermopiles, bolometers, silicon microbolometers and lead-salt focal plane arrays.
  • FIG. 7 depicts the control system 30 in greater detail, as well as the interconnections between the control system and other relevant portions of the noninvasive system.
  • the control system includes a temperature control subsystem and a data acquisition subsystem.
  • temperature sensors such as RTDs and/or thermistors located in the window assembly 12 provide a window temperature signal to a synchronous analog-to-digital conversion system 70 and an asynchronous analog-to-digital conversion system 72 .
  • the A/D systems 70 , 72 in turn provide a digital window temperature signal to a digital signal processor (DSP) 74 .
  • DSP digital signal processor
  • the processor 74 executes a window temperature control algorithm and determines appropriate control inputs for the heater layer 34 of the window assembly 12 and/or for the cooling system 14 , based on the information contained in the window temperature signal.
  • the processor 74 outputs one or more digital control signals to a digital-to-analog conversion system 76 which in turn provides one or more analog control signals to current drivers 78 .
  • the current drivers 78 regulate the power supplied to the heater layer 34 and/or to the cooling system 14 .
  • the processor 74 provides a control signal through a digital I/O device 77 to a pulse-width modulator (PWM) control 80 , which provides a signal that controls the operation of the current drivers 78 .
  • PWM pulse-width modulator
  • a low-pass filter (not shown) at the output of the PWM provides for continuous operation of the current drivers 78 .
  • temperature sensors may be located at the cooling system 14 and appropriately connected to the A/D system(s) and processor to provide closed-loop control of the cooling system as well.
  • a detector cooling system 82 is located in thermally conductive relation to one or more of the detectors 28 .
  • the detector cooling system 82 may comprise any of the devices disclosed above as comprising the cooling system 14 , and preferably comprises a Peltier-type thermoelectric device.
  • the temperature control subsystem may also include temperature sensors, such as RTDs and/or thermistors, located in or adjacent to the detector cooling system 82 , and electrical connections between these sensors and the asynchronous A/D system 72 .
  • the temperature sensors of the detector cooling system 82 provide detector temperature signals to the processor 74 .
  • the detector cooling system 82 operates independently of the window temperature control system, and the detector cooling system temperature signals are sampled using the asynchronous A/D system 72 .
  • the processor 74 determines appropriate control inputs for the detector cooling system 82 , based on the information contained in the detector temperature signal.
  • the processor 74 outputs digital control signals to the D/A system 76 which in turn provides analog control signals to the current drivers 78 .
  • the current drivers 78 regulate the power supplied to the detector cooling system 14 .
  • the processor 74 also provides a control signal through the digital I/O device 77 and the PWM control 80 , to control the operation of the detector cooling system 82 by the current drivers 78 .
  • a low-pass filter (not shown) at the output of the PWM provides for continuous operation of the current drivers 78 .
  • the detectors 28 respond to the infrared energy E incident thereon by passing one or more analog detector signals to a preamp 84 .
  • the preamp 84 amplifies the detector signals and passes them to the synchronous A/D system 70 , which converts the detector signals to digital form and passes them to the processor 74 .
  • the processor 74 determines the concentrations of the analyte(s) of interest, based on the detector signals and a concentration-analysis algorithm and/or phase/concentration regression model stored in a memory module 88 .
  • the concentration-analysis algorithm and/or phase/concentration regression model may be developed according to any of the analysis methodologies discussed herein.
  • the processor may communicate the concentration results and/or other information to a display controller 86 , which operates a display (not shown), such as an LCD display, to present the information to the user.
  • a watchdog timer 94 may be employed to ensure that the processor 74 is operating correctly. If the watchdog timer 94 does not receive a signal from the processor 74 within a specified time, the watchdog timer 94 resets the processor 74 .
  • the control system may also include a JTAG interface 96 to enable testing of the noninvasive system 10 .
  • the synchronous A/D system 70 comprises a 20-bit, 14 channel system
  • the asynchronous A/D system 72 comprises a 16-bit, 16 channel system.
  • the preamp may comprise a 12-channel preamp corresponding to an array of 12 detectors 28 .
  • the control system may also include a serial port 90 or other conventional data port to permit connection to a personal computer 92 .
  • the personal computer can be employed to update the algorithm(s) and/or phase/concentration regression model(s) stored in the memory module 88 , or to download a compilation of analyte-concentration data from the noninvasive system.
  • a real-time clock or other timing device may be accessible by the processor 74 to make any time-dependent calculations which may be desirable to a user.
  • the detector(s) 28 of the noninvasive system 10 are used to detect the infrared energy emitted by the material sample S in various desired wavelengths. At each measured wavelength, the material sample S emits infrared energy at an intensity which varies over time. The time-varying intensities arise largely in response to the use of the window assembly 12 (including its heater layer 34 ) and the cooling system 14 to induce a thermal gradient in the material sample S.
  • thermal gradient is a broad term and is used in its ordinary sense and refers, without limitation, to a difference in temperature and/or thermal energy between different locations, such as different depths, of a material sample, which can be induced by any suitable method of increasing or decreasing the temperature and/or thermal energy in one or more locations of the sample.
  • concentration of an analyte of interest such as glucose
  • the concentration of an analyte of interest can be determined with a device such as the noninvasive system 10 , by comparing the time-varying intensity profiles of the various measured wavelengths.
  • a first reference signal P may be measured at a first reference wavelength.
  • the first reference signal P is measured at a wavelength where water strongly absorbs (e.g., 2.9 ⁇ m or 6.1 ⁇ m). Because water strongly absorbs radiation at these wavelengths, the detector signal intensity is reduced at those wavelengths. Moreover, at these wavelengths water absorbs the photon emissions emanating from deep inside the sample. The net effect is that a signal emitted at these wavelengths from deep inside the sample is not easily detected.
  • the first reference signal P is thus a good indicator of thermal-gradient effects near the sample surface and may be known as a surface reference signal. This signal may be calibrated and normalized, in the absence of heating or cooling applied to the sample, to a baseline value of 1 . For greater accuracy, more than one first reference wavelength may be measured. For example, both 2.9 ⁇ m and 6.1 ⁇ m may be chosen as first reference wavelengths.
  • a second reference signal R may also be measured.
  • the second signal R may be measured at a wavelength where water has very low absorbance (e.g., 3.6 ⁇ m or 4.2 ⁇ m).
  • This second reference signal R thus provides the analyst with information concerning the deeper regions of the sample, whereas the first signal P provides information concerning the sample surface.
  • This signal may also be calibrated and normalized, in the absence of heating or cooling applied to the sample, to a baseline value of 1. As with the first (surface) reference signal P, greater accuracy may be obtained by using more than one second (deep) reference signal R.
  • a third (analytical) signal Q is also measured.
  • This signal is measured at an IR absorbance peak of the selected analyte.
  • the IR absorbance peaks for glucose are in the range of about 6.5 ⁇ m to 11.0 ⁇ m.
  • This detector signal may also be calibrated and normalized, in the absence of heating or cooling applied to the material sample S, to a baseline value of 1.
  • the analytical signal Q may be measured at more than one absorbance peak.
  • reference signals may be measured at wavelengths that bracket the analyte absorbance peak. These signals may be advantageously monitored at reference wavelengths which do not overlap the analyte absorbance peaks. Further, it is advantageous to measure reference wavelengths at absorbance peaks which do not overlap the absorbance peaks of other possible constituents contained in the sample.
  • the signal intensities P, Q, R are shown initially at the normalized baseline signal intensity of 1. This of course reflects the baseline radiative behavior of a test sample in the absence of applied heating or cooling.
  • the surface of the sample is subjected to a temperature event which induces a thermal gradient in the sample.
  • the gradient can be induced by heating or cooling the sample surface.
  • the example shown in FIG. 8 uses cooling, for example, using a 10° C. cooling event.
  • the intensities of the detector signals P, Q, R decrease over time.
  • the surface cools before the deeper regions of the sample cool.
  • the signals P, Q, R drop in intensity, a pattern emerges. Signal intensity declines as expected, but as the signals P, Q, R reach a given amplitude value (or series of amplitude values: 150 , 152 , 154 , 156 , 158 ), certain temporal effects are noted.
  • the first (surface) reference signal P declines in amplitude most rapidly, reaching a checkpoint 150 first, at time t P . This is due to the fact that the first reference signal P mirrors the sample's radiative characteristics near the surface of the sample. Since the sample surface cools before the underlying regions, the surface (first) reference signal P drops in intensity first.
  • the second reference signal R is monitored. Since the second reference signal R corresponds to the radiation characteristics of deeper regions of the sample, which do not cool as rapidly as the surface (due to the time needed for the surface cooling to propagate into the deeper regions of the sample), the intensity of signal R does not decline until slightly later. Consequently, the signal R does not reach the magnitude 150 until some later time t R . In other words, there exists a time delay between the time t P at which the amplitude of the first reference signal P reaches the checkpoint 150 and the time t R at which the second reference signal R reaches the same checkpoint 150 . This time delay can be expressed as a phase difference ⁇ ( ⁇ ). Additionally, a phase difference may be measured between the analytical signal Q and either or both reference signals P, R.
  • the concentration of analyte increases. This reduces the intensity of the analytical signal Q in a concentration-dependent way. Consequently, the analytical signal Q reaches intensity 150 at some intermediate time t Q .
  • the higher the concentration of analyte the more the analytical signal Q shifts to the left in FIG. 8 .
  • the phase difference ⁇ ( ⁇ ) decreases relative to the first (surface) reference signal P and increases relative to the second (deep tissue) reference signal R.
  • the phase difference(s) ⁇ ( ⁇ ) are directly related to analyte concentration and can be used to make accurate determinations of analyte concentration.
  • the magnitude of this phase difference decreases with increasing analyte concentration.
  • the magnitude of this phase difference increases with increasing analyte concentration.
  • Accuracy may be enhanced by choosing several checkpoints, for example, 150 , 152 , 154 , 156 , and 158 and averaging the phase differences observed at each checkpoint.
  • the accuracy of this method may be further enhanced by integrating the phase difference(s) continuously over the entire test period. Because in this example only a single temperature event (here, a cooling event) has been induced, the sample reaches a new lower equilibrium temperature and the signals stabilize at a new constant level I F .
  • the method works equally well with thermal gradients induced by heating or by the application or introduction of other forms of energy, such as but not limited to light, radiation, chemically induced heat, friction and vibration.
  • This methodology is not limited to the determination of phase difference.
  • the amplitude of the analytical signal Q may be compared to the amplitude of either or both of the reference signals P, R.
  • the difference in amplitude may be observed and processed to determine analyte concentration.
  • This method, the variants disclosed herein, and the apparatus disclosed as suitable for application of the method(s), are not limited to the detection of in-vivo glucose concentration.
  • the method and disclosed variants and apparatus may be used on human, animal, or even plant subjects, or on organic or inorganic compositions in a non-medical setting.
  • the method may be used to take measurements of in-vivo or in-vitro samples of virtually any kind.
  • the method is useful for measuring the concentration of a wide range of additional chemical analytes, including but not limited to, glucose, ethanol, insulin, water, carbon dioxide, blood oxygen, cholesterol, bilirubin, ketones, fatty acids, lipoproteins, albumin, urea, creatinine, white blood cells, red blood cells, hemoglobin, oxygenated hemoglobin, carboxyhemoglobin, organic molecules, inorganic molecules, pharmaceuticals, cytochrome, various proteins and chromophores, microcalcifications, hormones, as well as other chemical compounds.
  • additional chemical analytes including but not limited to, glucose, ethanol, insulin, water, carbon dioxide, blood oxygen, cholesterol, bilirubin, ketones, fatty acids, lipoproteins, albumin, urea, creatinine, white blood cells, red blood cells, hemoglobin, oxygenated hemoglobin, carboxyhemoglobin, organic molecules, inorganic molecules, pharmaceuticals, cytochrome, various proteins and chromophores, microcalcifications, hormone
  • the method is adaptable and may be used to determine chemical concentrations in samples of body fluids (e.g., blood, urine or saliva) once they have been extracted from a patient.
  • body fluids e.g., blood, urine or saliva
  • the method may be used for the measurement of in-vitro samples of virtually any kind.
  • a periodically modulated thermal gradient can be employed to make accurate determinations of analyte concentration.
  • FIG. 9 depicts detector signals emanating from a test sample.
  • one or more reference signals J, L are measured.
  • One or more analytical signals K are also monitored. These signals may be calibrated and normalized, in the absence of heating or cooling applied to the sample, to a baseline value of 1 .
  • FIG. 9 shows the signals after normalization.
  • a temperature event e.g., cooling
  • the signals (P, Q, R) decline until the thermal gradient disappears and a new equilibrium detector signal I F is reached.
  • a heating event at a time t W , is induced in the sample surface.
  • the detector output signals J, K, L will rise as the sample temperature rises.
  • another cooling event is induced, causing the temperature and detector signals to decline.
  • This cycle of cooling and heating may be repeated over a time interval of arbitrary length.
  • a periodically modulated thermal gradient may be induced in the test sample.
  • the phase difference ⁇ ( ⁇ ) may be measured and used to determine analyte concentration.
  • FIG. 9 shows that the first (surface) reference signal J declines and rises in intensity first.
  • the second (deep tissue) reference signal L declines and rises in a time-delayed manner relative to the first reference signal J.
  • the analytical signal K exhibits a time/phase delay dependent on the analyte concentration. With increasing concentration, the analytical signal K shifts to the left in FIG. 9 .
  • the phase difference ⁇ ( ⁇ ) may be measured.
  • a phase difference ⁇ ( ⁇ ) between the second reference signal L and the analytical signal K may be measured at a set amplitude 162 as shown in FIG. 9 .
  • the magnitude of the phase signal reflects the analyte concentration of the sample.
  • phase-difference information compiled by any of the methodologies disclosed herein can correlated by the control system 30 (see FIG. 1 ) with previously determined phase-difference information to determine the analyte concentration in the sample.
  • This correlation could involve comparison of the phase-difference information received from analysis of the sample, with a data set containing the phase-difference profiles observed from analysis of wide variety of standards of known analyte concentration.
  • a phase/concentration curve or regression model is established by applying regression techniques to a set of phase-difference data observed in standards of known analyte concentration. This curve is used to estimate the analyte concentration in a sample based on the phase-difference information received from the sample.
  • phase difference ⁇ ( ⁇ ) may be measured continuously throughout the test period.
  • the phase-difference measurements may be integrated over the entire test period for an extremely accurate measure of phase difference ⁇ ( ⁇ ).
  • Accuracy may also be improved by using more than one reference signal and/or more than one analytical signal.
  • differences in amplitude between the analytical and reference signal(s) may be measured and employed to determine analyte concentration. Additional details relating to this technique and not necessary to repeat here may be found in the Assignee's U.S. patent application Ser. No. 09/538,164, incorporated by reference below.
  • phase differences can be simultaneously measured and processed to determine analyte concentrations.
  • FIG. 9 illustrates the method used in conjunction with a sinusoidally modulated thermal gradient, the principle applies to thermal gradients conforming to any periodic function. In more complex cases, analysis using signal processing with Fourier transforms or other techniques allows accurate determinations of phase difference D(k) and analyte concentration.
  • the magnitude of the phase differences may be determined by measuring the time intervals between the amplitude peaks (or troughs) of the reference signals J, L and the analytical signal K.
  • the time intervals between the “zero crossings” may be used to determine the phase difference between the analytical signal K and the reference signals J, L. This information is subsequently processed and a determination of analyte concentration may then be made.
  • This particular method has the advantage of not requiring normalized signals.
  • two or more driving frequencies may be employed to determine analyte concentrations at selected depths within the sample.
  • a slow (e.g., 1 Hz) driving frequency creates a thermal gradient which penetrates deeper into the sample than the gradient created by a fast (e.g., 3 Hz) driving frequency. This is because the individual heating and/or cooling events are longer in duration where the driving frequency is lower.
  • a slow driving frequency provides analyte-concentration information from a deeper “slice” of the sample than does the use of a fast driving frequency.
  • a temperature event of 10° C. creates a thermal gradient which penetrates to a depth of about 150 ⁇ m, after about 500 ms of exposure. Consequently, a cooling/heating cycle or driving frequency of 1 Hz provides information to a depth of about 150 ⁇ m. It has also been determined that exposure to a temperature event of 10° C. for about 167 ms creates a thermal gradient that penetrates to a depth of about 50 ⁇ m. Therefore, a cooling/heating cycle of 3 Hz provides information to a depth of about 50 ⁇ m.
  • analyte concentration(s) in the region of skin between 50 and 150 ⁇ m.
  • a similar approach can be used to determine analyte concentrations at any desired depth range within any suitable type of sample.
  • alternating deep and shallow thermal gradients may be induced by alternating slow and fast driving frequencies.
  • this variation also involves the detection and measurement of phase differences ⁇ ( ⁇ ) between reference signals G, G′ and analytical signals H, H′. Phase differences are measured at both fast (e.g., 3 Hz) and slow (e.g., 1 Hz) driving frequencies.
  • the slow driving frequency may continue for an arbitrarily chosen number of cycles (in region SL 1 ), for example, two full cycles.
  • the fast driving frequency is employed for a selected duration, in region F 1 .
  • the phase difference data is compiled in the same manner as disclosed above.
  • the fast frequency (shallow sample) phase difference data may be subtracted from the slow frequency (deep sample) data to provide an accurate determination of analyte concentration in the region of the sample between the gradient penetration depth associated with the fast driving frequency and that associated with the slow driving frequency.
  • the driving frequencies (e.g., 1 Hz and 3 Hz) can be multiplexed as shown in FIG. 12 .
  • the fast (3 Hz) and slow (1 Hz) driving frequencies can be superimposed rather than sequentially implemented.
  • the data can be separated by frequency (using Fourier transform or other techniques) and independent measurements of phase delay at each of the driving frequencies may be calculated. Once resolved, the two sets of phase delay data are processed to determine absorbance and analyte concentration.
  • FIG. 13 is a schematic view of a reagentless whole-blood analyte detection system 200 (hereinafter “whole-blood system”) in a preferred configuration.
  • the whole-blood system 200 may comprise a radiation source 220 , a filter 230 , a cuvette 240 that includes a sample cell 242 , and a radiation detector 250 .
  • the whole-blood system 200 preferably also comprises a signal processor 260 and a display 270 .
  • a cuvette 240 is shown here, other sample elements, as described below, could also be used in the system 200 .
  • the whole-blood system 200 can also comprise a sample extractor 280 , which can be used to access bodily fluid from an appendage, such as the finger 290 , forearm, or any other suitable location.
  • the terms “whole-blood analyte detection system” and “whole-blood system” are broad, synonymous terms and are used in their ordinary sense and refer, without limitation, to analyte detection devices which can determine the concentration of an analyte in a material sample by passing electromagnetic radiation into the sample and detecting the absorbance of the radiation by the sample.
  • the term “whole-blood” is a broad term and is used in its ordinary sense and refers, without limitation, to blood that has been withdrawn from a patient but that has not been otherwise processed, e.g., it has not been hemolysed, lyophilized, centrifuged, or separated in any other manner, after being removed from the patient.
  • Whole-blood may contain amounts of other fluids, such as interstitial fluid or intracellular fluid, which may enter the sample during the withdrawal process or are naturally present in the blood. It should be understood, however, that the whole-blood system 200 disclosed herein is not limited to analysis of whole-blood, as the whole-blood system 10 may be employed to analyze other substances, such as saliva, urine, sweat, interstitial fluid, intracellular fluid, hemolysed, lyophilized, or centrifuged blood or any other organic or inorganic materials.
  • other substances such as saliva, urine, sweat, interstitial fluid, intracellular fluid, hemolysed, lyophilized, or centrifuged blood or any other organic or inorganic materials.
  • the whole-blood system 200 may comprise a near-patient testing system.
  • near-patient testing system is a broad term and is used in its ordinary sense, and includes, without limitation, test systems that are configured to be used where the patient is rather than exclusively in a laboratory, e.g., systems that can be used at a patient's home, in a clinic, in a hospital, or even in a mobile environment. Users of near-patient testing systems can include patients, family members of patients, clinicians, nurses, or doctors. A “near-patient testing system” could also include a “point-of-care” system.
  • the whole-blood system 200 may in one embodiment be configured to be operated easily by the patient or user.
  • the system 200 is preferably a portable device.
  • portable is a broad term and is used in its ordinary sense and means, without limitation, that the system 200 can be easily transported by the patient and used where convenient.
  • the system 200 is advantageously small.
  • the system 200 is small enough to fit into a purse or backpack.
  • the system 200 is small enough to fit into a pants pocket.
  • the system 200 is small enough to be held in the palm of a hand of the user.
  • sample element is a broad term and is used in its ordinary sense and includes, without limitation, structures that have a sample cell and at least one sample cell wall, but more generally includes any of a number of structures that can hold, support or contain a material sample and that allow electromagnetic radiation to pass through a sample held, supported or contained thereby; e.g., a cuvette, test strip, etc.
  • the term “disposable” when applied to a component, such as a sample element, is a broad term and is used in its ordinary sense and means, without limitation, that the component in question is used a finite number of times and then discarded. Some disposable components are used only once and then discarded. Other disposable components are used more than once and then discarded.
  • the radiation source 220 of the whole-blood system 200 emits electro-magnetic radiation in any of a number of spectral ranges, e.g., within infrared wavelengths; in the mid-infrared wavelengths; above about 0.8 ⁇ m; between about 5.0 ⁇ m and about 20.0 ⁇ m; and/or between about 5.25 ⁇ m and about 12.0 ⁇ m.
  • the whole-blood system 200 may employ a radiation source 220 which emits in wavelengths found anywhere from the visible spectrum through the microwave spectrum, for example anywhere from about 0.4 ⁇ m to greater than about 100 ⁇ m.
  • the radiation source emits electromagnetic radiation in wavelengths between about 3.5 ⁇ m and about 14 ⁇ m, or between about 0.8 ⁇ m and about 2.5 ⁇ m, or between about 2.5 ⁇ m and about 20 ⁇ m, or between about 20 ⁇ m and about 100 ⁇ m, or between about 6.85 ⁇ m and about 10.10 ⁇ m.
  • the radiation emitted from the source 220 is in one embodiment modulated at a frequency between about one-half hertz and about one hundred hertz, in another embodiment between about 2.5 hertz and about 7.5 hertz, in still another embodiment at about 50 hertz, and in yet another embodiment at about 5 hertz.
  • a modulated radiation source ambient light sources, such as a flickering fluorescent lamp, can be more easily identified and rejected when analyzing the radiation incident on the detector 250 .
  • One source that is suitable for this application is produced by ION OPTICS, INC. and sold under the part number NL5LNC.
  • the filter 230 permits electromagnetic radiation of selected wavelengths to pass through and impinge upon the cuvette/sample element 240 .
  • the filter 230 permits radiation at least at about the following wavelengths to pass through to the cuvette/sample element: 3.9, 4.0 ⁇ m, 4.05 ⁇ m, 4.2 ⁇ m, 4.75, 4.95 ⁇ m, 5.25 ⁇ m, 6.12 ⁇ m, 7.4 ⁇ m, 8.0 ⁇ m, 8.45 ⁇ m, 9.25 ⁇ m, 9.5 ⁇ m, 9.65 ⁇ m, 10.4 ⁇ m, 12.2 ⁇ m.
  • the filter 230 permits radiation at least at about the following wavelengths to pass through to the cuvette/sample element: 5.25 ⁇ m, 6.12 ⁇ m, 6.8 ⁇ m, 8.03 ⁇ m, 8.45 ⁇ m, 9.25 ⁇ m, 9.65 ⁇ m, 10.4 ⁇ m, 12 ⁇ m.
  • the filter 230 permits radiation at least at about the following wavelengths to pass through to the cuvette/sample element: 6.85 ⁇ m, 6.97 ⁇ m, 7.39 ⁇ m, 8.23 ⁇ m, 8.62 ⁇ m, 9.02 ⁇ m, 9.22 ⁇ m, 9.43 ⁇ m, 9.62 ⁇ m, and 10.10 ⁇ m.
  • the sets of wavelengths recited above correspond to specific embodiments within the scope of this disclosure. Furthermore, other subsets of the foregoing sets or other combinations of wavelengths can be selected. Finally, other sets of wavelengths can be selected within the scope of this disclosure based on cost of production, development time, availability, and other factors relating to cost, manufacturability, and time to market of the filters used to generate the selected wavelengths, and/or to reduce the total number of filters needed.
  • the filter 230 is capable of cycling its passband among a variety of narrow spectral bands or a variety of selected wavelengths.
  • the filter 230 may thus comprise a solid-state tunable infrared filter, such as that available from ION OPTICS INC.
  • the filter 230 could also be implemented as a filter wheel with a plurality of fixed-passband filters mounted on the wheel, generally perpendicular to the direction of the radiation emitted by the source 220 . Rotation of the filter wheel alternately presents filters that pass radiation at wavelengths that vary in accordance with the filters as they pass through the field of view of the detector 250 .
  • the detector 250 preferably comprises a 3 mm long by 3 mm wide pyroelectric detector. Suitable examples are produced by DIAS Angewandte Sensorik GmbH of Dresden, Germany, or by BAE Systems (such as its TGS model detector).
  • the detector 250 could alternatively comprise a thermopile, a bolometer, a silicon microbolometer, a lead-salt focal plane array, or a mercury-cadmium-telluride (MCT) detector. Whichever structure is used as the detector 250 , it is desirably configured to respond to the radiation incident upon its active surface 254 to produce electrical signals that correspond to the incident radiation.
  • the sample element comprises a cuvette 240 which in turn comprises a sample cell 242 configured to hold a sample of tissue and/or fluid (such as whole-blood, blood components, interstitial fluid, intercellular fluid, saliva, urine, sweat and/or other organic or inorganic materials) from a patient within its sample cell.
  • the cuvette 240 is installed in the whole-blood system 200 with the sample cell 242 located at least partially in the optical path 243 between the radiation source 220 and the detector 250 .
  • the detector 250 detects the radiation signal strength at the wavelength(s) of interest. Based on this signal strength, the signal processor 260 determines the degree to which the sample in the cell 242 absorbs radiation at the detected wavelength(s). The concentration of the analyte of interest is then determined from the absorption data via any suitable spectroscopic technique.
  • the whole-blood system 200 can also comprise a sample extractor 280 .
  • sample extractor is a broad term and is used in its ordinary sense and refers, without limitation, to any device which is suitable for drawing a sample material, such as whole-blood, other bodily fluids, or any other sample material, through the skin of a patient.
  • the sample extractor may comprise a lance, laser lance, iontophoretic sampler, gas-jet, fluid-jet or particle-jet perforator, ultrasonic enhancer (used with or without a chemical enhancer), or any other suitable device.
  • the sample extractor 280 could form an opening in an appendage, such as the finger 290 , to make whole-blood available to the cuvette 240 . It should be understood that other appendages could be used to draw the sample, including but not limited to the forearm. With some embodiments of the sample extractor 280 , the user forms a tiny hole or slice through the skin, through which flows a sample of bodily fluid such as whole-blood. Where the sample extractor 280 comprises a lance (see FIG. 14 ), the sample extractor 280 may comprise a sharp cutting implement made of metal or other rigid materials. One suitable laser lance is the Lasette Plus® produced by Cell Robotics International, Inc. of Albuquerque, N.M.
  • sample extractor 280 If a laser lance, iontophoretic sampler, gas-jet or fluid-jet perforator is used as the sample extractor 280 , it could be incorporated into the whole-blood system 200 (see FIG. 13 ), or it could be a separate device.
  • FIG. 14 shows one embodiment of a sample element, in the form of a cuvette 240 , in greater detail.
  • the cuvette 240 further comprises a sample supply passage 248 , a pierceable portion 249 , a first window 244 , and a second window 246 , with the sample cell 242 extending between the windows 244 , 246 .
  • the cuvette 240 does not have a second window 246 .
  • the first window 244 (or second window 246 ) is one form of a sample cell wall; in other embodiments of the sample elements and cuvettes disclosed herein, any sample cell wall may be used that at least partially contains, holds or supports a material sample, such as a biological fluid sample, and which is transmissive of at least some bands of electromagnetic radiation, and which may but need not be transmissive of electromagnetic radiation in the visible range.
  • the pierceable portion 249 is an area of the sample supply passage 248 that can be pierced by suitable embodiments of the sample extractor 280 .
  • Suitable embodiments of the sample extractor 280 can pierce the portion 249 and the appendage 290 to create a wound in the appendage 290 and to provide an inlet for the blood or other fluid from the wound to enter the cuvette 240 .
  • the sample extractor 280 is shown on the opposite side of the sample element in FIG. 14 , as compared to FIG. 13 , as it may pierce the portion 249 from either side.
  • the windows 244 , 246 are preferably optically transmissive in the range of electromagnetic radiation that is emitted by the source 220 , or that is permitted to pass through the filter 230 .
  • the material that makes up the windows 244 , 246 is completely transmissive, i.e., it does not absorb any of the electromagnetic radiation from the source 220 and filter 230 that is incident upon it.
  • the material of the windows 244 , 246 has some absorption in the electromagnetic range of interest, but its absorption is negligible.
  • the absorption of the material of the windows 244 , 246 is not negligible, but it is known and stable for a relatively long period of time.
  • the absorption of the windows 244 , 246 is stable for only a relatively short period of time, but the whole-blood system 200 is configured to observe the absorption of the material and eliminate it from the analyte measurement before the material properties can change measurably.
  • the windows 244 , 246 are made of polypropylene in one embodiment.
  • the windows 244 , 246 are made of polyethylene.
  • Polyethylene and polypropylene are materials having particularly advantageous properties for handling and manufacturing, as is known in the art.
  • polypropylene can be arranged in a number of structures, e.g., isotactic, atactic and syndiotactic, which may enhance the flow characteristics of the sample in the sample element.
  • the windows 244 , 246 are made of durable and easily manufactureable materials, such as the above-mentioned polypropylene or polyethylene, or silicon or any other suitable material.
  • the windows 244 , 246 can be made of any suitable polymer, which can be isotactic, atactic or syndiotactic in structure.
  • the distance between the windows 244 , 246 comprises an optical pathlength and can be between about 1 ⁇ m and about 100 ⁇ m. In one embodiment, the optical pathlength is between about 10 ⁇ m and about 40 ⁇ m, or between about 25 ⁇ m and about 60 ⁇ m, or between about 30 ⁇ m and about 50 ⁇ m. In still another embodiment, the optical pathlength is about 25 ⁇ m.
  • the transverse size of each of the windows 244 , 246 is preferably about equal to the size of the detector 250 . In one embodiment, the windows are round with a diameter of about 3 mm. In this embodiment, where the optical pathlength is about 25 ⁇ m the volume of the sample cell 242 is about 0.177 ⁇ L.
  • the length of the sample supply passage 248 is about 6 mm
  • the height of the sample supply passage 248 is about 1 mm
  • the thickness of the sample supply passage 248 is about equal to the thickness of the sample cell, e.g., 25 ⁇ m.
  • the volume of the sample supply passage is about 0.150 ⁇ L.
  • the total volume of the cuvette 240 in one embodiment is about 0.327 ⁇ L.
  • the transport of fluid to the sample cell 242 is achieved preferably through capillary action, but may also be achieved through wicking, or a combination of wicking and capillary action.
  • FIGS. 15-17 depict another embodiment of a cuvette 305 that could be used in connection with the whole-blood system 200 .
  • the cuvette 305 comprises a sample cell 310 , a sample supply passage 315 , an air vent passage 320 , and a vent 325 .
  • the cuvette also comprises a first sample cell window 330 having an inner side 332 , and a second sample cell window 335 having an inner side 337 .
  • the window(s) 330 / 335 in some embodiments also comprise sample cell wall(s).
  • the cuvette 305 also comprises an opening 317 at the end of the sample supply passage 315 opposite the sample cell 310 .
  • the cuvette 305 is preferably about 1 ⁇ 4-1 ⁇ 8 inch wide and about 3 ⁇ 4 inch long; however, other dimensions are possible while still achieving the advantages of the cuvette 305 .
  • the sample cell 310 is defined between the inner side 332 of the first sample cell window 330 and the inner side 337 of the second sample cell window 335 .
  • the perpendicular distance T between the two inner sides 332 , 337 comprises an optical pathlength that can be between about 1 ⁇ m and about 1.22 mm.
  • the optical pathlength can alternatively be between about 1 ⁇ m and about 100 ⁇ m.
  • the optical pathlength could still alternatively be about 80 ⁇ m, but is preferably between about 10 ⁇ m and about 50 ⁇ m. In another embodiment, the optical pathlength is about 25 ⁇ m.
  • the windows 330 , 335 are preferably formed from any of the materials discussed above as possessing sufficient radiation transmissivity.
  • the thickness of each window is preferably as small as possible without overly weakening the sample cell 310 or cuvette 305 .
  • the opening 317 of the sample supply passage 315 of the cuvette 305 is placed in contact with the fluid that flows from the wound.
  • the sample is obtained without creating a wound, e.g. as is done with a saliva sample.
  • the opening 317 of the sample supply passage 315 of the cuvette 305 is placed in contact with the fluid obtained without creating a wound.
  • the fluid is then transported through the sample supply passage 315 and into the sample cell 310 via capillary action.
  • the air vent passage 320 improves the capillary action by preventing the buildup of air pressure within the cuvette and allowing the blood to displace the air as the blood flows therein.
  • wicking could be used by providing a wicking material in at least a portion of the sample supply passage 315 .
  • wicking and capillary action could be used together to transport the sample to the sample cell 310 .
  • Membranes could also be positioned within the sample supply passage 315 to move the blood while at the same time filtering out components that might complicate the optical measurement performed by the whole-blood system 200 .
  • FIGS. 16 and 16 A depict one approach to constructing the cuvette 305 .
  • the cuvette 305 comprises a first layer 350 , a second layer 355 , and a third layer 360 .
  • the second layer 355 is positioned between the first layer 350 and the third layer 360 .
  • the first layer 350 forms the first sample cell window 330 and the vent 325 .
  • the vent 325 provides an escape for the air that is in the sample cell 310 . While the vent 325 is shown on the first layer 350 , it could also be positioned on the third layer 360 , or could be a cutout in the second layer, and would then be located between the first layer 360 and the third layer 360
  • the third layer 360 forms the second sample cell window 335 .
  • the second layer 355 may be formed entirely of an adhesive that joins the first and third layers 350 , 360 . In other embodiments, the second layer may be formed from similar materials as the first and third layers, or any other suitable material. The second layer 355 may also be formed as a carrier with an adhesive deposited on both sides thereof. The second layer 355 forms the sample supply passage 315 , the air vent passage 320 , and the sample cell 310 .
  • the thickness of the second layer 355 can be between about 1 ⁇ m and about 1.22 mm. This thickness can alternatively be between about 1 ⁇ m and about 100 ⁇ m. This thickness could alternatively be about 80 ⁇ m, but is preferably between about 10 ⁇ m and about 50 ⁇ m. In another embodiment, the second layer thickness is about 25 ⁇ m.
  • the second layer 355 can be constructed as an adhesive film having a cutout portion to define the passages 315 , 320 , or as a cutout surrounded by adhesive.
  • an analyte detection system 500 is shown connected to remote stations 524 , 528 over a network 520 , which may comprise one or more wireless or hardwired links, or a combination of wireless and hardwired links, and/or the Internet.
  • the analyte detection system 500 comprises the noninvasive system 10 described above.
  • the analyte detection system may comprise any other suitable noninvasive system such as (but not limited to) those described in U.S. Pat. No. 5,900,632 to Sterling et al. and U.S. Pat. No. 5,615,972 to Braig et al., the entirety of each of which is hereby incorporated by reference herein and made a part of this specification.
  • the analyte detection system 500 may comprise any suitable invasive system such as (but not limited to) the whole-blood system 200 disclosed above.
  • the noninvasive system 10 is depicted in the embodiment of FIG. 18 , the hand and forearm 512 of a patient is shown positioned to allow a measurement to be performed by an analyte detector element 514 of the analyte detection system 500 .
  • the analyte detection system 500 includes a signal processing system 516 which collects the measurements and/or other suitable information from the detector element 514 and processes the data into a set of results.
  • the analyte detection system 500 includes input and output devices, such as a display and a set of control inputs (not shown) for communicating information directly to and from the patient.
  • the signal processing system 516 is equipped with a network interface 517 along with one or more processing elements 519 for processing the measurement signals and for control of network communications.
  • Measurement data is communicated over the network 520 as determined by the configuration of the system 500 and the state and condition of the measurement being performed. Measurement data may accordingly be communicated to the remote station(s) 524 , 528 at the time the measurement is performed, or it may be retained within the system 500 and sent to the remote station(s) according to a schedule or other selection criterion.
  • the system 500 and/or remote station(s) 524 , 284 may be capable of comparing each measurement with a set of limits and providing alerts to a supervisory authority regarding excursions therefrom.
  • the measurement data is shown passing through a connection 518 to the network 520 , and from there through another connection 522 to a centralized monitoring computer 524 or to a server.
  • the centralized computer 524 may be capable of checking the data for emergency conditions and logging the data for later use.
  • the centralized computer 524 may monitor the status of the system(s) 500 for proper operation and calibration. It will be appreciated that multiple centralized computers 524 or servers can be provided for communicating with the system(s) 500 .
  • the network interface 517 is a wireless interface (and the connection 518 is a wireless connection), such as but not limited to a Bluetooth interface, an IEEE 802.11 (b) interface or a cellular interface, implemented through appropriate hardware built into the system 500 .
  • the centralized computer 524 may simultaneously transfer or route the data (e.g., measurements, system status, etc.) via connection 526 to a computer 528 in the office of a medical practitioner over the network 520 .
  • the network may include connections to a computer 528 ′ located at the manufacturer of the analyte detection system 500 , to a computer 528 ′′ located at the patient's home, and/or to a computer 528 ′′′ located at the home or place of business of a parent of the patient.
  • the data may be directly sent over the network 520 to the medical practitioner 528 /manufacturer 528 ′/patient's home 528 ′′/patient's parent 528 ′′′ from the signal processing system 516 ; in this instance the centralized computer 524 is not necessary and may be omitted from the network 520 . Where the centralized computer 524 is omitted, any of the computer(s) 528 / 528 ′/ 528 ′′/ 528 ′′′ (hereinafter, collectively “ 528 ”) may be capable of checking the data received from the system 500 for emergency conditions, logging the data for later use, and/or monitoring the status of the system 500 for proper operation and calibration. It will be appreciated that the foregoing data routing is provided as an example, and not as a limitation, of the data routing utilized to provide the network services in support of a patient's use of the system 500 .
  • the system 500 includes a panic button 530 which permits the patient to alert a medical practitioner should an important concern arise.
  • sound and/or visual output may be provided by the system 500 for signaling the patient when the time arrives to perform a measurement, or of a directive from a supervisory authority as received over the network 520 .
  • the system 500 includes a location button 531 which permits the patient to signal his or her location (as well as the location of the system 500 ) to any of the remote station(s) 524 , 528 .
  • a remote user at a remote station 524 / 528 can direct emergency assistance to the location of the patient/system, should the remote user discover that the patient's condition merits immediate medical attention.
  • the location information is generated via GPS (Global Positioning System) equipment built into the system 500 and accessible by the processing element(s) 519 .
  • the system 500 continually, intermittently or otherwise automatically transmits its location to any or all of the remote station(s) 524 , 528 , and the location button 531 may be omitted.
  • the system 500 is configured to transmit its location to remote station(s) 524 , 528 in response to a query sent from the remote station(s) to the system 500 .
  • the GPS equipment is supplemented by storage, within appropriate memory accessible by the processing element(s) 519 and/or the GPS equipment, of favorite locations frequented by the patient.
  • favorite locations include Home, Work, School, etc. and/or a widely recognizable expression thereof, such as the associated street address, nearest cross streets, ZIP or postal code, and/or longitude and latitude.
  • the purpose of such storage is to counteract the tendency of GPS equipment to lose contact with the GPS satellite(s) when the GPS device in question is located inside of a building or other large structure.
  • the system 500 recognizes the loss of contact with the GPS satellite(s) and selects for transmission one of the patient's favorite locations based on the last GPS-computed position of the user/system prior to loss of contact with the GPS satellite(s). In one embodiment, the system 500 selects and transmits whichever favorite location is nearest the last GPS-computed position of the system 500 .
  • the system 500 selects and transmits this nearest favorite location only when the nearest favorite location is within a given minimum distance (e.g., 10 miles, 5 miles, 1 mile, 0.5 miles) from the last GPS-computed position of the system 500 .
  • the system 500 displays a list of the patient's stored favorite locations on a suitable display, and the patient can select, using an appropriate input device (keypad, button, touchscreen, mouse, voice recognition system, etc.) built into or connected to the system 500 , his or her present location from a list of favorites and prompt the system 500 to transmit the selected location.
  • a given minimum distance e.g. 10 miles, 5 miles, 1 mile, 0.5 miles
  • any of the location-transmission processes discussed above may be implemented in an algorithm or program instructions executable by, and residing within memory accessible by, the processing element(s) 519 of the system 500 (in particular, by the signal processor 74 / 260 where the system 500 comprises the noninvasive system 10 or the whole-blood system 200 , respectively).
  • the system 500 and/or one or more of the remote station(s) 524 , 528 may be configured to encrypt any or all of the data that it transmits over the network 520 .
  • the recipient system 500 /remote station 524 , 528 is configured to decrypt the encrypted data, to make the data available to the device and/or the user thereof.
  • Encryption also permits transmission of data over wireless networks or public networks such as the Internet while preserving confidentiality of the transmitted data.
  • the encryption and decryption may be performed in any suitable manner, with any suitable methods, software and/or hardware presently known or hereafter developed.
  • the encryption and/or decryption processes may be implemented in an algorithm or program instructions executable by, and residing within memory accessible by, the processing element(s) 519 of the system 500 (in particular, by the signal processor 74 / 260 where the system 500 comprises the noninvasive system 10 or the whole-blood system 200 , respectively).
  • the encryption and/or decryption processes may be implemented in an algorithm or program instructions executable by, and residing within memory accessible by, processing element(s) (not shown) of the remote station 524 / 528 in question.
  • connection of the system 500 to the network 520 provides either a direct or indirect link from the patient to the practitioner.
  • the practitioner is thereby accorded an ability to monitor the status of the patient and may elect to be alerted should deviations in the measurement values the or timeliness thereof arise.
  • the system may be configured to transmit measurement data at predetermined intervals, or at the time each measurement is performed.
  • the measurements can be transmitted using various network protocols which include standard internet protocols, encrypted protocols, or email protocols.
  • the signal processing system 516 is additionally capable of providing visual or audible cues to the patient when the time arrives to conduct a measurement. These alerts may be augmented by requests, transmitted over the network 520 to the instrument, from the practitioner. Errors introduced within measurements and recordation within a manual system can thereby be eliminated with the electronically logged measurements. It will be appreciated that the system provides enhanced utility and measurement credibility in comparison to the use of an instrument that requires manual logging of the measurements and permits no practitioner interaction therewith.
  • Secretive non-compliance may also be eliminated as the patient is not conferred the responsibility of manually logging measurements.
  • the measurements collected within the instrument by the patient are capable of being transmitted to a practitioner, or a centralized computer, such that if a patient is not being diligent in conducting measurements, the practitioner may immediately contact the patient to reinforce the need for compliance.
  • the information provided over the network can be used to warn the practitioner when measurement readings appear abnormal, so that the practitioner may then investigate the situation and verify the status of the patient.
  • the invention has particular utility for patients preferring to receive direct guidance from a practitioner.
  • the information that flows between the patient and the practitioner increases the ability of the practitioner to provide knowledgeable patient guidance.
  • FIG. 19 illustrates the functional blocks of an embodiment of circuitry 532 for implementing the signal processing hardware 516 shown in FIG. 18 .
  • a network connection 534 connects to a network processing circuit, exemplified by an Internet Protocol (IP) circuit or processor 536 .
  • IP Internet Protocol
  • Numerous circuits are available for providing internet connectivity, such as the SX-StackTM chip from Scenix Semiconductor, and the iChipTM from Connect One Electronics. These integrated circuit chips and other available chips provide interface layers for supporting a Transmission Control Protocol/Internet Protocol (TCP/IP).
  • the internet protocol chip 536 has an interface 538 with a control processor section 540 , which preferably comprises a microcontroller or the like.
  • the control processor section 540 in turn has access to conventional memory 542 .
  • control processor 540 has an interface 544 with the instrumentation circuits 546 , which is in turn configured with an interface 548 to the analyte detection element 514 shown in FIG. 18 .
  • the network link provides a mechanism to facilitate performing and recording analyte measurements under supervision, while it additionally provides for periodic instrument calibration, and the ability to assure both measurement and calibration compliance.
  • Calibration data can be communicated from systems 500 in the field to the system manufacturer, or a service organization, so that the systems 500 and their calibrations may be logged.
  • the disclosed network link can be utilized to provide various mechanisms for assuring calibration compliance. Generally the mechanisms are of two categories, those that provide information or a warning about calibration, and those that prevent use of an instrument which is out of calibration.
  • systems 500 which have exceeded their calibration interval, or schedule are to be locked out from further use until recalibration is performed.
  • the system 500 may be set to operate for thirteen months for a given calibration interval of twelve months.
  • the system 500 may issue warnings prior to the expiration of calibration, and warnings of increased severity after the expiration of the calibration interval. If the system 500 , however, is not properly calibrated by the end of the thirteen months, normal operation ceases, thereby locking out the user after providing an appropriate error message in regard to the expired calibration. Upon recalibration, the calibrated operation interval is restored to provide for another thirteen month period of calibrated operation.
  • a “lockout command” can be sent to the system 500 over the network 520 from the manufacturer, practitioner or system maintenance organization, thereby engaging a lockout mode of the system 500 , so that operation may not be continued until the system 500 has been serviced.
  • the lockout command could also be sent in the event that the patient has not paid his or her bills, or be sent under other circumstances warranting lockout of the system 500 .
  • Another mode is that of locking out normal system use after the expiration of calibration, and allowing limited use thereafter only after a code, or token, has been downloaded from a supervisory site.
  • the code could for instance be provided when a calibration appointment is made for the system 500 .
  • the patient may be allowed to perform calibration checks of the system 500 .
  • the patient is supplied with a small set of analyte calibration standards which are read by the system 500 once it is put into a calibration mode and preferably connected to a remote site for supervising the process. Should the calibration check pass, wherein the instrument readings fall within normal levels, or be capable of being automatically adjusted thereto, the calibration interval may be extended. Failure of the calibration check would typically necessitate returning the system 500 for service.
  • FIG. 20 illustrates an embodiment of a process 550 for assuring calibration compliance within the analyte detection system 500 by utilizing a lockout mechanism.
  • the programmed instructions associated with the analyte detection system 500 are started at block 552 and initialized at block 554 , and a check is made on a lockout flag at block 556 to determine if it was set during a prior session by a command received via the network 520 , or due to being out of calibration. Not having been locked out from a prior session, the real-time clock (RTC) of the system 500 is read at block 558 and a calculation is performed at block 560 comparing the current date with the stored calibration date and calibration interval.
  • RTC real-time clock
  • a calculation is performed at block 564 comparing the current date with the stored calibration date and near-calibration interval. Near-calibration is checked at block 566 and, if calibration is to expire soon, then a user warning is issued at block 568 , preferably informing the user of the date of the upcoming expiration of the calibration interval.
  • the lockout flag is cleared at block 570 and processing within the system 500 continues with normal instrument functions being accessible at block 572 , along with calibration and other limited functions at block 574 , until the user shuts down the instrument and processing ends at block 576 .
  • a lockout flag would be set at block 578 , and the instrument functionality would thereby be restricted to execution of the calibration procedures and other limited functions at block 578 while the normal instrument functionality would not be accessible.
  • the calibration procedure itself may be augmented and improved by providing interaction between the servicing party and the manufacturer, such interaction may include providing guidance information to the servicing party, and the collection of measurement information by the manufacturer.
  • the present invention provides functionality beyond that which can be provided by a stand-alone analyte detection system, as the practitioner, or practitioner's office, is involved in the analyte measurement process to confer a portion of the benefits normally associated with an office visit.
  • the aforesaid description illustrates how these features provide the capability for two-way data flow which facilitates the conducting and recording of correct measurements while encouraging compliance in regard to both measurements and instrument calibration.
  • the data collected by the system may be utilized by others in addition to the practitioner, such as pharmaceutical companies which may be provided data access to alter or administer medication programs, and insurance companies which may require data regarding patient diligence according to the specified treatment program.
  • FIG. 21 illustrates one embodiment of a software update system 600 .
  • the software update system 600 includes an analyte detection system 602 that is connectable to a centralized computer 604 via a network 606 .
  • the analyte detection system 602 may comprise a portable, near-patient device that is capable of optically measuring analytes in a material sample.
  • Other examples of the analyte measuring device 602 include, but not limited to, the noninvasive system 10 discussed in this disclosure, the whole-blood system 200 discussed in this disclosure, or any other suitable invasive or noninvasive analyte detection system.
  • the term “computer” is a broad term and is used in its ordinary sense and refers, without limitation, to any programmable electronic device that can store, retrieve and process data.
  • computers include terminal devices, such as personal computers, workstations, servers, mini computers, main-frame computers, laptop computers, a network of individual computers, mobile computers, palm top computers, hand held computers, set top for a TV, an interactive television, an interactive kiosk, a personal digital assistant (“PDA”), an interactive wireless communications device, or a combination thereof.
  • PDA personal digital assistant
  • the computers may further possess storage devices, input devices such as a keyboard, mouse or scanner, and output devices such as a computer screen or a speaker.
  • the computers may serve as clients, servers, or a combination thereof.
  • network is a broad term and is used in its ordinary sense and refers, without limitation, to a series of points or nodes interconnected by communication paths, such as a group of interconnected computers. Examples of networks are the Internet, storage networks, local area networks and wide area networks.
  • the analyte detection system 602 includes a network interface 608 , a processor 610 and software 612 .
  • the centralized computer 604 includes at least one software update 614 .
  • the analyte detection system 602 may send information (e.g., analyte measurements) to the centralized computer 604 and the centralized computer 604 may send information (e.g., a software update 614 ) to the analyte measuring device 602 .
  • FIG. 21 Other architectures of networked systems, as known by those skilled in the art, may also be used in place of the architecture set forth in FIG. 21 .
  • the architecture shown in FIG. 18 and/or any of the variants thereof discussed above in connection with FIG. 18 . may be used instead of the system 600 shown in FIG. 21 .
  • one or more of the computers 528 / 528 ′/ 528 ′′/ 528 ′′′ may share the herein-described functions of, or replace entirely, the centralized computer 604 , in which case the centralized computer 604 may be omitted.
  • processor is a broad term and is used in its ordinary sense and refers, without limitation, to the part of a computer that operates on data. Examples of processors are central processing units (“CPU”) and microprocessors.
  • software is a broad term and is used in its ordinary sense and refers, without limitation, to instructions executable by a computer or related device. Examples of software include computer programs and operating systems.
  • software update or “update” is a broad term and is used in its ordinary sense and refers, without limitation, to information used by a computer to modify software.
  • a software update may be, for example, data, algorithms or programs.
  • a process flow diagram of a preferred software update process 700 is shown in FIG. 22 .
  • a user performs analyte measurements with the analyte detection system 602 .
  • the user may perform analyte measurements using the analyte detection system 602 at a remote location (e.g., the user's home).
  • the analyte detection system 602 detects analytes in a material sample and calculates an analyte concentration in accordance to the analyte detection system's software 612 . Additionally, the analyte detection system may issue alerts to the user, for example, in response to exceeded tolerances defined in the software 612 . The alerts may be visually displayed to the user and/or audibly sounded to the user. For instance, the analyte detection system 602 may issue an alert in response to an elapsed calibration time tolerance defined in the software 612 . Other alerts may be issued when the software or analyte-concentration calculation algorithm is out of date, or when the analyte concentration readings made by the detection system 602 are higher or lower than defined safe limits or ranges.
  • the software 612 is contained in the analyte detection system 602 internally. In another embodiment, the software 612 is retained external to the analyte detection system 602 .
  • the analyte detection system 602 is connected to the centralized computer 604 via the network 606 .
  • the network interface 608 readily connects the analyte detection system 602 to the network 606 .
  • the analyte measuring device 602 is, in one embodiment, in two-way communication with the centralized computer 604 .
  • the communication between the analyte measuring device 602 and the centralized computer 604 is established without any intervention from a user.
  • the process 700 then proceeds to a decision act 706 where the centralized computer 604 determines an update status for the analyte measuring device's software 612 .
  • Various conditions may trigger the centralized computer 604 to update the software 612 .
  • a condition for updating the software 612 is the presence of a new drug in the material sample (e.g., a new drug taken by the user) that alters the analyte calculations.
  • the centralized computer 604 determines whether the software 612 currently in use accounts for the use of the new drug.
  • a condition for updating the software 612 is where a new analyte-detection algorithm is developed. For example, the new algorithm may improve the accuracy or speed of the analyte detection system 602 over the software 612 currently in use.
  • a condition for updating the software 612 is where the analyte detection system 602 should display a new warning or where the monitoring device should display an existing warning in response to new or different events. The existing warning or the new warning may be displayed, for instance, in response to new information learned from a subset of a customer population.
  • other conditions not specifically mentioned herein may also trigger the centralized computer 604 to update the software 612 .
  • the update process 700 proceeds via the “No” path to an act 708 .
  • the user disconnects the analyte detection system 602 from the network and the software 612 is not updated.
  • the analyte detection system 602 operates in the same manner as the analyte detection system 602 previously operated in the act 702 .
  • the update process 700 proceeds via the “Yes” path to an act 710 .
  • the centralized computer 604 sends a software update 614 to the analyte detection system 602 .
  • the centralized computer 604 contains a database of various software updates 614 , and consequently, the centralized computer 604 selects the appropriate software update 614 from the database and then sends the software update 614 to the analyte detection system 602 .
  • the analyte detection system 602 receives (e.g. downloads) the software update 614 .
  • the analyte detection system 602 then preferably modifies the software 612 to an updated version of the software 612 .
  • the process then proceeds to an act 714 .
  • the user performs analyte measurements in accordance with the updated software 612 .
  • the analyte measuring device 602 operates differently than the manner in which the analyte measuring device 602 previously operated in act 702 .
  • the analyte detection system 602 may calculate analyte concentrations differently.
  • the analyte detection system 602 may displays new warnings to the user.
  • the analyte detection system 602 may display the same warnings, but the warnings are triggered by different events.
  • the analyte detection system 602 and/or the centralized computer 604 may be configured to encrypt any or all of the data that it transmits over the network 606 .
  • the recipient system 602 /computer 604 is configured to decrypt the encrypted data, to make the data available to the device and/or the user thereof.
  • Encryption also permits transmission of data over wireless networks or public networks such as the Internet while preserving confidentiality of the transmitted data.
  • the encryption and decryption may be performed in any suitable manner, with any suitable methods, software and/or hardware presently known or hereafter developed.
  • the encryption and/or decryption processes may be implemented in an algorithm or program instructions executable by, and residing within memory accessible by, the processor 610 of the analyte detection system 602 (in particular, by the signal processor 74 / 260 where the analyte detection system 602 comprises the noninvasive system 10 or the whole-blood system 200 , respectively).
  • the encryption and/or decryption processes may be implemented in an algorithm or program instructions executable by, and residing within memory accessible by, processing element(s) (not shown) of the computer 604 / 528 in question.
  • the software update process 700 has many advantages.
  • One advantage is that the software 612 of the analyte measuring device 602 may be updated without requiring significant user participation.
  • Another advantage is that the software 612 may be quickly and conveniently updated at a remote location (e.g., the user's home) rather than requiring the user to travel to, for example, a doctor's office or other administrative center.

Abstract

An analyte concentration monitoring system having network-based communication features which provide a link between an analyte detection system and a centralized computer. The analyte detection system has a processor that calculates analyte concentration in accordance with software executable by the processor. Under certain conditions, the software needs to be updated. Accordingly, when the analyte detection system is connected to the centralized computer, the centralized computer determines whether a software update is needed. If a software update is needed, then the centralized computer conveniently provides the software update to the analyte detection system without intervention from a user.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • This invention pertains, in certain embodiments, to medical equipment for measuring blood analyte levels, and more particularly to a blood analyte measuring instrument having internet-based communication features.
  • 2. Description of the Related Art
  • A patient, having been taught how to use an existing portable analyte monitor is generally required thereafter to independently conduct and record his or her own measurements. Furthermore, the patient typically is required to both record and assess the measurements without benefit from a practitioner or supervising authority. Numerous errors can arise from these unsupervised procedures that may result in serious health risks for patients which knowingly, or inadvertently, are not in compliance with medical directives.
  • Typically, patients using an analyte monitor are given a schedule of measurements they are required to take and a notebook in which to record the measurements. Patients often forget, or in some instances forego, conducting and correctly recording their analyte levels as measured by the instrument. If patients skip a measurement they may even elect to write down a “likely” number in the notebook as if such a measurement had been taken. Patient interaction with such a manual analyte monitoring instrument therefore provides no assurance of correct measurement and recordation. Furthermore, patients in a myriad of situations may require additional information and assistance with regard to the use and maintenance of their analyte measurement instrument.
  • In addition, to assure analyte measurement accuracy, a measuring instrument may require periodic calibration or software updates. Assuring calibration compliance on instruments or updating the instrument's software in the field is burdensome.
  • SUMMARY OF THE INVENTION
  • Therefore, a need exists for an analyte monitoring system that encourages patient compliance and facilitates equipment calibration and software updates. The present invention, in certain embodiments, satisfies those needs, as well as others, and overcomes deficiencies in current monitoring systems and procedures.
  • The present invention, in certain embodiments, is an analyte measuring device with remote communications capabilities. According to an aspect of the invention, a data link is provided between the equipment and a centralized station, or server. The centralized station can monitor important information, such as: equipment calibration, the diligence of a patient taking and recording measurements according to a schedule, whether a software update is needed and the actual measurements taken by the patient. The centralized station is preferably capable of forwarding information to the patient's physician for evaluation. In addition, the centralized station can have optional capability of locking out the patient if the patient has not paid his or her bills. According to another aspect of the invention, the information is communicated from the analyte measuring device directly to the physician. Accordingly to another aspect, the centralized station can determine an update status of the analyte measuring device's software and automatically send a software update to the analyte measuring device. As can be seen, therefore, the preferred embodiments link the monitoring activities performed by the patient and the assessment of those activities by the physician while reducing the chance of human error introduced into the long-term monitoring and treatment process.
  • By way of example, and not of limitation, a non-invasive subsurface spectrophotometer instrument equipped with a communications link according to the invention takes the analyte measurements and communicates them over a network, such as the internet. The spectrophotometer instrument comprises data communication circuitry, such as dial-up circuitry, and additional session control protocols which integrate a number of the functions within the instrument for communication over a network connection. A destination site, or sites, on the network are configured to receive information from the instrument and to transmit information and services.
  • In accordance with yet another embodiment, an analyte concentration monitoring system comprises an analyte detection system having a processor that calculates analyte concentration in accordance with software executable by the processor. The monitoring system further comprises a network interface that is configured to provide connectivity to a computer. The analyte detection system is configured to receive an update to the software from the computer.
  • In accordance with yet another embodiment, a method of automatically updating software on an analyte detection system, comprises connecting an analyte detection system to a computer via a network, and checking, in the computer, an update status of software included in the analyte detection system. The method further comprises sending, when the update status indicates that a software update is needed, the software update to the analyte detection system via the network without intervention from a user. The method further comprises updating, in the analyte detection system, the software with the software update.
  • In accordance with yet another embodiment, an analyte concentration monitoring system comprises an analyte detection system comprising a processor, a software, and a network interface. The processor is configured to calculate analyte concentration in accordance to the software, and the network interface is configured to provide connectivity to a computer. The analyte detection system is configured to update the software according to instructions from the computer.
  • In accordance with yet another embodiment, a method of automatically updating software on an analyte detection system comprises connecting an analyte detection system to a computer via a network. The method further comprises checking, in the computer, an update status of software included in the analyte detection system. The method further comprises encrypting, when the update status indicates that a software update is needed, the software update and sending the software update to the analyte detection system via the network. The method further comprises updating, in the analyte detection system, the software with the software update.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a schematic view of a noninvasive optical detection system.
  • FIG. 2 is a perspective view of a window assembly for use with the noninvasive detection system.
  • FIG. 2A is a plan view of another embodiment of a window assembly for use with the noninvasive detection system.
  • FIG. 3 is an exploded schematic view of another embodiment of a window assembly for use with the noninvasive detection system.
  • FIG. 4 is a plan view of the window assembly connected to a cooling system.
  • FIG. 5 is a plan view of the window assembly connected to a cold reservoir.
  • FIG. 6 is a cutaway view of a heat sink for use with the noninvasive detection system.
  • FIG. 6A is a cutaway perspective view of a lower portion of the noninvasive detection system of FIG. 1.
  • FIG. 6B is an exploded perspective view of a window mounting system for use with the noninvasive optical detection system.
  • FIG. 6C is a partial plan view of the window mounting system of FIG. 6B.
  • FIG. 6D is a sectional view of the window mounting system of FIG. 6C.
  • FIG. 7 is a schematic view of a control system for use with the noninvasive optical detection system.
  • FIG. 8 depicts a first methodology for determining the concentration of an analyte of interest.
  • FIG. 9 depicts a second methodology for determining the concentration of an analyte of interest.
  • FIG. 10 depicts a third methodology for determining the concentration of an analyte of interest.
  • FIG. 11 depicts a fourth methodology for determining the concentration of an analyte of interest.
  • FIG. 12 depicts a fifth methodology for determining the concentration of an analyte of interest.
  • FIG. 13 is a schematic view of a reagentless whole-blood detection system.
  • FIG. 14 is a perspective view of one embodiment of a cuvette for use with the reagentless whole-blood detection system.
  • FIG. 15 is a plan view of another embodiment of a cuvette for use with the reagentless whole-blood detection system.
  • FIG. 16 is a disassembled plan view of the cuvette shown in FIG. 15.
  • FIG. 16A is an exploded perspective view of the cuvette of FIG. 15.
  • FIG. 17 is a side view of the cuvette of FIG. 15.
  • FIG. 18 is a functional block diagram showing an analyte monitoring system with network connectivity.
  • FIG. 19 is a block diagram of the electronic circuits within the analyte monitoring system of FIG. 18.
  • FIG. 20 is a flowchart exemplifying calibration lockout according to one embodiment disclosed herein.
  • FIG. 21 is a block diagram of components of an analyte monitoring system having software update capabilities.
  • FIG. 22 is a flowchart exemplifying updating a analyte monitoring device's software according to another embodiment disclosed herein.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The devices and methods summarized above are described in greater detail below. Part I contains a description of a number of analyte detection systems, including a noninvasive system and a whole-blood system, as well as associated methods of analyte detection. Parts II and III includes a discussion of further systems and methods for, inter alia, updating software executed by analyte detection systems such as (but not limited to) those described in Part I. Accordingly, the systems and methods described in Parts II and III may (but need not) be employed by, within and/or in connection with those described in Part I.
  • Although certain preferred embodiments and examples are disclosed below, it will be understood by those skilled in the art that the invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. Thus, it is intended that the scope of the invention herein disclosed should not be limited by the particular disclosed embodiments described below.
  • I. Overview of Analyte Detection Systems
  • Disclosed herein are analyte detection systems, including a noninvasive system discussed largely in part A below and a whole-blood system discussed largely in part B below. Also disclosed are various methods, including methods for detecting the concentration of an analyte in a material sample. Both the noninvasive system/method and the whole-blood system/method can employ optical measurement. As used herein with reference to measurement apparatus and methods, “optical” is a broad term and is used in its ordinary sense and refers, without limitation, to identification of the presence or concentration of an analyte in a material sample without requiring a chemical reaction to take place. As discussed in more detail below, the two approaches each can operate independently to perform an optical analysis of a material sample. The two approaches can also be combined in an apparatus, or the two approaches can be used together to perform different steps of a method.
  • In one embodiment, the two approaches are combined to perform calibration of an apparatus, e.g., of an apparatus that employs a noninvasive approach. In another embodiment, an advantageous combination of the two approaches performs an invasive measurement to achieve greater accuracy and a whole-blood measurement to minimize discomfort to the patient. For example, the whole-blood technique may be more accurate than the noninvasive technique at certain times of the day, e.g., at certain times after a meal has been consumed, or after a drug has been administered.
  • It should be understood, however, that any of the disclosed devices may be operated in accordance with any suitable detection methodology, and that any disclosed method may be employed in the operation of any suitable device. Furthermore, the disclosed devices and methods are applicable in a wide variety of situations or modes of operation, including but not limited to invasive, noninvasive, intermittent or continuous measurement, subcutaneous implantation, wearable detection systems, or any combination thereof.
  • Any method which is described and illustrated herein is not limited to the exact sequence of acts described, nor is it necessarily limited to the practice of all of the acts set forth. Other sequences of events or acts, or less than all of the events, or simultaneous occurrence of the events, may be utilized in practicing the method(s) in question.
  • A. Noninvasive System
  • 1. Monitor Structure
  • FIG. 1 depicts a noninvasive optical detection system (hereinafter “noninvasive system”) 10 in a presently preferred configuration. The depicted noninvasive system 10 is particularly suited for noninvasively detecting the concentration of an analyte in a material sample S, by observing the infrared energy emitted by the sample, as will be discussed in further detail below.
  • As used herein, the term “noninvasive” is a broad term and is used in its ordinary sense and refers, without limitation, to analyte detection devices and methods which have the capability to determine the concentration of an analyte in in-vivo tissue samples or bodily fluids. It should be understood, however, that the noninvasive system 10 disclosed herein is not limited to noninvasive use, as the noninvasive system 10 may be employed to analyze an in-vitro fluid or tissue sample which has been obtained invasively or noninvasively. As used herein, the term “invasive” (or, alternatively, “traditional”) is a broad term and is used in its ordinary sense and refers, without limitation, to analyte detection methods which involve the removal of fluid samples through the skin. As used herein, the term “material sample” is a broad term and is used in its ordinary sense and refers, without limitation, to any collection of material which is suitable for analysis by the noninvasive system 10. For example, the material sample S may comprise a tissue sample, such as a human forearm, placed against the noninvasive system 10. The material sample S may also comprise a volume of a bodily fluid, such as whole blood, blood component(s), interstitial fluid or intercellular fluid obtained invasively, or saliva or urine obtained noninvasively, or any collection of organic or inorganic material. As used herein, the term “analyte” is a broad term and is used in its ordinary sense and refers, without limitation, to any chemical species the presence or concentration of which is sought in the material sample S by the noninvasive system 10. For example, the analyte(s) which may be detected by the noninvasive system 10 include but not are limited to glucose, ethanol, insulin, water, carbon dioxide, blood oxygen, cholesterol, bilirubin, ketones, fatty acids, lipoproteins, albumin, urea, creatinine, white blood cells, red blood cells, hemoglobin, oxygenated hemoglobin, carboxyhemoglobin, organic molecules, inorganic molecules, pharmaceuticals, cytochrome, various proteins and chromophores, microcalcifications, electrolytes, sodium, potassium, chloride, bicarbonate, and hormones. As used herein to describe measurement techniques, the term “continuous” is a broad term and is used in its ordinary sense and refers, without limitation, to the taking of discrete measurements more frequently than about once every 10 minutes, and/or the taking of a stream or series of measurements or other data over any suitable time interval, for example, over an interval of one to several seconds, minutes, hours, days, or longer. As used herein to describe measurement techniques, the term “intermittent” is a broad term and is used in its ordinary sense and refers, without limitation, to the taking of measurements less frequently than about once every 10 minutes.
  • The noninvasive system 10 preferably comprises a window assembly 12, although in some embodiments the window assembly 12 may be omitted. One function of the window assembly 12 is to permit infrared energy E to enter the noninvasive system 10 from the sample S when it is placed against an upper surface 12a of the window assembly 12. The window assembly 12 includes a heater layer (see discussion below) which is employed to heat the material sample S and stimulate emission of infrared energy therefrom. A cooling system 14, preferably comprising a Peltier-type thermoelectric device, is in thermally conductive relation to the window assembly 12 so that the temperature of the window assembly 12 and the material sample S can be manipulated in accordance with a detection methodology discussed in greater detail below. The cooling system 14 includes a cold surface 14 a which is in thermally conductive relation to a cold reservoir 16 and the window assembly 12, and a hot surface 14 b which is in thermally conductive relation to a heat sink 18.
  • As the infrared energy E enters the noninvasive system 10, it first passes through the window assembly 12, then through an optical mixer 20, and then through a collimator 22. The optical mixer 20 preferably comprises a light pipe having highly reflective inner surfaces which randomize the directionality of the infrared energy E as it passes therethrough and reflects against the mixer walls. The collimator 22 also comprises a light pipe having highly-reflective inner walls, but the walls diverge as they extend away from the mixer 20. The divergent walls cause the infrared energy E to tend to straighten as it advances toward the wider end of the collimator 22, due to the angle of incidence of the infrared energy when reflecting against the collimator walls.
  • From the collimator 22 the infrared energy E passes through an array of filters 24, each of which allows only a selected wavelength or band of wavelengths to pass therethrough. These wavelengths/bands are selected to highlight or isolate the absorptive effects of the analyte of interest in the detection methodology discussed in greater detail below. Each filter 24 is preferably in optical communication with a concentrator 26 and an infrared detector 28. The concentrators 26 have highly reflective, converging inner walls which concentrate the infrared energy as it advances toward the detectors 28, increasing the density of the energy incident upon the detectors 28.
  • The detectors 28 are in electrical communication with a control system 30 which receives electrical signals from the detectors 28 and computes the concentration of the analyte in the sample S. The control system 30 is also in electrical communication with the window 12 and cooling system 14, so as to monitor the temperature of the window 12 and/or cooling system 14 and control the delivery of electrical power to the window 12 and cooling system 14.
      • a. Window Assembly
  • A preferred configuration of the window assembly 12 is shown in perspective, as viewed from its underside (in other words, the side of the window assembly 12 opposite the sample S), in FIG. 2. The window assembly 12 generally comprises a main layer 32 formed of a highly infrared-transmissive material and a heater layer 34 affixed to the underside of the main layer 32. The main layer 32 is preferably formed from diamond, most preferably from chemical-vapor-deposited (“CVD”) diamond, with a preferred thickness of about 0.25 millimeters. In other embodiments alternative materials which are highly infrared-transmissive, such as silicon or germanium, may be used in forming the main layer 32.
  • The heater layer 34 preferably comprises bus bars 36 located at opposing ends of an array of heater elements 38. The bus bars 36 are in electrical communication with the elements 38 so that, upon connection of the bus bars 36 to a suitable electrical power source (not shown) a current may be passed through the elements 38 to generate heat in the window assembly 12. The heater layer 34 may also include one or more temperature sensors (not shown), such as thermistors or resistance temperature devices (RTDs), to measure the temperature of the window assembly 12 and provide temperature feedback to the control system 30 (see FIG. 1).
  • Still referring to FIG. 2, the heater layer 34 preferably comprises a first adhesion layer of gold or platinum (hereinafter, referred to as the “gold” layer) deposited over an alloy layer which is applied to the main layer 32. The alloy layer comprises a material suitable for implementation of the heater layer 34, such as, by way of example, 10/90 titanium/tungsten, titanium/platinum, nickel/chromium, or other similar material. The gold layer preferably has a thickness of about 4000 Å, and the alloy layer preferably has a thickness ranging between about 300 Å and about 500 Å. The gold layer and/or the alloy layer may be deposited onto the main layer 32 by chemical deposition including, but not necessarily limited to, vapor deposition, liquid deposition, plating, laminating, casting, sintering, or other forming or deposition methodologies well known to those or ordinary skill in the art. If desired, the heater layer 34 may be covered with an electrically insulating coating which also enhances adhesion to the main layer 32. One preferred coating material is aluminum oxide. Other acceptable materials include, but are not limited to, titanium dioxide or zinc selenide.
  • The heater layer 34 may incorporate a variable pitch distance between centerlines of adjacent heater elements 38 to maintain a constant power density, and promote a uniform temperature, across the entire layer 34. Where a constant pitch distance is employed, the preferred distance is at least about 50-100 microns. Although the heater elements 38 generally have a preferred width of about 25 microns, their width may also be varied as needed for the same reasons stated above.
  • Alternative structures suitable for use as the heater layer 34 include, but are not limited to, thermoelectric heaters, radiofrequency (RF) heaters, infrared radiation heaters, optical heaters, heat exchangers, electrical resistance heating grids, wire bridge heating grids, or laser heaters. Whichever type of heater layer is employed, it is preferred that the heater layer obscures about 10% or less of the window assembly 12.
  • In a preferred embodiment, the window assembly 12 comprises substantially only the main layer 32 and the heater layer 34. Thus, when installed in an optical detection system such as the noninvasive system 10 shown in FIG. 1, the window assembly 12 will facilitate a minimally obstructed optical path between a (preferably flat) upper surface 12 a of the window assembly 12 and the infrared detectors 28 of the noninvasive system 10. The optical path 32 in the preferred noninvasive system 10 proceeds only through the main layer 32 and heater layer 34 of the window assembly 12 (including any antireflective, index-matching, electrical insulating or protective coatings applied thereto or placed therein), through the optical mixer 20 and collimator 22 and to the detectors 28.
  • FIG. 2A shows another embodiment of the window assembly 12, that may be used in place of the window assembly 12 depicted in FIG. 2. The window assembly 12 shown in FIG. 2A may be similar to that shown in FIG. 2, except as described below. In the embodiment of FIG. 2A the main layer 32 has a preferred thickness of up to about 0.012″ and more preferably about 0.010″ or less. The heater layer 34 may also include one or more resistance temperature devices (RTD's) 55 to measure the temperature of the window assembly 12 and provide temperature feedback to a control system 30. The RTDs 55 terminate in RTD connection pads 57.
  • In the embodiment of FIG. 2A, the heater elements 38 are typically provided with a width of about 25 microns. The pitch distance separating centerlines of adjacent heater elements 38 may be reduced, and/or the width of the heater elements 38 may be increased, in the regions of the window assembly 12 near the point(s) of contact with the thermal diffuser 410 (see FIGS. 6B-6D and discussion below). This arrangement advantageously promotes an isothermal temperature profile at the upper surface of the main layer 32 despite thermal contact with the thermal diffuser.
  • The embodiment shown in FIG. 2A includes a plurality of heater elements 38 of substantially equal width which are variably spaced across the width of the main layer 32. In the embodiment of FIG. 2A, the centerlines of the heater elements 38 are spaced at a first pitch distance of about 0.0070″ at peripheral portions 34 a of the heater layer 34, and at a second pitch distance of about 0.015″ at a central portion 34 b of the main layer 32. The heater elements 38 closest to the center are preferably sufficiently spaced to allow the RTDs 55 to extend therebetween. In the embodiment of FIG. 2A, the main layer 32 includes peripheral regions 32 a which extend about 0.053″ from the outermost heater element on each side of the heater layer 34 to the adjacent edge of the main layer 32. As shown, the bus bars 36 are preferably configured and segmented to allow space for the RTDs 55 and the RTD connection pads 57, in intermediate gaps 36 a. The RTDs 55 preferably extend into the array of heater elements 38 by distance that is slightly longer than half of the length of an individual heater element 38. In alternative embodiments, the RTDs 55 may be located at the edges of the main layer 32, or at other locations as desired for a particular noninvasive system.
  • With continued reference to FIG. 2A, the peripheral regions of the main layer 32 may include metallized edge portions 35 for facilitating connection to the diffuser 410 (discussed below in connection with FIGS. 6B-6D). The metallized edge portions 35 may be formed by the same or similar processes used in forming the heater elements 38 and RTDs 55. In the embodiment of FIG. 2A, the edge portions 35 are typically between about 0.040″ and about 0.060″ wide by about 0.450″ and about 0.650″ long, and in one embodiment, they are about 0.050″ by about 0.550″. Other dimensions may be appropriately used so long as the window assembly 12 may be joined in thermal communication with the diffuser 410 as needed.
  • In the embodiment shown in FIG. 2A, the main layer 32 is about 0.690″ long by about 0.571″ wide, and the heater layer (excluding the metallized edge portions 35) is about 0.640″ long by about 0.465″ wide. The main layer 32 is about 0.010″-0.012″ thick, and is advantageously thinner than about 0.010″ where possible. Each heater element 38 is about 0.570″ long, and each peripheral region 34 a is about 0.280″ wide. These dimensions are merely exemplary; of course, other dimensions may be used as desired.
  • FIG. 3 depicts an exploded side view of an alternative configuration for the window assembly 12, which may be used in place of the configuration shown in FIG. 2. The window assembly 12 depicted in FIG. 3 includes near its upper surface (the surface intended for contact with the sample S) a highly infrared-transmissive, thermally conductive spreader layer 42. Underlying the spreader layer 42 is a heater layer 44. A thin electrically insulating layer (not shown), such as layer of aluminum oxide, titanium dioxide or zinc selenide, may be disposed between the heater layer 44 and the spreader layer 42. (An aluminum oxide layer also increases adhesion of the heater layer 44 to the spreader layer 42.) Adjacent to the heater layer 44 is a thermal insulating and impedance matching layer 46. Adjacent to the thermal insulating layer 46 is a thermally conductive inner layer 48. The spreader layer 42 is coated on its top surface with a thin layer of protective coating 50. The bottom surface of the inner layer 48 is coated with a thin overcoat layer 52. Preferably, the protective coating 50 and the overcoat layer 52 have antireflective properties.
  • The spreader layer 42 is preferably formed of a highly infrared-transmissive material having a high thermal conductivity sufficient to facilitate heat transfer from the heater layer 44 uniformly into the material sample S when it is placed against the window assembly 12. Other effective materials include, but are not limited to, CVD diamond, diamondlike carbon, gallium arsenide, germanium, and other infrared-transmissive materials having sufficiently high thermal conductivity. Preferred dimensions for the spreader layer 42 are about one inch in diameter and about 0.010 inch thick. As shown in FIG. 3, a preferred embodiment of the spreader layer 42 incorporates a beveled edge. Although not required, an approximate 45-degree bevel is preferred.
  • The protective layer 50 is intended to protect the top surface of the spreader layer 42 from damage. Ideally, the protective layer is highly infrared-transmissive and highly resistant to mechanical damage, such as scratching or abrasion. It is also preferred that the protective layer 50 and the overcoat layer 52 have high thermal conductivity and antireflective and/or index-matching properties. A satisfactory material for use as the protective layer 50 and the overcoat layer 52 is the multi-layer Broad Band Anti-Reflective Coating produced by Deposition Research Laboratories, Inc. of St. Charles, Mo. Diamondlike carbon coatings are also suitable.
  • Except as noted below, the heater layer 44 is generally similar to the heater layer 34 employed in the window assembly shown in FIG. 2. Alternatively, the heater layer 44 may comprise a doped infrared-transmissive material, such as a doped silicon layer, with regions of higher and lower resistivity. The heater layer 44 preferably has a resistance of about 2 ohms and has a preferred thickness of about 1,500 angstroms. A preferred material for forming the heater layer 44 is a gold alloy, but other acceptable materials include, but are not limited to, platinum, titanium, tungsten, copper, and nickel.
  • The thermal insulating layer 46 prevents the dissipation of heat from the heater element 44 while allowing the cooling system 14 to effectively cool the material sample S (see FIG. 1). This layer 46 comprises a material having thermally insulative (e.g., lower thermal conductivity than the spreader layer 42) and infrared transmissive qualities. A preferred material is a germanium-arsenic-selenium compound of the calcogenide glass family known as AMTIR-1 produced by Amorphous Materials, Inc. of Garland, Tex. The pictured embodiment has a diameter of about 0.85 inches and a preferred thickness in the range of about 0.005 to about 0.010 inches. As heat generated by the heater layer 44 passes through the spreader layer 42 into the material sample S, the thermal insulating layer 46 insulates this heat.
  • The inner layer 48 is formed of thermally conductive material, preferably crystalline silicon formed using a conventional floatzone crystal growth method. The purpose of the inner layer 48 is to serve as a cold-conducting mechanical base for the entire layered window assembly.
  • The overall optical transmission of the window assembly 12 shown in FIG. 3 is preferably at least 70%. The window assembly 12 of FIG. 3 is preferably held together and secured to the noninvasive system 10 by a holding bracket (not shown). The bracket is preferably formed of a glass-filled plastic, for example Ultem 2300, manufactured by General Electric. Ultem 2300 has low thermal conductivity which prevents heat transfer from the layered window assembly 12.
      • b. Cooling System
  • The cooling system 14 (see FIG. 1) preferably comprises a Peltier-type thermoelectric device. Thus, the application of an electrical current to the preferred cooling system 14 causes the cold surface 14 a to cool and causes the opposing hot surface 14 b to heat up. The cooling system 14 cools the window assembly 12 via the situation of the window assembly 12 in thermally conductive relation to the cold surface 14 a of the cooling system 14. It is contemplated that the cooling system 14, the heater layer 34, or both, can be operated to induce a desired time-varying temperature in the window assembly 12 to create an oscillating thermal gradient in the sample S, in accordance with various analyte-detection methodologies discussed herein.
  • Preferably, the cold reservoir 16 is positioned between the cooling system 14 and the window assembly 12, and functions as a thermal conductor between the system 14 and the window assembly 12. The cold reservoir 16 is formed from a suitable thermally conductive material, preferably brass. Alternatively, the window assembly 12 can be situated in direct contact with the cold surface 14 a of the cooling system 14.
  • In alternative embodiments, the cooling system 14 may comprise a heat exchanger through which a coolant, such as air, nitrogen or chilled water, is pumped, or a passive conduction cooler such as a heat sink. As a further alternative, a gas coolant such as nitrogen may be circulated through the interior of the noninvasive system 10 so as to contact the underside of the window assembly 12 (see FIG. 1) and conduct heat therefrom.
  • FIG. 4 is a top schematic view of a preferred arrangement of the window assembly 12 (of the types shown in FIG. 2 or 2A) and the cold reservoir 16, and FIG. 5 is a top schematic view of an alternative arrangement in which the window assembly 12 directly contacts the cooling system 14. The cold reservoir 16/cooling system 14 preferably contacts the underside of the window assembly 12 along opposing edges thereof, on either side of the heater layer 34. With thermal conductivity thus established between the window assembly 12 and the cooling system 14, the window assembly can be cooled as needed during operation of the noninvasive system 10. In order to promote a substantially uniform or isothermal temperature profile over the upper surface of the window assembly 12, the pitch distance between centerlines of adjacent heater elements 38 may be made smaller (thereby increasing the density of heater elements 38) near the region(s) of contact between the window assembly 12 and the cold reservoir 16/cooling system 14. As a supplement or alternative, the heater elements 38 themselves may be made wider near these regions of contact. As used herein, “isothermal” is a broad term and is used in its ordinary sense and refers, without limitation, to a condition in which, at a given point in time, the temperature of the window assembly 12 or other structure is substantially uniform across a surface intended for placement in thermally conductive relation to the material sample S. Thus, although the temperature of the structure or surface may fluctuate over time, at any given point in time the structure or surface may nonetheless be isothermal.
  • The heat sink 18 drains waste heat from the hot surface 14 b of the cooling system 16 and stabilizes the operational temperature of the noninvasive system 10. The preferred heat sink 18 (see FIG. 6) comprises a hollow structure formed from brass or any other suitable material having a relatively high specific heat and high heat conductivity. The heat sink 18 has a conduction surface 18a which, when the heat sink 18 is installed in the noninvasive system 18, is in thermally conductive relation to the hot surface 14 b of the cooling system 14 (see FIG. 1). A cavity 54 is formed in the heat sink 18 and preferably contains a phase-change material (not shown) to increase the capacity of the sink 18. A preferred phase change material is a hydrated salt, such as calciumchloride hexahydrate, available under the name TH29 from PCM Thermal Solutions, Inc., of Naperville, Ill. Alternatively, the cavity 54 may be omitted to create a heat sink 18 comprising a solid, unitary mass. The heat sink 18 also forms a number of fins 56 to further increase the conduction of heat from the sink 18 to surrounding air.
  • Alternatively, the heat sink 18 may be formed integrally with the optical mixer 20 and/or the collimator 22 as a unitary mass of rigid, heat-conductive material such as brass or aluminum. In such a heat sink, the mixer 20 and/or collimator 22 extend axially through the heat sink 18, and the heat sink defines the inner walls of the mixer 20 and/or collimator 22. These inner walls are coated and/or polished to have appropriate reflectivity and nonabsorbance in infrared wavelengths as will be further described below. Where such a unitary heat sink-mixer-collimator is employed, it is desirable to thermally insulate the detector array from the heat sink.
  • It should be understood that any suitable structure may be employed to heat and/or cool the material sample S, instead of or in addition to the window assembly 12/cooling system 14 disclosed above, so long a proper degree of cycled heating and/or cooling are imparted to the material sample S. In addition other forms of energy, such as but not limited to light, radiation, chemically induced heat, friction and vibration, may be employed to heat the material sample S. It will be further appreciated that heating of the sample can achieved by any suitable method, such as convection, conduction, radiation, etc.
      • c. Window Mounting System
  • FIG. 6B illustrates an exploded view of a window mounting system 400 which, in one embodiment, is employed as part of the noninvasive system 10 disclosed above. Where employed in connection with the noninvasive system 10, the window mounting system 400 supplements or, where appropriate, replaces any of the window assembly 12, cooling system 14, cold reservoir 16 and heat sink 18 shown in FIG. 1. In one embodiment, the window mounting system 400 is employed in conjunction with the window assembly 12 depicted in FIG. 2A; in alternative embodiments, the window assemblies shown in FIGS. 2 and 3 and described above may also be used in conjunction with the window mounting system 400 illustrated in FIG. 6B.
  • In the window mounting system 400, the window assembly 12 is physically and electrically connected (typically by soldering) to a first printed circuit board (“first PCB”) 402. The window assembly 12 is also in thermally conductive relation (typically by contact) to a thermal diffuser 410. The window assembly may also be fixed to the diffuser 410 by soldering.
  • The thermal diffuser 410 generally comprises a heat spreader layer 412 which, as mentioned, preferably contacts the window assembly 12, and a conductive layer 414 which is typically soldered to the heat spreader layer 412. The conductive layer 414 may then be placed in direct contact with a cold side 418 a of a thermoelectric cooler (TEC) 418 or other cooling device. The TEC 418, which in one embodiment comprises a 25 W TEC manufactured by MELCOR, is in electrical communication with a second PCB 403, which includes TEC power leads 409 and TEC power terminals 411 for connection of the TEC 418 to an appropriate power source (not shown). The second PCB 403 also includes contacts 408 for connection with RTD terminals 407 (see FIG. 6C) of the first PCB 402. A heat sink 419, which may take the form of the illustrated water jacket, the heat sink 18 shown in FIG. 6, any other heat sink structures mentioned herein, or any other appropriate device, is in thermal communication with a hot side 418 b of the TEC 418 (or other cooling device), in order to remove any excess heat created by the TEC 418.
  • FIG. 6C illustrates a plan view of the interconnection of the window assembly 12, the first PCB 402, the diffuser 410 and the thermoelectric cooler 418. The first PCB includes RTD bonding leads 406 and heater bonding pads 404 which permit attachment of the RTDs 55 and bus bars 36, respectively, of the window assembly 12 to the first PCB 402 via soldering or other conventional techniques. Electrical communication is thus established between the heater elements 38 of the heater layer 34, and heater terminals 405 formed in the heater bonding pads 404. Similarly, electrical communication is established between the RTDs 55 and RTD terminals 407 formed at the ends of the RTD bonding leads 406. Electrical connections can be established with the heater elements 38 and the RTDs 55 via simple connection to the terminals 405, 407 of the first PCB 402.
  • With further reference to FIGS. 2A and 6B-6C, the heat spreader layer 412 of the thermal diffuser 410 contacts the underside of the main layer 32 of the window assembly 12 via a pair of rails 416. The rails 416 may contact the main layer 32 at the metallized edge portions 35, or at any other appropriate location. The physical and thermal connection between the rails 416 and the window main layer 32 may be achieved by soldering, as indicated above. Alternatively, the connection may be achieved by an adhesive such as epoxy, or any other appropriate method. The material chosen for the window main layer 32 is preferably sufficiently thermally conductive that heat may be quickly removed from the main layer 32 through the rails 416, the diffuser 410, and the TEC 128.
  • FIG. 6D shows a cross-sectional view of the assembly of FIG. 6C through line 22-22. As can be seen in FIG. 6D, the window assembly 12 contacts the rails 416 of the heat spreader layer 412. The conductive layer 414 underlies the spreader layer 412 and may comprise protrusions 426 configured to extend through openings 424 formed in the spreader layer 412. The openings 424 and protrusions 426 are sized to leave sufficient expansion space therebetween, to allow expansion and contraction of the conductive layer 414 without interference with, or causing deformation of, the window assembly 12 or the heat spreader layer 412. Moreover, the protrusions 426 and openings 424 coact to prevent displacement of the spreader layer 412 with respect to the conductive layer 414 as the conductive layer 414 expands and contracts.
  • The thermal diffuser 410 provides a thermal impedance between the TEC 418 and the window assembly 12, which impedance is selected to drain heat from the window assembly at a rate proportional to the power output of the heater layer 34. In this way, the temperature of the main layer 32 can be rapidly cycled between a “hot” and a “cold” temperatures, thereby allowing a time-varying thermal gradient to be induced in a sample S placed against the window assembly 12.
  • The heat spreader layer 412 is preferably made of a material which has substantially the same coefficient of thermal expansion as the material used to form the window assembly main layer 32, within the expected operating temperature range. Preferably, both the material used to form the main layer 32 and the material used to form the heat spreader layer 412 have substantially the same, extremely low, coefficient of thermal expansion. For this reason, CVD diamond is preferred for the main layer 32 (as mentioned above); with a CVD diamond main layer 32 the preferred material for the heat spreader layer 412 is Invar. Invar advantageously has an extremely low coefficient of thermal expansion and a relatively high thermal conductivity. Because Invar is a metal, the main layer 32 and the heat spreader layer 412 can be thermally bonded to one another with little difficulty. Alternatively, other materials may be used for the heat spreader layer 412; for example, any of a number of glass and ceramic materials with low coefficients of thermal expansion may be employed.
  • The conductive layer 414 of the thermal diffuser 410 is typically a highly thermally conductive material such as copper (or, alternatively, other metals or non-metals exhibiting comparable thermal conductivities). The conductive layer 414 is typically soldered or otherwise bonded to the underside of the heat spreader layer 412.
  • In the illustrated embodiment, the heat spreader layer 412 may be constructed according to the following dimensions, which are to be understood as exemplary; accordingly the dimensions may be varied as desired. The heat spreader layer 412 has an overall length and width of about 1.170″, with a central opening of about 0.590″ long by 0.470″ wide. Generally, the heat spreader layer 412 is about 0.030″ thick; however, the rails 416 extend a further 0.045″ above the basic thickness of the heat spreader layer 412. Each rail 416 has an overall length of about 0.710″; over the central 0.525″ of this length each rail 416 is about 0.053″ wide. On either side of the central width each rail 416 tapers, at a radius of about 0.6″, down to a width of about 0.023″. Each opening 424 is about 0.360″ long by about 0.085″ wide, with comers rounded at a radius of about 0.033″.
  • In the illustrated embodiment, conductive layer 414 may be constructed according to the following dimensions, which are to be understood as exemplary; accordingly the dimensions may be varied as desired. The conductive layer 414 has an overall length and width of about 1.170″, with a central opening of about 0.590″ long by 0.470″ wide. Generally, the conductive layer 412 is about 0.035″ thick; however, the protrusions 426 extend a further 0.075″-0.085″ above the basic thickness of the conductive layer 414. Each protrusion 426 is about 0.343″ long by about 0.076″ wide, with corners rounded at a radius of about 0.035″.
  • As shown in FIG. 6B, first and second clamping plates 450 and 452 may be used to clamp the portions of the window mounting system 400 to one another. For example, the second clamping plate 452 is configured to clamp the window assembly 12 and the first PCB 402 to the diffuser 410 with screws or other fasteners extending through the openings shown in the second clamping plate 452, the heat spreader layer 412 and the conductive layer 414. Similarly, the first clamping plate 450 is configured overlie the second clamping plate 452 and clamp the rest of the window mounting system 400 to the heat sink 419, thus sandwiching the second clamping plate 452, the window assembly 12, the first PCB 402, the diffuser 410, the second PCB 403, and the TEC 418 therebetween. The first clamping plate 450 prevents undesired contact between the sample S and any portion of the window mounting system 400, other than the window assembly 12 itself. Other mounting plates and mechanisms may also be used as desired.
      • d. Optics
  • As shown in FIG. 1, the optical mixer 20 comprises a light pipe with an inner surface coating which is highly reflective and minimally absorptive in infrared wavelengths, preferably a polished gold coating, although other suitable coatings may be used where other wavelengths of electromagnetic radiation are employed. The pipe itself may be fabricated from a another rigid material such as aluminum or stainless steel, as long as the inner surfaces are coated or otherwise treated to be highly reflective. Preferably, the optical mixer 20 has a rectangular cross-section (as taken orthogonal to the longitudinal axis A-A of the mixer 20 and the collimator 22), although other cross-sectional shapes, such as other polygonal shapes or circular or elliptical shapes, may be employed in alternative embodiments. The inner walls of the optical mixer 20 are substantially parallel to the longitudinal axis A-A of the mixer 20 and the collimator 22. The highly reflective and substantially parallel inner walls of the mixer 20 maximize the number of times the infrared energy E will be reflected between the walls of the mixer 20, thoroughly mixing the infrared energy E as it propagates through the mixer 20. In a presently preferred embodiment, the mixer 20 is about 1.2 inches to 2.4 inches in length and its cross-section is a rectangle of about 0.4 inches by about 0.6 inches. Of course, other dimensions may be employed in constructing the mixer 20. In particular it is be advantageous to miniaturize the mixer or otherwise make it as small as possible
  • Still referring to FIG. 1, the collimator 22 comprises a tube with an inner surface coating which is highly reflective and minimally absorptive in infrared wavelengths, preferably a polished gold coating. The tube itself may be fabricated from a another rigid material such as aluminum, nickel or stainless steel, as long as the inner surfaces are coated or otherwise treated to be highly reflective. Preferably, the collimator 22 has a rectangular cross-section, although other cross-sectional shapes, such as other polygonal shapes or circular, parabolic or elliptical shapes, may be employed in alternative embodiments. The inner walls of the collimator 22 diverge as they extend away from the mixer 20. Preferably, the inner walls of the collimator 22 are substantially straight and form an angle of about 7 degrees with respect to the longitudinal axis A-A. The collimator 22 aligns the infrared energy E to propagate in a direction that is generally parallel to the longitudinal axis A-A of the mixer 20 and the collimator 22, so that the infrared energy E will strike the surface of the filters 24 at an angle as close to 90 degrees as possible.
  • In a presently preferred embodiment, the collimator is about 7.5 inches in length. At its narrow end 22 a, the cross-section of the collimator 22 is a rectangle of about 0.4 inches by 0.6 inches. At its wide end 22 b, the collimator 22 has a rectangular cross-section of about 1.8 inches by 2.6 inches. Preferably, the collimator 22 aligns the infrared energy E to an angle of incidence (with respect to the longitudinal axis A-A) of about 0-15 degrees before the energy E impinges upon the filters 24. Of course, other dimensions or incidence angles may be employed in constructing and operating the collimator 22.
  • With further reference to FIGS. 1 and 6A, each concentrator 26 comprises a tapered surface oriented such that its wide end 26 a is adapted to receive the infrared energy exiting the corresponding filter 24, and such that its narrow end 26 b is adjacent to the corresponding detector 28. The inward-facing surfaces of the concentrators 26 have an inner surface coating which is highly reflective and minimally absorptive in infrared wavelengths, preferably a polished gold coating. The concentrators 26 themselves may be fabricated from a another rigid material such as aluminum, nickel or stainless steel, so long as their inner surfaces are coated or otherwise treated to be highly reflective.
  • Preferably, the concentrators 26 have a rectangular cross-section (as taken orthogonal to the longitudinal axis A-A), although other cross-sectional shapes, such as other polygonal shapes or circular, parabolic or elliptical shapes, may be employed in alternative embodiments. The inner walls of the concentrators converge as they extend toward the narrow end 26 b. Preferably, the inner walls of the collimators 26 are substantially straight and form an angle of about 8 degrees with respect to the longitudinal axis A-A. Such a configuration is adapted to concentrate infrared energy as it passes through the concentrators 26 from the wide end 26 a to the narrow end 26 b, before reaching the detectors 28.
  • In a presently preferred embodiment, each concentrator 26 is about 1.5 inches in length. At the wide end 26 a, the cross-section of each concentrator 26 is a rectangle of about 0.6 inches by 0.57 inches. At the narrow end 26 b, each concentrator 26 has a rectangular cross-section of about 0.177 inches by 0.177 inches. Of course, other dimensions or incidence angles may be employed in constructing the concentrators 26.
      • e. Filters
  • The filters 24 preferably comprise standard interference-type infrared filters, widely available from manufacturers such as Optical Coating Laboratory, Inc. (“OCLI”) of Santa Rosa, Calif. In the embodiment illustrated in FIG. 1, a 3×4 array of filters 24 is positioned above a 3×4 array of detectors 28 and concentrators 26. As employed in this embodiment, the filters 24 are arranged in four groups of three filters having the same wavelength sensitivity. These four groups have bandpass center wavelengths of 7.15 μm±0.03 μm, 8.40 μm±0.03 μm, 9.48 μm±0.04 μm, and 11.10 μm±0.04 μm, respectively, which correspond to wavelengths around which water and glucose absorb electromagnetic radiation. Typical bandwidths for these filters range from 0.20 μm to 0.50 μm.
  • In an alternative embodiment, the array of wavelength-specific filters 24 may be replaced with a single Fabry-Perot interferometer, which can provide wavelength sensitivity which varies as a sample of infrared energy is taken from the material sample S. Thus, this embodiment permits the use of only one detector 28, the output signal of which varies in wavelength specificity over time. The output signal can be de-multiplexed based on the wavelength sensitivities induced by the Fabry-Perot interferometer, to provide a multiple-wavelength profile of the infrared energy emitted by the material sample S. In this embodiment, the optical mixer 20 may be omitted, as only one detector 28 need be employed.
  • In still other embodiments, the array of filters 24 may comprise a filter wheel that rotates different filters with varying wavelength sensitivities over a single detector 24. Alternatively, an electronically tunable infrared filter may be employed in a manner similar to the Fabry-Perot interferometer discussed above, to provide wavelength sensitivity which varies during the detection process. In either of these embodiments, the optical mixer 20 may be omitted, as only one detector 28 need be employed.
      • f. Detectors
  • The detectors 28 may comprise any detector type suitable for sensing infrared energy, preferably in the mid-infrared wavelengths. For example, the detectors 28 may comprise mercury-cadmium-telluride (MCT) detectors. A detector such as a Fermionics (Simi Valley, Calif.) model PV-9.1 with a PVA481-1 pre-amplifier is acceptable. Similar units from other manufacturers such as Graseby (Tampa, Fla.) can be substituted. Other suitable components for use as the detectors 28 include pyroelectric detectors, thermopiles, bolometers, silicon microbolometers and lead-salt focal plane arrays.
      • g. Control System
  • FIG. 7 depicts the control system 30 in greater detail, as well as the interconnections between the control system and other relevant portions of the noninvasive system. The control system includes a temperature control subsystem and a data acquisition subsystem.
  • In the temperature control subsystem, temperature sensors (such as RTDs and/or thermistors) located in the window assembly 12 provide a window temperature signal to a synchronous analog-to-digital conversion system 70 and an asynchronous analog-to-digital conversion system 72. The A/D systems 70, 72 in turn provide a digital window temperature signal to a digital signal processor (DSP) 74. The processor 74 executes a window temperature control algorithm and determines appropriate control inputs for the heater layer 34 of the window assembly 12 and/or for the cooling system 14, based on the information contained in the window temperature signal. The processor 74 outputs one or more digital control signals to a digital-to-analog conversion system 76 which in turn provides one or more analog control signals to current drivers 78. In response to the control signal(s), the current drivers 78 regulate the power supplied to the heater layer 34 and/or to the cooling system 14. In one embodiment, the processor 74 provides a control signal through a digital I/O device 77 to a pulse-width modulator (PWM) control 80, which provides a signal that controls the operation of the current drivers 78. Alternatively, a low-pass filter (not shown) at the output of the PWM provides for continuous operation of the current drivers 78.
  • In another embodiment, temperature sensors may be located at the cooling system 14 and appropriately connected to the A/D system(s) and processor to provide closed-loop control of the cooling system as well.
  • In yet another embodiment, a detector cooling system 82 is located in thermally conductive relation to one or more of the detectors 28. The detector cooling system 82 may comprise any of the devices disclosed above as comprising the cooling system 14, and preferably comprises a Peltier-type thermoelectric device. The temperature control subsystem may also include temperature sensors, such as RTDs and/or thermistors, located in or adjacent to the detector cooling system 82, and electrical connections between these sensors and the asynchronous A/D system 72. The temperature sensors of the detector cooling system 82 provide detector temperature signals to the processor 74. In one embodiment, the detector cooling system 82 operates independently of the window temperature control system, and the detector cooling system temperature signals are sampled using the asynchronous A/D system 72. In accordance with the temperature control algorithm, the processor 74 determines appropriate control inputs for the detector cooling system 82, based on the information contained in the detector temperature signal. The processor 74 outputs digital control signals to the D/A system 76 which in turn provides analog control signals to the current drivers 78. In response to the control signals, the current drivers 78 regulate the power supplied to the detector cooling system 14. In one embodiment, the processor 74 also provides a control signal through the digital I/O device 77 and the PWM control 80, to control the operation of the detector cooling system 82 by the current drivers 78. Alternatively, a low-pass filter (not shown) at the output of the PWM provides for continuous operation of the current drivers 78.
  • In the data acquisition subsystem, the detectors 28 respond to the infrared energy E incident thereon by passing one or more analog detector signals to a preamp 84. The preamp 84 amplifies the detector signals and passes them to the synchronous A/D system 70, which converts the detector signals to digital form and passes them to the processor 74. The processor 74 determines the concentrations of the analyte(s) of interest, based on the detector signals and a concentration-analysis algorithm and/or phase/concentration regression model stored in a memory module 88. The concentration-analysis algorithm and/or phase/concentration regression model may be developed according to any of the analysis methodologies discussed herein. The processor may communicate the concentration results and/or other information to a display controller 86, which operates a display (not shown), such as an LCD display, to present the information to the user.
  • A watchdog timer 94 may be employed to ensure that the processor 74 is operating correctly. If the watchdog timer 94 does not receive a signal from the processor 74 within a specified time, the watchdog timer 94 resets the processor 74. The control system may also include a JTAG interface 96 to enable testing of the noninvasive system 10.
  • In one embodiment, the synchronous A/D system 70 comprises a 20-bit, 14 channel system, and the asynchronous A/D system 72 comprises a 16-bit, 16 channel system. The preamp may comprise a 12-channel preamp corresponding to an array of 12 detectors 28.
  • The control system may also include a serial port 90 or other conventional data port to permit connection to a personal computer 92. The personal computer can be employed to update the algorithm(s) and/or phase/concentration regression model(s) stored in the memory module 88, or to download a compilation of analyte-concentration data from the noninvasive system. A real-time clock or other timing device may be accessible by the processor 74 to make any time-dependent calculations which may be desirable to a user.
  • 2. Analysis Methodology
  • The detector(s) 28 of the noninvasive system 10 are used to detect the infrared energy emitted by the material sample S in various desired wavelengths. At each measured wavelength, the material sample S emits infrared energy at an intensity which varies over time. The time-varying intensities arise largely in response to the use of the window assembly 12 (including its heater layer 34) and the cooling system 14 to induce a thermal gradient in the material sample S. As used herein, “thermal gradient” is a broad term and is used in its ordinary sense and refers, without limitation, to a difference in temperature and/or thermal energy between different locations, such as different depths, of a material sample, which can be induced by any suitable method of increasing or decreasing the temperature and/or thermal energy in one or more locations of the sample. As will be discussed in detail below, the concentration of an analyte of interest (such as glucose) in the material sample S can be determined with a device such as the noninvasive system 10, by comparing the time-varying intensity profiles of the various measured wavelengths.
  • Analysis methodologies are discussed herein within the context of detecting the concentration of glucose within a material sample, such as a tissue sample, which includes a large proportion of water. However, it will evident that these methodologies are not limited to this context and may be applied to the detection of a wide variety of analytes within a wide variety of sample types. It should also be understood that other suitable analysis methodologies and suitable variations of the disclosed methodologies may be employed in operating an analyte detection system, such as the noninvasive system 10.
  • As shown in FIG. 8, a first reference signal P may be measured at a first reference wavelength. The first reference signal P is measured at a wavelength where water strongly absorbs (e.g., 2.9 μm or 6.1 μm). Because water strongly absorbs radiation at these wavelengths, the detector signal intensity is reduced at those wavelengths. Moreover, at these wavelengths water absorbs the photon emissions emanating from deep inside the sample. The net effect is that a signal emitted at these wavelengths from deep inside the sample is not easily detected. The first reference signal P is thus a good indicator of thermal-gradient effects near the sample surface and may be known as a surface reference signal. This signal may be calibrated and normalized, in the absence of heating or cooling applied to the sample, to a baseline value of 1. For greater accuracy, more than one first reference wavelength may be measured. For example, both 2.9 μm and 6.1 μm may be chosen as first reference wavelengths.
  • As further shown in FIG. 8, a second reference signal R may also be measured. The second signal R may be measured at a wavelength where water has very low absorbance (e.g., 3.6 μm or 4.2 μm). This second reference signal R thus provides the analyst with information concerning the deeper regions of the sample, whereas the first signal P provides information concerning the sample surface. This signal may also be calibrated and normalized, in the absence of heating or cooling applied to the sample, to a baseline value of 1. As with the first (surface) reference signal P, greater accuracy may be obtained by using more than one second (deep) reference signal R.
  • In order to determine analyte concentration, a third (analytical) signal Q is also measured. This signal is measured at an IR absorbance peak of the selected analyte. The IR absorbance peaks for glucose are in the range of about 6.5 μm to 11.0 μm. This detector signal may also be calibrated and normalized, in the absence of heating or cooling applied to the material sample S, to a baseline value of 1. As with the reference signals P, R, the analytical signal Q may be measured at more than one absorbance peak.
  • Optionally, or additionally, reference signals may be measured at wavelengths that bracket the analyte absorbance peak. These signals may be advantageously monitored at reference wavelengths which do not overlap the analyte absorbance peaks. Further, it is advantageous to measure reference wavelengths at absorbance peaks which do not overlap the absorbance peaks of other possible constituents contained in the sample.
      • a. Basic Thermal Gradient
  • As further shown in FIG. 8, the signal intensities P, Q, R are shown initially at the normalized baseline signal intensity of 1. This of course reflects the baseline radiative behavior of a test sample in the absence of applied heating or cooling. At a time tC, the surface of the sample is subjected to a temperature event which induces a thermal gradient in the sample. The gradient can be induced by heating or cooling the sample surface. The example shown in FIG. 8 uses cooling, for example, using a 10° C. cooling event. In response to the cooling event, the intensities of the detector signals P, Q, R decrease over time.
  • Since the cooling of the sample is neither uniform nor instantaneous, the surface cools before the deeper regions of the sample cool. As each of the signals P, Q, R drop in intensity, a pattern emerges. Signal intensity declines as expected, but as the signals P, Q, R reach a given amplitude value (or series of amplitude values: 150, 152, 154, 156, 158), certain temporal effects are noted. After the cooling event is induced at tC, the first (surface) reference signal P declines in amplitude most rapidly, reaching a checkpoint 150 first, at time tP. This is due to the fact that the first reference signal P mirrors the sample's radiative characteristics near the surface of the sample. Since the sample surface cools before the underlying regions, the surface (first) reference signal P drops in intensity first.
  • Simultaneously, the second reference signal R is monitored. Since the second reference signal R corresponds to the radiation characteristics of deeper regions of the sample, which do not cool as rapidly as the surface (due to the time needed for the surface cooling to propagate into the deeper regions of the sample), the intensity of signal R does not decline until slightly later. Consequently, the signal R does not reach the magnitude 150 until some later time tR. In other words, there exists a time delay between the time tP at which the amplitude of the first reference signal P reaches the checkpoint 150 and the time tR at which the second reference signal R reaches the same checkpoint 150. This time delay can be expressed as a phase difference Φ(λ). Additionally, a phase difference may be measured between the analytical signal Q and either or both reference signals P, R.
  • As the concentration of analyte increases, the amount of absorbance at the analytical wavelength increases. This reduces the intensity of the analytical signal Q in a concentration-dependent way. Consequently, the analytical signal Q reaches intensity 150 at some intermediate time tQ. The higher the concentration of analyte, the more the analytical signal Q shifts to the left in FIG. 8. As a result, with increasing analyte concentration, the phase difference Φ(λ) decreases relative to the first (surface) reference signal P and increases relative to the second (deep tissue) reference signal R. The phase difference(s) Φ(λ) are directly related to analyte concentration and can be used to make accurate determinations of analyte concentration.
  • The phase difference Φ(λ) between the first (surface) reference signal P and the analytical signal Q is represented by the equation:
    Φ(λ)=|t P −t Q|
    The magnitude of this phase difference decreases with increasing analyte concentration.
  • The phase difference Φ(λ) between the second (deep tissue) reference signal R and the analytical signal Q signal is represented by the equation:
    Φ(λ)=|t Q −t R|
    The magnitude of this phase difference increases with increasing analyte concentration.
  • Accuracy may be enhanced by choosing several checkpoints, for example, 150, 152, 154, 156, and 158 and averaging the phase differences observed at each checkpoint. The accuracy of this method may be further enhanced by integrating the phase difference(s) continuously over the entire test period. Because in this example only a single temperature event (here, a cooling event) has been induced, the sample reaches a new lower equilibrium temperature and the signals stabilize at a new constant level IF. Of course, the method works equally well with thermal gradients induced by heating or by the application or introduction of other forms of energy, such as but not limited to light, radiation, chemically induced heat, friction and vibration.
  • This methodology is not limited to the determination of phase difference. At any given time (for example, at a time tX) the amplitude of the analytical signal Q may be compared to the amplitude of either or both of the reference signals P, R. The difference in amplitude may be observed and processed to determine analyte concentration.
  • This method, the variants disclosed herein, and the apparatus disclosed as suitable for application of the method(s), are not limited to the detection of in-vivo glucose concentration. The method and disclosed variants and apparatus may be used on human, animal, or even plant subjects, or on organic or inorganic compositions in a non-medical setting. The method may be used to take measurements of in-vivo or in-vitro samples of virtually any kind. The method is useful for measuring the concentration of a wide range of additional chemical analytes, including but not limited to, glucose, ethanol, insulin, water, carbon dioxide, blood oxygen, cholesterol, bilirubin, ketones, fatty acids, lipoproteins, albumin, urea, creatinine, white blood cells, red blood cells, hemoglobin, oxygenated hemoglobin, carboxyhemoglobin, organic molecules, inorganic molecules, pharmaceuticals, cytochrome, various proteins and chromophores, microcalcifications, hormones, as well as other chemical compounds. To detect a given analyte, one needs only to select appropriate analytical and reference wavelengths.
  • The method is adaptable and may be used to determine chemical concentrations in samples of body fluids (e.g., blood, urine or saliva) once they have been extracted from a patient. In fact, the method may be used for the measurement of in-vitro samples of virtually any kind.
      • b. Modulated Thermal Gradient
  • In some embodiments of the methodology described above, a periodically modulated thermal gradient can be employed to make accurate determinations of analyte concentration.
  • As previously shown in FIG. 8, once a thermal gradient is induced in the sample, the reference and analytical signals P, Q, R fall out of phase with respect to each other. This phase difference Φ(λ) is present whether the thermal gradient is induced through heating or cooling. By alternatively subjecting the test sample to cyclic pattern of heating, cooling, or alternately heating and cooling, an oscillating thermal gradient may be induced in a sample for an extended period of time.
  • An oscillating thermal gradient is illustrated using a sinusoidally modulated gradient. FIG. 9 depicts detector signals emanating from a test sample. As with the methodology shown in FIG. 8, one or more reference signals J, L are measured. One or more analytical signals K are also monitored. These signals may be calibrated and normalized, in the absence of heating or cooling applied to the sample, to a baseline value of 1. FIG. 9 shows the signals after normalization. At some time tC, a temperature event (e.g., cooling) is induced at the sample surface. This causes a decline in the detector signal. As shown in FIG. 8, the signals (P, Q, R) decline until the thermal gradient disappears and a new equilibrium detector signal IF is reached. In the method shown in FIG. 9, as the gradient begins to disappear at a signal intensity 160, a heating event, at a time tW, is induced in the sample surface. As a result the detector output signals J, K, L will rise as the sample temperature rises. At some later time tC2, another cooling event is induced, causing the temperature and detector signals to decline. This cycle of cooling and heating may be repeated over a time interval of arbitrary length. Moreover, if the cooling and heating events are timed properly, a periodically modulated thermal gradient may be induced in the test sample.
  • As previously explained in the discussions relating to FIG. 8, the phase difference Φ(λ) may be measured and used to determine analyte concentration. FIG. 9 shows that the first (surface) reference signal J declines and rises in intensity first. The second (deep tissue) reference signal L declines and rises in a time-delayed manner relative to the first reference signal J. The analytical signal K exhibits a time/phase delay dependent on the analyte concentration. With increasing concentration, the analytical signal K shifts to the left in FIG. 9. As with FIG. 8, the phase difference Φ(λ) may be measured. For example, a phase difference Φ(λ) between the second reference signal L and the analytical signal K, may be measured at a set amplitude 162 as shown in FIG. 9. Again, the magnitude of the phase signal reflects the analyte concentration of the sample.
  • The phase-difference information compiled by any of the methodologies disclosed herein can correlated by the control system 30 (see FIG. 1) with previously determined phase-difference information to determine the analyte concentration in the sample. This correlation could involve comparison of the phase-difference information received from analysis of the sample, with a data set containing the phase-difference profiles observed from analysis of wide variety of standards of known analyte concentration. In one embodiment, a phase/concentration curve or regression model is established by applying regression techniques to a set of phase-difference data observed in standards of known analyte concentration. This curve is used to estimate the analyte concentration in a sample based on the phase-difference information received from the sample.
  • Advantageously, the phase difference Φ(λ) may be measured continuously throughout the test period. The phase-difference measurements may be integrated over the entire test period for an extremely accurate measure of phase difference Φ(λ). Accuracy may also be improved by using more than one reference signal and/or more than one analytical signal.
  • As an alternative or as a supplement to measuring phase difference(s), differences in amplitude between the analytical and reference signal(s) may be measured and employed to determine analyte concentration. Additional details relating to this technique and not necessary to repeat here may be found in the Assignee's U.S. patent application Ser. No. 09/538,164, incorporated by reference below.
  • Additionally, these methods may be advantageously employed to simultaneously measure the concentration of one or more analytes. By choosing reference and analyte wavelengths that do not overlap, phase differences can be simultaneously measured and processed to determine analyte concentrations. Although FIG. 9 illustrates the method used in conjunction with a sinusoidally modulated thermal gradient, the principle applies to thermal gradients conforming to any periodic function. In more complex cases, analysis using signal processing with Fourier transforms or other techniques allows accurate determinations of phase difference D(k) and analyte concentration.
  • As shown in FIG. 10, the magnitude of the phase differences may be determined by measuring the time intervals between the amplitude peaks (or troughs) of the reference signals J, L and the analytical signal K. Alternatively, the time intervals between the “zero crossings” (the point at which the signal amplitude changes from positive to negative, or negative to positive) may be used to determine the phase difference between the analytical signal K and the reference signals J, L. This information is subsequently processed and a determination of analyte concentration may then be made. This particular method has the advantage of not requiring normalized signals.
  • As a further alternative, two or more driving frequencies may be employed to determine analyte concentrations at selected depths within the sample. A slow (e.g., 1 Hz) driving frequency creates a thermal gradient which penetrates deeper into the sample than the gradient created by a fast (e.g., 3 Hz) driving frequency. This is because the individual heating and/or cooling events are longer in duration where the driving frequency is lower. Thus, the use of a slow driving frequency provides analyte-concentration information from a deeper “slice” of the sample than does the use of a fast driving frequency.
  • It has been found that when analyzing a sample of human skin, a temperature event of 10° C. creates a thermal gradient which penetrates to a depth of about 150 μm, after about 500 ms of exposure. Consequently, a cooling/heating cycle or driving frequency of 1 Hz provides information to a depth of about 150 μm. It has also been determined that exposure to a temperature event of 10° C. for about 167 ms creates a thermal gradient that penetrates to a depth of about 50 μm. Therefore, a cooling/heating cycle of 3 Hz provides information to a depth of about 50 μm. By subtracting the detector signal information measured at a 3 Hz driving frequency from the detector signal information measured at a 1 Hz driving frequency, one can determine the analyte concentration(s) in the region of skin between 50 and 150 μm. Of course, a similar approach can be used to determine analyte concentrations at any desired depth range within any suitable type of sample.
  • As shown in FIG. 11, alternating deep and shallow thermal gradients may be induced by alternating slow and fast driving frequencies. As with the methods described above, this variation also involves the detection and measurement of phase differences Φ(λ) between reference signals G, G′ and analytical signals H, H′. Phase differences are measured at both fast (e.g., 3 Hz) and slow (e.g., 1 Hz) driving frequencies. The slow driving frequency may continue for an arbitrarily chosen number of cycles (in region SL1), for example, two full cycles. Then the fast driving frequency is employed for a selected duration, in region F1. The phase difference data is compiled in the same manner as disclosed above. In addition, the fast frequency (shallow sample) phase difference data may be subtracted from the slow frequency (deep sample) data to provide an accurate determination of analyte concentration in the region of the sample between the gradient penetration depth associated with the fast driving frequency and that associated with the slow driving frequency.
  • The driving frequencies (e.g., 1 Hz and 3 Hz) can be multiplexed as shown in FIG. 12. The fast (3 Hz) and slow (1 Hz) driving frequencies can be superimposed rather than sequentially implemented. During analysis, the data can be separated by frequency (using Fourier transform or other techniques) and independent measurements of phase delay at each of the driving frequencies may be calculated. Once resolved, the two sets of phase delay data are processed to determine absorbance and analyte concentration.
  • Additional details not necessary to repeat here may be found in U.S. Pat. No. 6,198,949, titled SOLID-STATE NON-INVASIVE INFRARED ABSORPTION SPECTROMETER FOR THE GENERATION AND CAPTURE OF THERMAL GRADIENT SPECTRA FROM LIVING TISSUE, issued Mar. 6, 2001; U.S. Pat. No. 6,161,028, titled METHOD FOR DETERMINING ANALYTE CONCENTRATION USING PERIODIC TEMPERATURE MODULATION AND PHASE DETECTION, issued Dec. 12, 2000; U.S. Pat. No. 5,877,500, titled MULTICHANNEL INFRARED DETECTOR WITH OPTICAL CONCENTRATORS FOR EACH CHANNEL, issued on Mar. 2, 1999; U.S. patent application Ser. No. 09/538,164, filed Mar. 30, 2000 and titled METHOD AND APPARATUS FOR DETERMINING ANALYTE CONCENTRATION USING PHASE AND MAGNITUDE DETECTION OF A RADIATION TRANSFER FUNCTION; U.S. Provisional Patent Application No. 60/336,404, filed Oct. 29, 2001, titled WINDOW ASSEMBLY; U.S. Provisional Patent Application No. 60/340,435, filed Dec. 12, 2001, titled CONTROL SYSTEM FOR BLOOD CONSTITUENT MONITOR; U.S. Provisional Patent Application No. 60/340,654, filed Dec. 12, 2001, titled SYSTEM AND METHOD FOR CONDUCTING AND DETECTING INFRARED RADIATION; U.S. Provisional Patent Application No. 60/336,294, filed Oct. 29, 2001, titled METHOD AND DEVICE FOR INCREASING ACCURACY OF BLOOD CONSTITUENT MEASUREMENT; and U.S. Provisional Patent Application No. 60/339,116, filed Nov. 7, 2001, titled METHOD AND APPARATUS FOR IMPROVING CLINICALLY SIGNIFICANT ACCURACY OF ANALYTE MEASUREMENTS. The entire disclosure of all of the above-mentioned patents, patent applications and publications is hereby incorporated by reference herein and made a part of this specification.
  • B. Whole-Blood Detection System
  • FIG. 13 is a schematic view of a reagentless whole-blood analyte detection system 200 (hereinafter “whole-blood system”) in a preferred configuration. The whole-blood system 200 may comprise a radiation source 220, a filter 230, a cuvette 240 that includes a sample cell 242, and a radiation detector 250. The whole-blood system 200 preferably also comprises a signal processor 260 and a display 270. Although a cuvette 240 is shown here, other sample elements, as described below, could also be used in the system 200. The whole-blood system 200 can also comprise a sample extractor 280, which can be used to access bodily fluid from an appendage, such as the finger 290, forearm, or any other suitable location.
  • As used herein, the terms “whole-blood analyte detection system” and “whole-blood system” are broad, synonymous terms and are used in their ordinary sense and refer, without limitation, to analyte detection devices which can determine the concentration of an analyte in a material sample by passing electromagnetic radiation into the sample and detecting the absorbance of the radiation by the sample. As used herein, the term “whole-blood” is a broad term and is used in its ordinary sense and refers, without limitation, to blood that has been withdrawn from a patient but that has not been otherwise processed, e.g., it has not been hemolysed, lyophilized, centrifuged, or separated in any other manner, after being removed from the patient. Whole-blood may contain amounts of other fluids, such as interstitial fluid or intracellular fluid, which may enter the sample during the withdrawal process or are naturally present in the blood. It should be understood, however, that the whole-blood system 200 disclosed herein is not limited to analysis of whole-blood, as the whole-blood system 10 may be employed to analyze other substances, such as saliva, urine, sweat, interstitial fluid, intracellular fluid, hemolysed, lyophilized, or centrifuged blood or any other organic or inorganic materials.
  • The whole-blood system 200 may comprise a near-patient testing system. As used herein, “near-patient testing system” is a broad term and is used in its ordinary sense, and includes, without limitation, test systems that are configured to be used where the patient is rather than exclusively in a laboratory, e.g., systems that can be used at a patient's home, in a clinic, in a hospital, or even in a mobile environment. Users of near-patient testing systems can include patients, family members of patients, clinicians, nurses, or doctors. A “near-patient testing system” could also include a “point-of-care” system.
  • The whole-blood system 200 may in one embodiment be configured to be operated easily by the patient or user. As such, the system 200 is preferably a portable device. As used herein, “portable” is a broad term and is used in its ordinary sense and means, without limitation, that the system 200 can be easily transported by the patient and used where convenient. For example, the system 200 is advantageously small. In one preferred embodiment, the system 200 is small enough to fit into a purse or backpack. In another embodiment, the system 200 is small enough to fit into a pants pocket. In still another embodiment, the system 200 is small enough to be held in the palm of a hand of the user.
  • Some of the embodiments described herein employ a sample element to hold a material sample, such as a sample of biological fluid. As used herein, “sample element” is a broad term and is used in its ordinary sense and includes, without limitation, structures that have a sample cell and at least one sample cell wall, but more generally includes any of a number of structures that can hold, support or contain a material sample and that allow electromagnetic radiation to pass through a sample held, supported or contained thereby; e.g., a cuvette, test strip, etc. As used herein, the term “disposable” when applied to a component, such as a sample element, is a broad term and is used in its ordinary sense and means, without limitation, that the component in question is used a finite number of times and then discarded. Some disposable components are used only once and then discarded. Other disposable components are used more than once and then discarded.
  • The radiation source 220 of the whole-blood system 200 emits electro-magnetic radiation in any of a number of spectral ranges, e.g., within infrared wavelengths; in the mid-infrared wavelengths; above about 0.8 μm; between about 5.0 μm and about 20.0 μm; and/or between about 5.25 μm and about 12.0 μm. However, in other embodiments the whole-blood system 200 may employ a radiation source 220 which emits in wavelengths found anywhere from the visible spectrum through the microwave spectrum, for example anywhere from about 0.4 μm to greater than about 100 μm. In still further embodiments the radiation source emits electromagnetic radiation in wavelengths between about 3.5 μm and about 14 μm, or between about 0.8 μm and about 2.5 μm, or between about 2.5 μm and about 20 μm, or between about 20 μm and about 100 μm, or between about 6.85 μm and about 10.10 μm.
  • The radiation emitted from the source 220 is in one embodiment modulated at a frequency between about one-half hertz and about one hundred hertz, in another embodiment between about 2.5 hertz and about 7.5 hertz, in still another embodiment at about 50 hertz, and in yet another embodiment at about 5 hertz. With a modulated radiation source, ambient light sources, such as a flickering fluorescent lamp, can be more easily identified and rejected when analyzing the radiation incident on the detector 250. One source that is suitable for this application is produced by ION OPTICS, INC. and sold under the part number NL5LNC.
  • The filter 230 permits electromagnetic radiation of selected wavelengths to pass through and impinge upon the cuvette/sample element 240. Preferably, the filter 230 permits radiation at least at about the following wavelengths to pass through to the cuvette/sample element: 3.9, 4.0 μm, 4.05 μm, 4.2 μm, 4.75, 4.95 μm, 5.25 μm, 6.12 μm, 7.4 μm, 8.0 μm, 8.45 μm, 9.25 μm, 9.5 μm, 9.65 μm, 10.4 μm, 12.2 μm. In another embodiment, the filter 230 permits radiation at least at about the following wavelengths to pass through to the cuvette/sample element: 5.25 μm, 6.12 μm, 6.8 μm, 8.03 μm, 8.45 μm, 9.25 μm, 9.65 μm, 10.4 μm, 12 μm. In still another embodiment, the filter 230 permits radiation at least at about the following wavelengths to pass through to the cuvette/sample element: 6.85 μm, 6.97 μm, 7.39 μm, 8.23 μm, 8.62 μm, 9.02 μm, 9.22 μm, 9.43 μm, 9.62 μm, and 10.10 μm. The sets of wavelengths recited above correspond to specific embodiments within the scope of this disclosure. Furthermore, other subsets of the foregoing sets or other combinations of wavelengths can be selected. Finally, other sets of wavelengths can be selected within the scope of this disclosure based on cost of production, development time, availability, and other factors relating to cost, manufacturability, and time to market of the filters used to generate the selected wavelengths, and/or to reduce the total number of filters needed.
  • In one embodiment, the filter 230 is capable of cycling its passband among a variety of narrow spectral bands or a variety of selected wavelengths. The filter 230 may thus comprise a solid-state tunable infrared filter, such as that available from ION OPTICS INC. The filter 230 could also be implemented as a filter wheel with a plurality of fixed-passband filters mounted on the wheel, generally perpendicular to the direction of the radiation emitted by the source 220. Rotation of the filter wheel alternately presents filters that pass radiation at wavelengths that vary in accordance with the filters as they pass through the field of view of the detector 250.
  • The detector 250 preferably comprises a 3 mm long by 3 mm wide pyroelectric detector. Suitable examples are produced by DIAS Angewandte Sensorik GmbH of Dresden, Germany, or by BAE Systems (such as its TGS model detector). The detector 250 could alternatively comprise a thermopile, a bolometer, a silicon microbolometer, a lead-salt focal plane array, or a mercury-cadmium-telluride (MCT) detector. Whichever structure is used as the detector 250, it is desirably configured to respond to the radiation incident upon its active surface 254 to produce electrical signals that correspond to the incident radiation.
  • In one embodiment, the sample element comprises a cuvette 240 which in turn comprises a sample cell 242 configured to hold a sample of tissue and/or fluid (such as whole-blood, blood components, interstitial fluid, intercellular fluid, saliva, urine, sweat and/or other organic or inorganic materials) from a patient within its sample cell. The cuvette 240 is installed in the whole-blood system 200 with the sample cell 242 located at least partially in the optical path 243 between the radiation source 220 and the detector 250. Thus, when radiation is emitted from the source 220 through the filter 230 and the sample cell 242 of the cuvette 240, the detector 250 detects the radiation signal strength at the wavelength(s) of interest. Based on this signal strength, the signal processor 260 determines the degree to which the sample in the cell 242 absorbs radiation at the detected wavelength(s). The concentration of the analyte of interest is then determined from the absorption data via any suitable spectroscopic technique.
  • As shown in FIG. 13, the whole-blood system 200 can also comprise a sample extractor 280. As used herein, the term “sample extractor” is a broad term and is used in its ordinary sense and refers, without limitation, to any device which is suitable for drawing a sample material, such as whole-blood, other bodily fluids, or any other sample material, through the skin of a patient. In various embodiments, the sample extractor may comprise a lance, laser lance, iontophoretic sampler, gas-jet, fluid-jet or particle-jet perforator, ultrasonic enhancer (used with or without a chemical enhancer), or any other suitable device.
  • As shown in FIG. 13, the sample extractor 280 could form an opening in an appendage, such as the finger 290, to make whole-blood available to the cuvette 240. It should be understood that other appendages could be used to draw the sample, including but not limited to the forearm. With some embodiments of the sample extractor 280, the user forms a tiny hole or slice through the skin, through which flows a sample of bodily fluid such as whole-blood. Where the sample extractor 280 comprises a lance (see FIG. 14), the sample extractor 280 may comprise a sharp cutting implement made of metal or other rigid materials. One suitable laser lance is the Lasette Plus® produced by Cell Robotics International, Inc. of Albuquerque, N.M. If a laser lance, iontophoretic sampler, gas-jet or fluid-jet perforator is used as the sample extractor 280, it could be incorporated into the whole-blood system 200 (see FIG. 13), or it could be a separate device.
  • Additional information on laser lances can be found in U.S. Pat. No. 5,908,416, issued Jun. 1, 1999, titled LASER DERMAL PERFORATOR; the entirety of this patent is hereby incorporated by reference herein and made a part of this specification. One suitable gas-jet, fluid-jet or particle-jet perforator is disclosed in U.S. Pat. No. 6,207,400, issued Mar. 27, 2001, titled NON- OR MINIMALLY INVASIVE MONITORING METHODS USING PARTICLE DELIVERY METHODS; the entirety of this patent is hereby incorporated by reference herein and made a part of this specification. One suitable iontophoretic sampler is disclosed in U.S. Pat. No. 6,298,254, issued Oct. 2, 2001, titled DEVICE FOR SAMPLING SUBSTANCES USING ALTERNATING POLARITY OF IONTOPHORETIC CURRENT; the entirety of this patent is hereby incorporated by reference herein and made a part of this specification. One suitable ultrasonic enhancer, and chemical enhancers suitable for use therewith, are disclosed in U.S. Pat. No. 5,458,140, titled ENHANCEMENT OF TRANSDERMAL MONITORING APPLICATIONS WITH ULTRASOUND AND CHEMICAL ENHANCERS, issued Oct. 17, 1995, the entire disclosure of which is hereby incorporated by reference and made a part of this specification.
  • FIG. 14 shows one embodiment of a sample element, in the form of a cuvette 240, in greater detail. The cuvette 240 further comprises a sample supply passage 248, a pierceable portion 249, a first window 244, and a second window 246, with the sample cell 242 extending between the windows 244, 246. In one embodiment, the cuvette 240 does not have a second window 246. The first window 244 (or second window 246) is one form of a sample cell wall; in other embodiments of the sample elements and cuvettes disclosed herein, any sample cell wall may be used that at least partially contains, holds or supports a material sample, such as a biological fluid sample, and which is transmissive of at least some bands of electromagnetic radiation, and which may but need not be transmissive of electromagnetic radiation in the visible range. The pierceable portion 249 is an area of the sample supply passage 248 that can be pierced by suitable embodiments of the sample extractor 280. Suitable embodiments of the sample extractor 280 can pierce the portion 249 and the appendage 290 to create a wound in the appendage 290 and to provide an inlet for the blood or other fluid from the wound to enter the cuvette 240. (The sample extractor 280 is shown on the opposite side of the sample element in FIG. 14, as compared to FIG. 13, as it may pierce the portion 249 from either side.)
  • The windows 244, 246 are preferably optically transmissive in the range of electromagnetic radiation that is emitted by the source 220, or that is permitted to pass through the filter 230. In one embodiment, the material that makes up the windows 244, 246 is completely transmissive, i.e., it does not absorb any of the electromagnetic radiation from the source 220 and filter 230 that is incident upon it. In another embodiment, the material of the windows 244, 246 has some absorption in the electromagnetic range of interest, but its absorption is negligible. In yet another embodiment, the absorption of the material of the windows 244, 246 is not negligible, but it is known and stable for a relatively long period of time. In another embodiment, the absorption of the windows 244, 246 is stable for only a relatively short period of time, but the whole-blood system 200 is configured to observe the absorption of the material and eliminate it from the analyte measurement before the material properties can change measurably.
  • The windows 244, 246 are made of polypropylene in one embodiment. In another embodiment, the windows 244, 246 are made of polyethylene. Polyethylene and polypropylene are materials having particularly advantageous properties for handling and manufacturing, as is known in the art. Also, polypropylene can be arranged in a number of structures, e.g., isotactic, atactic and syndiotactic, which may enhance the flow characteristics of the sample in the sample element. Preferably the windows 244, 246 are made of durable and easily manufactureable materials, such as the above-mentioned polypropylene or polyethylene, or silicon or any other suitable material. The windows 244, 246 can be made of any suitable polymer, which can be isotactic, atactic or syndiotactic in structure.
  • The distance between the windows 244, 246 comprises an optical pathlength and can be between about 1 μm and about 100 μm. In one embodiment, the optical pathlength is between about 10 μm and about 40 μm, or between about 25 μm and about 60 μm, or between about 30 μm and about 50 μm. In still another embodiment, the optical pathlength is about 25 μm. The transverse size of each of the windows 244, 246 is preferably about equal to the size of the detector 250. In one embodiment, the windows are round with a diameter of about 3 mm. In this embodiment, where the optical pathlength is about 25 μm the volume of the sample cell 242 is about 0.177 μL. In one embodiment, the length of the sample supply passage 248 is about 6 mm, the height of the sample supply passage 248 is about 1 mm, and the thickness of the sample supply passage 248 is about equal to the thickness of the sample cell, e.g., 25 μm. The volume of the sample supply passage is about 0.150 μL. Thus, the total volume of the cuvette 240 in one embodiment is about 0.327 μL. Of course, the volume of the cuvette 240/sample cell 242/etc. can vary, depending on many variables, such as the size and sensitivity of the detectors 250, the intensity of the radiation emitted by the source 220, the expected flow properties of the sample, and whether flow enhancers (discussed below) are incorporated into the cuvette 240. The transport of fluid to the sample cell 242 is achieved preferably through capillary action, but may also be achieved through wicking, or a combination of wicking and capillary action.
  • FIGS. 15-17 depict another embodiment of a cuvette 305 that could be used in connection with the whole-blood system 200. The cuvette 305 comprises a sample cell 310, a sample supply passage 315, an air vent passage 320, and a vent 325. As best seen in FIGS. 16,16A and 17, the cuvette also comprises a first sample cell window 330 having an inner side 332, and a second sample cell window 335 having an inner side 337. As discussed above, the window(s) 330/335 in some embodiments also comprise sample cell wall(s). The cuvette 305 also comprises an opening 317 at the end of the sample supply passage 315 opposite the sample cell 310. The cuvette 305 is preferably about ¼-⅛ inch wide and about ¾ inch long; however, other dimensions are possible while still achieving the advantages of the cuvette 305.
  • The sample cell 310 is defined between the inner side 332 of the first sample cell window 330 and the inner side 337 of the second sample cell window 335. The perpendicular distance T between the two inner sides 332, 337 comprises an optical pathlength that can be between about 1 μm and about 1.22 mm. The optical pathlength can alternatively be between about 1 μm and about 100 μm. The optical pathlength could still alternatively be about 80 μm, but is preferably between about 10 μm and about 50 μm. In another embodiment, the optical pathlength is about 25 μm. The windows 330, 335 are preferably formed from any of the materials discussed above as possessing sufficient radiation transmissivity. The thickness of each window is preferably as small as possible without overly weakening the sample cell 310 or cuvette 305.
  • Once a wound is made in the appendage 290, the opening 317 of the sample supply passage 315 of the cuvette 305 is placed in contact with the fluid that flows from the wound. In another embodiment, the sample is obtained without creating a wound, e.g. as is done with a saliva sample. In that case, the opening 317 of the sample supply passage 315 of the cuvette 305 is placed in contact with the fluid obtained without creating a wound. The fluid is then transported through the sample supply passage 315 and into the sample cell 310 via capillary action. The air vent passage 320 improves the capillary action by preventing the buildup of air pressure within the cuvette and allowing the blood to displace the air as the blood flows therein.
  • Other mechanisms may be employed to transport the sample to the sample cell 310. For example, wicking could be used by providing a wicking material in at least a portion of the sample supply passage 315. In another variation, wicking and capillary action could be used together to transport the sample to the sample cell 310. Membranes could also be positioned within the sample supply passage 315 to move the blood while at the same time filtering out components that might complicate the optical measurement performed by the whole-blood system 200.
  • FIGS. 16 and 16A depict one approach to constructing the cuvette 305. In this approach, the cuvette 305 comprises a first layer 350, a second layer 355, and a third layer 360. The second layer 355 is positioned between the first layer 350 and the third layer 360. The first layer 350 forms the first sample cell window 330 and the vent 325. As mentioned above, the vent 325 provides an escape for the air that is in the sample cell 310. While the vent 325 is shown on the first layer 350, it could also be positioned on the third layer 360, or could be a cutout in the second layer, and would then be located between the first layer 360 and the third layer 360 The third layer 360 forms the second sample cell window 335.
  • The second layer 355 may be formed entirely of an adhesive that joins the first and third layers 350, 360. In other embodiments, the second layer may be formed from similar materials as the first and third layers, or any other suitable material. The second layer 355 may also be formed as a carrier with an adhesive deposited on both sides thereof. The second layer 355 forms the sample supply passage 315, the air vent passage 320, and the sample cell 310. The thickness of the second layer 355 can be between about 1 μm and about 1.22 mm. This thickness can alternatively be between about 1 μm and about 100 μm. This thickness could alternatively be about 80 μm, but is preferably between about 10 μm and about 50 μm. In another embodiment, the second layer thickness is about 25 μm.
  • In other embodiments, the second layer 355 can be constructed as an adhesive film having a cutout portion to define the passages 315, 320, or as a cutout surrounded by adhesive.
  • Further information can be found in U.S. patent application Ser. No. 10/055,875, filed Jan. 21, 2002, titled REAGENT-LESS WHOLE-BLOOD GLUCOSE METER. The entire contents of this patent application are hereby incorporated by reference herein and made a part of this specification.
  • II. Analyte Monitoring Instrument Having Network Connectivity
  • Referring to FIG. 18, an analyte detection system 500 is shown connected to remote stations 524, 528 over a network 520, which may comprise one or more wireless or hardwired links, or a combination of wireless and hardwired links, and/or the Internet. In the illustrated embodiment, the analyte detection system 500 comprises the noninvasive system 10 described above. In other embodiments, the analyte detection system may comprise any other suitable noninvasive system such as (but not limited to) those described in U.S. Pat. No. 5,900,632 to Sterling et al. and U.S. Pat. No. 5,615,972 to Braig et al., the entirety of each of which is hereby incorporated by reference herein and made a part of this specification. In still other embodiments, the analyte detection system 500 may comprise any suitable invasive system such as (but not limited to) the whole-blood system 200 disclosed above.
  • Because the noninvasive system 10 is depicted in the embodiment of FIG. 18, the hand and forearm 512 of a patient is shown positioned to allow a measurement to be performed by an analyte detector element 514 of the analyte detection system 500. The analyte detection system 500 includes a signal processing system 516 which collects the measurements and/or other suitable information from the detector element 514 and processes the data into a set of results. In the illustrated embodiment, the analyte detection system 500 includes input and output devices, such as a display and a set of control inputs (not shown) for communicating information directly to and from the patient. The signal processing system 516 is equipped with a network interface 517 along with one or more processing elements 519 for processing the measurement signals and for control of network communications.
  • Data is communicated over the network 520 as determined by the configuration of the system 500 and the state and condition of the measurement being performed. Measurement data may accordingly be communicated to the remote station(s) 524, 528 at the time the measurement is performed, or it may be retained within the system 500 and sent to the remote station(s) according to a schedule or other selection criterion. The system 500 and/or remote station(s) 524, 284 may be capable of comparing each measurement with a set of limits and providing alerts to a supervisory authority regarding excursions therefrom.
  • In FIG. 18 the measurement data is shown passing through a connection 518 to the network 520, and from there through another connection 522 to a centralized monitoring computer 524 or to a server. The centralized computer 524 may be capable of checking the data for emergency conditions and logging the data for later use. In addition, the centralized computer 524 may monitor the status of the system(s) 500 for proper operation and calibration. It will be appreciated that multiple centralized computers 524 or servers can be provided for communicating with the system(s) 500. In one embodiment, the network interface 517 is a wireless interface (and the connection 518 is a wireless connection), such as but not limited to a Bluetooth interface, an IEEE 802.11 (b) interface or a cellular interface, implemented through appropriate hardware built into the system 500.
  • Furthermore, the centralized computer 524 may simultaneously transfer or route the data (e.g., measurements, system status, etc.) via connection 526 to a computer 528 in the office of a medical practitioner over the network 520. Instead of or in addition to the medical practitioner computer 528, the network may include connections to a computer 528′ located at the manufacturer of the analyte detection system 500, to a computer 528″ located at the patient's home, and/or to a computer 528′″ located at the home or place of business of a parent of the patient. Alternatively, the data may be directly sent over the network 520 to the medical practitioner 528/manufacturer 528′/patient's home 528″/patient's parent 528′″ from the signal processing system 516; in this instance the centralized computer 524 is not necessary and may be omitted from the network 520. Where the centralized computer 524 is omitted, any of the computer(s) 528/528′/528″/528′″ (hereinafter, collectively “528”) may be capable of checking the data received from the system 500 for emergency conditions, logging the data for later use, and/or monitoring the status of the system 500 for proper operation and calibration. It will be appreciated that the foregoing data routing is provided as an example, and not as a limitation, of the data routing utilized to provide the network services in support of a patient's use of the system 500.
  • In one embodiment, the system 500 includes a panic button 530 which permits the patient to alert a medical practitioner should an important concern arise. In addition, sound and/or visual output may be provided by the system 500 for signaling the patient when the time arrives to perform a measurement, or of a directive from a supervisory authority as received over the network 520.
  • In another embodiment, the system 500 includes a location button 531 which permits the patient to signal his or her location (as well as the location of the system 500) to any of the remote station(s) 524, 528. When so signaled, a remote user at a remote station 524/528 can direct emergency assistance to the location of the patient/system, should the remote user discover that the patient's condition merits immediate medical attention. In one embodiment, the location information is generated via GPS (Global Positioning System) equipment built into the system 500 and accessible by the processing element(s) 519. In another embodiment, the system 500 continually, intermittently or otherwise automatically transmits its location to any or all of the remote station(s) 524, 528, and the location button 531 may be omitted. In still another embodiment, the system 500 is configured to transmit its location to remote station(s) 524, 528 in response to a query sent from the remote station(s) to the system 500.
  • In another embodiment, the GPS equipment is supplemented by storage, within appropriate memory accessible by the processing element(s) 519 and/or the GPS equipment, of favorite locations frequented by the patient. Examples of favorite locations include Home, Work, School, etc. and/or a widely recognizable expression thereof, such as the associated street address, nearest cross streets, ZIP or postal code, and/or longitude and latitude. The purpose of such storage is to counteract the tendency of GPS equipment to lose contact with the GPS satellite(s) when the GPS device in question is located inside of a building or other large structure.
  • Accordingly, when the system 500 loses contact with the GPS satellite(s) and a need arises, under any of the circumstances discussed herein, to transmit the location of the patient/system to a remote user, the system 500 recognizes the loss of contact with the GPS satellite(s) and selects for transmission one of the patient's favorite locations based on the last GPS-computed position of the user/system prior to loss of contact with the GPS satellite(s). In one embodiment, the system 500 selects and transmits whichever favorite location is nearest the last GPS-computed position of the system 500. In another embodiment, the system 500 selects and transmits this nearest favorite location only when the nearest favorite location is within a given minimum distance (e.g., 10 miles, 5 miles, 1 mile, 0.5 miles) from the last GPS-computed position of the system 500. In still another embodiment, the system 500 displays a list of the patient's stored favorite locations on a suitable display, and the patient can select, using an appropriate input device (keypad, button, touchscreen, mouse, voice recognition system, etc.) built into or connected to the system 500, his or her present location from a list of favorites and prompt the system 500 to transmit the selected location.
  • Any of the location-transmission processes discussed above may be implemented in an algorithm or program instructions executable by, and residing within memory accessible by, the processing element(s) 519 of the system 500 (in particular, by the signal processor 74/260 where the system 500 comprises the noninvasive system 10 or the whole-blood system 200, respectively).
  • In any of the embodiments discussed herein, the system 500 and/or one or more of the remote station(s) 524, 528 may be configured to encrypt any or all of the data that it transmits over the network 520. Where the user of any of the system 500 and the remote station(s) 524, 528 (or the system/remote station itself) is authorized to receive, read and/or otherwise use the encrypted data, the recipient system 500/ remote station 524, 528 is configured to decrypt the encrypted data, to make the data available to the device and/or the user thereof. By encrypting the data, physician-patient confidentiality, or any physician-patient privilege may be preserved, preventing unauthorized reading or use of the data. Encryption also permits transmission of data over wireless networks or public networks such as the Internet while preserving confidentiality of the transmitted data.
  • It is contemplated that the encryption and decryption may be performed in any suitable manner, with any suitable methods, software and/or hardware presently known or hereafter developed. In the system 500, the encryption and/or decryption processes may be implemented in an algorithm or program instructions executable by, and residing within memory accessible by, the processing element(s) 519 of the system 500 (in particular, by the signal processor 74/260 where the system 500 comprises the noninvasive system 10 or the whole-blood system 200, respectively). In the remote station(s) 524, 528, the encryption and/or decryption processes may be implemented in an algorithm or program instructions executable by, and residing within memory accessible by, processing element(s) (not shown) of the remote station 524/528 in question.
  • The connection of the system 500 to the network 520, provides either a direct or indirect link from the patient to the practitioner. The practitioner is thereby accorded an ability to monitor the status of the patient and may elect to be alerted should deviations in the measurement values the or timeliness thereof arise. The system may be configured to transmit measurement data at predetermined intervals, or at the time each measurement is performed. The measurements can be transmitted using various network protocols which include standard internet protocols, encrypted protocols, or email protocols.
  • In one embodiment, the signal processing system 516 is additionally capable of providing visual or audible cues to the patient when the time arrives to conduct a measurement. These alerts may be augmented by requests, transmitted over the network 520 to the instrument, from the practitioner. Errors introduced within measurements and recordation within a manual system can thereby be eliminated with the electronically logged measurements. It will be appreciated that the system provides enhanced utility and measurement credibility in comparison to the use of an instrument that requires manual logging of the measurements and permits no practitioner interaction therewith.
  • Secretive non-compliance may also be eliminated as the patient is not conferred the responsibility of manually logging measurements. In using the system 500, the measurements collected within the instrument by the patient are capable of being transmitted to a practitioner, or a centralized computer, such that if a patient is not being diligent in conducting measurements, the practitioner may immediately contact the patient to reinforce the need for compliance. In addition, the information provided over the network can be used to warn the practitioner when measurement readings appear abnormal, so that the practitioner may then investigate the situation and verify the status of the patient.
  • It will be appreciated that the invention has particular utility for patients preferring to receive direct guidance from a practitioner. The information that flows between the patient and the practitioner increases the ability of the practitioner to provide knowledgeable patient guidance.
  • FIG. 19 illustrates the functional blocks of an embodiment of circuitry 532 for implementing the signal processing hardware 516 shown in FIG. 18. A network connection 534 connects to a network processing circuit, exemplified by an Internet Protocol (IP) circuit or processor 536. Numerous circuits are available for providing internet connectivity, such as the SX-Stack™ chip from Scenix Semiconductor, and the iChip™ from Connect One Electronics. These integrated circuit chips and other available chips provide interface layers for supporting a Transmission Control Protocol/Internet Protocol (TCP/IP). The internet protocol chip 536 has an interface 538 with a control processor section 540, which preferably comprises a microcontroller or the like. The control processor section 540 in turn has access to conventional memory 542. To provide security and fault tolerance of the instrument it is preferable for the control processor, or the internet protocol circuit, to encrypt and provide verification strings or tokens within the data being sent across the network, and accordingly to decrypt information being received and verify the received strings or tokens. The control processor 540 has an interface 544 with the instrumentation circuits 546, which is in turn configured with an interface 548 to the analyte detection element 514 shown in FIG. 18.
  • The network link provides a mechanism to facilitate performing and recording analyte measurements under supervision, while it additionally provides for periodic instrument calibration, and the ability to assure both measurement and calibration compliance. Calibration data can be communicated from systems 500 in the field to the system manufacturer, or a service organization, so that the systems 500 and their calibrations may be logged. The disclosed network link can be utilized to provide various mechanisms for assuring calibration compliance. Generally the mechanisms are of two categories, those that provide information or a warning about calibration, and those that prevent use of an instrument which is out of calibration. In one embodiment, systems 500 which have exceeded their calibration interval, or schedule, are to be locked out from further use until recalibration is performed. For example, the system 500 may be set to operate for thirteen months for a given calibration interval of twelve months. The system 500 may issue warnings prior to the expiration of calibration, and warnings of increased severity after the expiration of the calibration interval. If the system 500, however, is not properly calibrated by the end of the thirteen months, normal operation ceases, thereby locking out the user after providing an appropriate error message in regard to the expired calibration. Upon recalibration, the calibrated operation interval is restored to provide for another thirteen month period of calibrated operation.
  • Alternatively, or in addition thereto, a “lockout command” can be sent to the system 500 over the network 520 from the manufacturer, practitioner or system maintenance organization, thereby engaging a lockout mode of the system 500, so that operation may not be continued until the system 500 has been serviced. The lockout command could also be sent in the event that the patient has not paid his or her bills, or be sent under other circumstances warranting lockout of the system 500.
  • Another mode is that of locking out normal system use after the expiration of calibration, and allowing limited use thereafter only after a code, or token, has been downloaded from a supervisory site. Although many variations are possible, the code could for instance be provided when a calibration appointment is made for the system 500. To provide continued service and minimize cost, the patient may be allowed to perform calibration checks of the system 500. The patient is supplied with a small set of analyte calibration standards which are read by the system 500 once it is put into a calibration mode and preferably connected to a remote site for supervising the process. Should the calibration check pass, wherein the instrument readings fall within normal levels, or be capable of being automatically adjusted thereto, the calibration interval may be extended. Failure of the calibration check would typically necessitate returning the system 500 for service.
  • FIG. 20 illustrates an embodiment of a process 550 for assuring calibration compliance within the analyte detection system 500 by utilizing a lockout mechanism. The programmed instructions associated with the analyte detection system 500 are started at block 552 and initialized at block 554, and a check is made on a lockout flag at block 556 to determine if it was set during a prior session by a command received via the network 520, or due to being out of calibration. Not having been locked out from a prior session, the real-time clock (RTC) of the system 500 is read at block 558 and a calculation is performed at block 560 comparing the current date with the stored calibration date and calibration interval. If upon checking calibration at block 562 the calibration interval has not yet expired, then a calculation is performed at block 564 comparing the current date with the stored calibration date and near-calibration interval. Near-calibration is checked at block 566 and, if calibration is to expire soon, then a user warning is issued at block 568, preferably informing the user of the date of the upcoming expiration of the calibration interval. The lockout flag is cleared at block 570 and processing within the system 500 continues with normal instrument functions being accessible at block 572, along with calibration and other limited functions at block 574, until the user shuts down the instrument and processing ends at block 576. If the lockout flag was set from a prior instrument operation, or the calibration interval was exceeded, then a lockout flag would be set at block 578, and the instrument functionality would thereby be restricted to execution of the calibration procedures and other limited functions at block 578 while the normal instrument functionality would not be accessible. The calibration procedure itself may be augmented and improved by providing interaction between the servicing party and the manufacturer, such interaction may include providing guidance information to the servicing party, and the collection of measurement information by the manufacturer.
  • It will be appreciated that the present invention provides functionality beyond that which can be provided by a stand-alone analyte detection system, as the practitioner, or practitioner's office, is involved in the analyte measurement process to confer a portion of the benefits normally associated with an office visit. The aforesaid description illustrates how these features provide the capability for two-way data flow which facilitates the conducting and recording of correct measurements while encouraging compliance in regard to both measurements and instrument calibration. Furthermore, the data collected by the system may be utilized by others in addition to the practitioner, such as pharmaceutical companies which may be provided data access to alter or administer medication programs, and insurance companies which may require data regarding patient diligence according to the specified treatment program.
  • III. Software Download Capabilities
  • FIG. 21 illustrates one embodiment of a software update system 600. The software update system 600 includes an analyte detection system 602 that is connectable to a centralized computer 604 via a network 606. The analyte detection system 602 may comprise a portable, near-patient device that is capable of optically measuring analytes in a material sample. Other examples of the analyte measuring device 602 include, but not limited to, the noninvasive system 10 discussed in this disclosure, the whole-blood system 200 discussed in this disclosure, or any other suitable invasive or noninvasive analyte detection system.
  • As used herein, the term “computer” is a broad term and is used in its ordinary sense and refers, without limitation, to any programmable electronic device that can store, retrieve and process data. Examples of computers include terminal devices, such as personal computers, workstations, servers, mini computers, main-frame computers, laptop computers, a network of individual computers, mobile computers, palm top computers, hand held computers, set top for a TV, an interactive television, an interactive kiosk, a personal digital assistant (“PDA”), an interactive wireless communications device, or a combination thereof. The computers may further possess storage devices, input devices such as a keyboard, mouse or scanner, and output devices such as a computer screen or a speaker. Furthermore, the computers may serve as clients, servers, or a combination thereof.
  • As used herein, the term “network” is a broad term and is used in its ordinary sense and refers, without limitation, to a series of points or nodes interconnected by communication paths, such as a group of interconnected computers. Examples of networks are the Internet, storage networks, local area networks and wide area networks.
  • Further to FIG. 21, the analyte detection system 602 includes a network interface 608, a processor 610 and software 612. The centralized computer 604 includes at least one software update 614. In one embodiment, when the analyte measuring device 602 is connected to the network 606, the analyte detection system 602 and the centralized computer 604 are in two-way communication. Consequently, the analyte detection system 602 may send information (e.g., analyte measurements) to the centralized computer 604 and the centralized computer 604 may send information (e.g., a software update 614) to the analyte measuring device 602. Other architectures of networked systems, as known by those skilled in the art, may also be used in place of the architecture set forth in FIG. 21. For example, the architecture shown in FIG. 18, and/or any of the variants thereof discussed above in connection with FIG. 18. may be used instead of the system 600 shown in FIG. 21. For example, one or more of the computers 528/528′/528″/528′″ may share the herein-described functions of, or replace entirely, the centralized computer 604, in which case the centralized computer 604 may be omitted.
  • As used herein, the term “processor” is a broad term and is used in its ordinary sense and refers, without limitation, to the part of a computer that operates on data. Examples of processors are central processing units (“CPU”) and microprocessors.
  • As used herein, the term “software” is a broad term and is used in its ordinary sense and refers, without limitation, to instructions executable by a computer or related device. Examples of software include computer programs and operating systems.
  • As used herein, the term “software update” or “update” is a broad term and is used in its ordinary sense and refers, without limitation, to information used by a computer to modify software. A software update may be, for example, data, algorithms or programs.
  • A process flow diagram of a preferred software update process 700 is shown in FIG. 22. First, in an act 702, a user performs analyte measurements with the analyte detection system 602. Advantageously, as discussed above, the user may perform analyte measurements using the analyte detection system 602 at a remote location (e.g., the user's home).
  • Further to the act 702, the analyte detection system 602 detects analytes in a material sample and calculates an analyte concentration in accordance to the analyte detection system's software 612. Additionally, the analyte detection system may issue alerts to the user, for example, in response to exceeded tolerances defined in the software 612. The alerts may be visually displayed to the user and/or audibly sounded to the user. For instance, the analyte detection system 602 may issue an alert in response to an elapsed calibration time tolerance defined in the software 612. Other alerts may be issued when the software or analyte-concentration calculation algorithm is out of date, or when the analyte concentration readings made by the detection system 602 are higher or lower than defined safe limits or ranges.
  • In one embodiment, the software 612 is contained in the analyte detection system 602 internally. In another embodiment, the software 612 is retained external to the analyte detection system 602.
  • Next, in an act 704, the analyte detection system 602 is connected to the centralized computer 604 via the network 606. Advantageously, the network interface 608 readily connects the analyte detection system 602 to the network 606. Furthermore, once the analyte measuring device 602 is connected to the network 606, the analyte measuring device 602 is, in one embodiment, in two-way communication with the centralized computer 604. In one embodiment, the communication between the analyte measuring device 602 and the centralized computer 604 is established without any intervention from a user.
  • The process 700 then proceeds to a decision act 706 where the centralized computer 604 determines an update status for the analyte measuring device's software 612. Various conditions may trigger the centralized computer 604 to update the software 612. In one embodiment, a condition for updating the software 612 is the presence of a new drug in the material sample (e.g., a new drug taken by the user) that alters the analyte calculations. Specifically, the centralized computer 604 determines whether the software 612 currently in use accounts for the use of the new drug. If the current software does not account for the new drug, the centralized computer 604 sends a software update 614 over the network 706 that does account for the new drug, and as a result, corrects future analyte calculations performed by the analyte measuring device 602. In another embodiment, a condition for updating the software 612 is where a new analyte-detection algorithm is developed. For example, the new algorithm may improve the accuracy or speed of the analyte detection system 602 over the software 612 currently in use. In another embodiment, a condition for updating the software 612 is where the analyte detection system 602 should display a new warning or where the monitoring device should display an existing warning in response to new or different events. The existing warning or the new warning may be displayed, for instance, in response to new information learned from a subset of a customer population. Advantageously, other conditions not specifically mentioned herein may also trigger the centralized computer 604 to update the software 612.
  • If the centralized computer 604 decides that the software 612 does not need to be updated in the decision act 706, then the update process 700 proceeds via the “No” path to an act 708. In the act 708, the user disconnects the analyte detection system 602 from the network and the software 612 is not updated. Thus, the analyte detection system 602 operates in the same manner as the analyte detection system 602 previously operated in the act 702.
  • If the centralized computer 604 decides that the software 612 needs to be updated in the decision act 706, then the update process 700 proceeds via the “Yes” path to an act 710. In the act 710, the centralized computer 604 sends a software update 614 to the analyte detection system 602. In one embodiment, the centralized computer 604 contains a database of various software updates 614, and consequently, the centralized computer 604 selects the appropriate software update 614 from the database and then sends the software update 614 to the analyte detection system 602.
  • Next, in an act 712, the analyte detection system 602 receives (e.g. downloads) the software update 614. The analyte detection system 602 then preferably modifies the software 612 to an updated version of the software 612. The process then proceeds to an act 714.
  • In the act 714, the user performs analyte measurements in accordance with the updated software 612. Thus, depending upon the software update 614, the analyte measuring device 602 operates differently than the manner in which the analyte measuring device 602 previously operated in act 702. One example is that the analyte detection system 602 may calculate analyte concentrations differently. Another example is that the analyte detection system 602 may displays new warnings to the user. A further example is that the analyte detection system 602 may display the same warnings, but the warnings are triggered by different events.
  • In any of the embodiments of the software update system 600 discussed herein, the analyte detection system 602 and/or the centralized computer 604 (or, where applicable, the computer(s) 528) may be configured to encrypt any or all of the data that it transmits over the network 606. Where the user of any of the analyte detection system 602 and the centralized computer 604 (or the analyte detection system/centralized computer itself) is authorized to receive, read and/or otherwise use the encrypted data, the recipient system 602/computer 604 is configured to decrypt the encrypted data, to make the data available to the device and/or the user thereof. By encrypting the data, physician-patient confidentiality, or any physician-patient privilege may be preserved, preventing unauthorized reading or use of the data. Encryption also permits transmission of data over wireless networks or public networks such as the Internet while preserving confidentiality of the transmitted data.
  • It is contemplated that the encryption and decryption may be performed in any suitable manner, with any suitable methods, software and/or hardware presently known or hereafter developed. In the analyte detection system 602, the encryption and/or decryption processes may be implemented in an algorithm or program instructions executable by, and residing within memory accessible by, the processor 610 of the analyte detection system 602 (in particular, by the signal processor 74/260 where the analyte detection system 602 comprises the noninvasive system 10 or the whole-blood system 200, respectively). In the centralized computer 604 (or, where applicable, the computer(s) 528), the encryption and/or decryption processes may be implemented in an algorithm or program instructions executable by, and residing within memory accessible by, processing element(s) (not shown) of the computer 604/528 in question.
  • The software update process 700 has many advantages. One advantage is that the software 612 of the analyte measuring device 602 may be updated without requiring significant user participation. Another advantage is that the software 612 may be quickly and conveniently updated at a remote location (e.g., the user's home) rather than requiring the user to travel to, for example, a doctor's office or other administrative center.
  • Although described above in connection with particular embodiments of the present invention, it should be understood the descriptions of the embodiments are illustrative of the invention and are not intended to be limiting. Various modifications and applications may occur to those skilled in the art without departing from the true spirit and scope of the invention. Furthermore, any method which is described and/or illustrated herein is not limited to the exact sequence of acts described, nor is it necessarily limited to the practice of all of the acts set forth. Other sequences of events or acts, or less than all of the events, or simultaneous occurrence of the events, may be utilized in practicing the method(s) in question.

Claims (26)

1-45. (canceled)
46. An analyte concentration monitoring system, comprising:
a non-interferometric analyte detection system comprising:
a source capable of emitting a beam of radiation along an optical path;
a detector located in said optical path, wherein said analyte detection system is configured to hold a sample element situated in said optical path;
a processor that calculates an analyte concentration in a sample in said sample element in accordance with software executable by said processor; and
a network interface that is configured to provide a connection to a computing network and to support communication between said computing network and said analyte detection system;
wherein said analyte detection system is configured to receive an update from said computing network without intervention from a user, said update being configured to alter the calculation of said analyte concentration by said processor.
47. The monitoring system of claim 46, wherein the analyte detection system is configured to automatically receive an update from said computing network.
48. The monitoring system of claim 46, further comprising a computing network configured to send said update to said analyte detection system.
49. The monitoring system of claim 46, wherein said analyte detection system is dimensioned for handheld portability.
50. The monitoring system of claim 46, wherein said analyte detection system is configured to continuously calculate said analyte concentration in said sample in said sample element.
51. An analyte concentration monitoring system, comprising:
a non-interferometric, optical analyte detection system comprising:
a housing;
a sample extractor configured to draw a sample through a patient's skin;
a processor that calculates an analyte concentration in a sample in accordance with software executable by said processor; and
a network interface that is configured to provide connectivity to a computing network;
wherein said analyte detection system is configured to receive an update to said software from a computing network via said network interface, the update is configured to update said software which is executable by said processor.
52. The monitoring system of claim 51, wherein said optical analyte detection system is configured to calculate an analyte concentration of a sample of a patient, when said sample is positioned within said analyte detection system.
53. The monitoring system of claim 51, wherein said analyte detection system executes said software to calculate an analyte concentration in a sample of blood.
54. The monitoring system of claim 51, wherein the optical analyte detection system is dimensioned for handheld portability.
55. The monitoring system of claim 51, wherein said software comprises one selected from the group consisting of algorithm, data, instructions, programs, and combinations thereof.
56. The monitoring system of claim 51, further comprising a computing network configured to send said update to said analyte detection system, the computing network checks an update status of said analyte detection system and selects said update based on said update status.
57. The monitoring system of claim 56, wherein said computing network automatically checks said update status upon connection of said computing network to said analyte detection system via said network interface.
58. The monitoring system of claim 51, further comprising a computing network at a remote location and said network interface connects to said computing network via an Internet connection.
59. The monitoring system of claim 51, wherein said network interface comprises a wireless interface.
60. The monitoring system of claim 59, wherein said wireless interface comprises a Bluetooth interface or IEEE 802.11(b) interface.
61. The monitoring system of claim 59, wherein said analyte detection system uses optical transmission spectroscopy to determine said analyte concentration.
62. A method of updating software on an analyte detection system, comprising:
providing a computer;
in said computer checking an update status of software included in a non-interferometric, optical analyte detection system, the analyte detection system having a sample extractor, the analyte detection system being configured to calculate an analyte concentration;
when said update status indicates that a software update is needed, sending said software update to said analyte detection system without intervention from a user; and
wherein said software update is configured to update said software in said analyte detection system.
63. The method of claim 62, further comprising in said analyte detection system, updating said software with said software update.
64. The method of claim 62, further comprising receiving information from said analyte detection system via a network connected to said computer.
65. The method of claim 64, wherein said information includes analyte concentration measurements.
66. The method of claim 62, wherein said software update includes at least one warning and instructions for communication of said at least one warning to a user of said analyte detection system.
67. The method of claim 62, further comprising displaying a warning on said analyte detection system.
68. The method of claim 62, further comprising calculating the analyte concentration, wherein said software update alters said calculating.
69. The method of claim 62, further comprising encrypting said software update.
70. The method of claim 69, further comprising decrypting said software update.
US11/106,352 2002-11-08 2005-04-14 Analyte detection system with software download capabilities Abandoned US20050238538A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/106,352 US20050238538A1 (en) 2002-11-08 2005-04-14 Analyte detection system with software download capabilities

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/291,908 US6931328B2 (en) 2002-11-08 2002-11-08 Analyte detection system with software download capabilities
US11/106,352 US20050238538A1 (en) 2002-11-08 2005-04-14 Analyte detection system with software download capabilities

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/291,908 Continuation US6931328B2 (en) 2002-11-08 2002-11-08 Analyte detection system with software download capabilities

Publications (1)

Publication Number Publication Date
US20050238538A1 true US20050238538A1 (en) 2005-10-27

Family

ID=32229310

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/291,908 Expired - Lifetime US6931328B2 (en) 2002-11-08 2002-11-08 Analyte detection system with software download capabilities
US11/106,352 Abandoned US20050238538A1 (en) 2002-11-08 2005-04-14 Analyte detection system with software download capabilities

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/291,908 Expired - Lifetime US6931328B2 (en) 2002-11-08 2002-11-08 Analyte detection system with software download capabilities

Country Status (6)

Country Link
US (2) US6931328B2 (en)
EP (1) EP1565103A1 (en)
JP (1) JP2006508713A (en)
AU (1) AU2003290619A1 (en)
CA (1) CA2505185A1 (en)
WO (1) WO2004043250A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060047455A1 (en) * 2004-08-25 2006-03-02 Catelani Mark P Method and apparatus for management of calibration data
US20060200071A1 (en) * 2005-02-14 2006-09-07 Sterling Bernhard B Method and apparatus for detection of multiple analytes
US7445389B2 (en) 2006-04-10 2008-11-04 Finisar Corporation Active optical cable with integrated eye safety
US20090295910A1 (en) * 2005-03-24 2009-12-03 Jose Mir Hyperspectral Imaging System and Methods Thereof
US8292826B1 (en) 2011-06-21 2012-10-23 YofiMETER, Inc. Cocking and advancing mechanism for analyte testing device
US8333717B1 (en) 2011-06-21 2012-12-18 Yofimeter, Llc Test unit cartridge for analyte testing device
US8425444B2 (en) 2006-04-11 2013-04-23 Optiscan Biomedical Corporation Anti-clotting apparatus and methods for fluid handling system
US8487822B1 (en) * 2007-09-13 2013-07-16 Rockwell Collins, Inc. Adaptible antenna using liquid metal structures
US8597190B2 (en) 2007-05-18 2013-12-03 Optiscan Biomedical Corporation Monitoring systems and methods with fast initialization
US8961432B2 (en) 2011-06-21 2015-02-24 Yofimeter, Llc Analyte testing devices

Families Citing this family (288)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
AU6255699A (en) * 1998-10-08 2000-04-26 Minimed, Inc. Telemetered characteristic monitor system
US7766873B2 (en) 1998-10-29 2010-08-03 Medtronic Minimed, Inc. Method and apparatus for detecting occlusions in an ambulatory infusion pump
US7621893B2 (en) * 1998-10-29 2009-11-24 Medtronic Minimed, Inc. Methods and apparatuses for detecting occlusions in an ambulatory infusion pump
US7806886B2 (en) 1999-06-03 2010-10-05 Medtronic Minimed, Inc. Apparatus and method for controlling insulin infusion with state variable feedback
US6978212B1 (en) * 1999-11-01 2005-12-20 Smiths Detection Inc. System for portable sensing
US20030060765A1 (en) * 2000-02-16 2003-03-27 Arthur Campbell Infusion device menu structure and method of using the same
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
JP4498636B2 (en) 2001-04-27 2010-07-07 日本サーモスタット株式会社 Thermostat device
ATE485766T1 (en) 2001-06-12 2010-11-15 Pelikan Technologies Inc ELECTRICAL ACTUATING ELEMENT FOR A LANCET
US7025774B2 (en) 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
ATE497731T1 (en) 2001-06-12 2011-02-15 Pelikan Technologies Inc DEVICE FOR INCREASING THE SUCCESS RATE OF BLOOD YIELD OBTAINED BY A FINGER PICK
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
WO2002100254A2 (en) 2001-06-12 2002-12-19 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US7344507B2 (en) 2002-04-19 2008-03-18 Pelikan Technologies, Inc. Method and apparatus for lancet actuation
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
CA2448905C (en) 2001-06-12 2010-09-07 Pelikan Technologies, Inc. Blood sampling apparatus and method
US7316700B2 (en) 2001-06-12 2008-01-08 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US6827702B2 (en) 2001-09-07 2004-12-07 Medtronic Minimed, Inc. Safety limits for closed-loop infusion pump control
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7291117B2 (en) 2002-04-19 2007-11-06 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7371247B2 (en) 2002-04-19 2008-05-13 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US8512276B2 (en) 2002-07-24 2013-08-20 Medtronic Minimed, Inc. System for providing blood glucose measurements to an infusion device
US20040068230A1 (en) * 2002-07-24 2004-04-08 Medtronic Minimed, Inc. System for providing blood glucose measurements to an infusion device
US7278983B2 (en) 2002-07-24 2007-10-09 Medtronic Minimed, Inc. Physiological monitoring device for controlling a medication infusion device
US20040031029A1 (en) * 2002-08-06 2004-02-12 Kyu-Woong Lee Methods and systems for automatically updating software components in a network
US20040122353A1 (en) * 2002-12-19 2004-06-24 Medtronic Minimed, Inc. Relay device for transferring information between a sensor system and a fluid delivery system
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US7529754B2 (en) * 2003-03-14 2009-05-05 Websense, Inc. System and method of monitoring and controlling application files
US7185015B2 (en) 2003-03-14 2007-02-27 Websense, Inc. System and method of monitoring and controlling application files
US8718943B2 (en) * 2003-04-01 2014-05-06 Abbott Diabetes Care Inc. Method and device for utilizing analyte levels to assist in the treatment of diabetes
US20050038674A1 (en) * 2003-04-15 2005-02-17 Braig James R. System and method for managing a chronic medical condition
WO2004107964A2 (en) 2003-06-06 2004-12-16 Pelikan Technologies, Inc. Blood harvesting device with electronic control
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US20050027166A1 (en) * 2003-06-17 2005-02-03 Shinya Matsumoto Endoscope system for fluorescent observation
US20190357827A1 (en) 2003-08-01 2019-11-28 Dexcom, Inc. Analyte sensor
EP1671096A4 (en) 2003-09-29 2009-09-16 Pelikan Technologies Inc Method and apparatus for an improved sample capture device
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc Method and apparatus for a variable user interface
JP2005190068A (en) * 2003-12-25 2005-07-14 Fanuc Ltd Software download system for controller
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
WO2005111580A1 (en) * 2004-05-07 2005-11-24 Optiscan Biomedical Corporation Sample element with fringing-reduction capabilities
CA2566470A1 (en) * 2004-05-14 2005-12-01 Brian C. Thompson Method and apparatus for implementing patient data download for multiple different meter types
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc Method and apparatus for a fluid sampling device
US20070100222A1 (en) * 2004-06-14 2007-05-03 Metronic Minimed, Inc. Analyte sensing apparatus for hospital use
US7344500B2 (en) * 2004-07-27 2008-03-18 Medtronic Minimed, Inc. Sensing system with auxiliary display
US7303543B1 (en) * 2004-12-03 2007-12-04 Medtronic Minimed, Inc. Medication infusion set
RU2430264C2 (en) * 2004-12-16 2011-09-27 Индепендент Нэчурэл Ресорсиз, Инк. Power system built around float-type pump
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US7704229B2 (en) 2005-02-03 2010-04-27 Medtronic Minimed, Inc. Insertion device
US8251907B2 (en) 2005-02-14 2012-08-28 Optiscan Biomedical Corporation System and method for determining a treatment dose for a patient
US7785258B2 (en) 2005-10-06 2010-08-31 Optiscan Biomedical Corporation System and method for determining a treatment dose for a patient
US20060184104A1 (en) * 2005-02-15 2006-08-17 Medtronic Minimed, Inc. Needle guard
US20070033074A1 (en) * 2005-06-03 2007-02-08 Medtronic Minimed, Inc. Therapy management system
US20060272652A1 (en) * 2005-06-03 2006-12-07 Medtronic Minimed, Inc. Virtual patient software system for educating and treating individuals with diabetes
US8251904B2 (en) 2005-06-09 2012-08-28 Roche Diagnostics Operations, Inc. Device and method for insulin dosing
US20070016449A1 (en) * 2005-06-29 2007-01-18 Gary Cohen Flexible glucose analysis using varying time report deltas and configurable glucose target ranges
US9129038B2 (en) 2005-07-05 2015-09-08 Andrew Begel Discovering and exploiting relationships in software repositories
US20070066956A1 (en) * 2005-07-27 2007-03-22 Medtronic Minimed, Inc. Systems and methods for entering temporary basal rate pattern in an infusion device
US20070060870A1 (en) * 2005-08-16 2007-03-15 Tolle Mike Charles V Controller device for an infusion pump
US20070093786A1 (en) * 2005-08-16 2007-04-26 Medtronic Minimed, Inc. Watch controller for a medical device
US20090227855A1 (en) 2005-08-16 2009-09-10 Medtronic Minimed, Inc. Controller device for an infusion pump
US20070060869A1 (en) * 2005-08-16 2007-03-15 Tolle Mike C V Controller device for an infusion pump
US7737581B2 (en) 2005-08-16 2010-06-15 Medtronic Minimed, Inc. Method and apparatus for predicting end of battery life
US7713240B2 (en) 2005-09-13 2010-05-11 Medtronic Minimed, Inc. Modular external infusion device
US9072476B2 (en) 2005-09-23 2015-07-07 Medtronic Minimed, Inc. Flexible sensor apparatus
US7725148B2 (en) * 2005-09-23 2010-05-25 Medtronic Minimed, Inc. Sensor with layered electrodes
US8453243B2 (en) 2005-12-28 2013-05-28 Websense, Inc. Real time lockdown
US20070169533A1 (en) * 2005-12-30 2007-07-26 Medtronic Minimed, Inc. Methods and systems for detecting the hydration of sensors
US20070173712A1 (en) * 2005-12-30 2007-07-26 Medtronic Minimed, Inc. Method of and system for stabilization of sensors
US7985330B2 (en) * 2005-12-30 2011-07-26 Medtronic Minimed, Inc. Method and system for detecting age, hydration, and functional states of sensors using electrochemical impedance spectroscopy
US7774038B2 (en) * 2005-12-30 2010-08-10 Medtronic Minimed, Inc. Real-time self-calibrating sensor system and method
US8114268B2 (en) 2005-12-30 2012-02-14 Medtronic Minimed, Inc. Method and system for remedying sensor malfunctions detected by electrochemical impedance spectroscopy
US8114269B2 (en) 2005-12-30 2012-02-14 Medtronic Minimed, Inc. System and method for determining the point of hydration and proper time to apply potential to a glucose sensor
US8224034B2 (en) * 2006-02-02 2012-07-17 NL Giken Incorporated Biometrics system, biologic information storage, and portable device
US7630748B2 (en) 2006-10-25 2009-12-08 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US9675290B2 (en) 2012-10-30 2017-06-13 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US8224415B2 (en) 2009-01-29 2012-07-17 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US8073008B2 (en) * 2006-04-28 2011-12-06 Medtronic Minimed, Inc. Subnetwork synchronization and variable transmit synchronization techniques for a wireless medical device network
US7942844B2 (en) 2006-04-28 2011-05-17 Medtronic Minimed, Inc. Remote monitoring for networked fluid infusion systems
US20070255126A1 (en) * 2006-04-28 2007-11-01 Moberg Sheldon B Data communication in networked fluid infusion systems
WO2007134146A2 (en) * 2006-05-12 2007-11-22 Invivo Corporation Isolation system for mri-compatible wireless patient monitors
US20080139910A1 (en) * 2006-12-06 2008-06-12 Metronic Minimed, Inc. Analyte sensor and method of using the same
JP5191664B2 (en) * 2007-01-09 2013-05-08 ベックマン コールター, インコーポレイテッド Analysis equipment
US8265957B2 (en) * 2007-01-18 2012-09-11 At&T Intellectual Property I, L.P. Methods, systems, and computer-readable media for disease management
US10154804B2 (en) * 2007-01-31 2018-12-18 Medtronic Minimed, Inc. Model predictive method and system for controlling and supervising insulin infusion
US20080269714A1 (en) 2007-04-25 2008-10-30 Medtronic Minimed, Inc. Closed loop/semi-closed loop therapy modification system
US8417311B2 (en) 2008-09-12 2013-04-09 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
US20080300572A1 (en) * 2007-06-01 2008-12-04 Medtronic Minimed, Inc. Wireless monitor for a personal medical device system
US8160900B2 (en) 2007-06-29 2012-04-17 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
RU2010103330A (en) * 2007-07-03 2011-08-10 Смитс Дитекшн Инк. (US) SYSTEM (OPTIONS) AND PORTABLE DETECTOR AND METHOD (OPTIONS) FOR TESTING AN UNKNOWN SUBJECT, PORTABLE DETECTOR CONSUMPTION
MX2010003855A (en) 2007-10-10 2010-04-27 Optiscan Biomedical Corp Fluid component analysis system and method for glucose monitoring and control.
WO2009049245A1 (en) * 2007-10-11 2009-04-16 Optiscan Biomedical Corporation Synchronization and configuration of patient monitoring devices
US20090112626A1 (en) * 2007-10-30 2009-04-30 Cary Talbot Remote wireless monitoring, processing, and communication of patient data
US8313467B2 (en) 2007-12-27 2012-11-20 Medtronic Minimed, Inc. Reservoir pressure equalization systems and methods
US20090210169A1 (en) * 2008-02-15 2009-08-20 Ge-Hitachi Nuclear Energy Americas Llc Hand-held systems and methods for detection of contaminants in a liquid
EP2265324B1 (en) 2008-04-11 2015-01-28 Sanofi-Aventis Deutschland GmbH Integrated analyte measurement system
CN102046069A (en) * 2008-05-12 2011-05-04 心脏技术有限公司 Method and system for monitoring a health condition
US9295786B2 (en) 2008-05-28 2016-03-29 Medtronic Minimed, Inc. Needle protective device for subcutaneous sensors
US8591410B2 (en) 2008-05-30 2013-11-26 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US8924159B2 (en) 2008-05-30 2014-12-30 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
US8208973B2 (en) * 2008-11-05 2012-06-26 Medtronic Minimed, Inc. System and method for variable beacon timing with wireless devices
US9326707B2 (en) 2008-11-10 2016-05-03 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
US8898660B2 (en) * 2008-11-25 2014-11-25 Fisher-Rosemount Systems, Inc. Systems and methods to provide customized release notes during a software system upgrade of a process control system
US8914783B2 (en) * 2008-11-25 2014-12-16 Fisher-Rosemount Systems, Inc. Software deployment manager integration within a process control system
US9330237B2 (en) 2008-12-24 2016-05-03 Medtronic Minimed, Inc. Pattern recognition and filtering in a therapy management system
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US20110006880A1 (en) * 2009-07-09 2011-01-13 Medtronic Minimed, Inc. Fingerprint-linked control of a portable medical device
US8344847B2 (en) 2009-07-09 2013-01-01 Medtronic Minimed, Inc. Coordination of control commands in a medical device system having at least one therapy delivery device and at least one wireless controller device
US20110009725A1 (en) * 2009-07-09 2011-01-13 Medtronic Minimed, Inc. Providing contextually relevant advertisements and e-commerce features in a personal medical device system
US8487758B2 (en) * 2009-09-02 2013-07-16 Medtronic Minimed, Inc. Medical device having an intelligent alerting scheme, and related operating methods
EP2494323A4 (en) 2009-10-30 2014-07-16 Abbott Diabetes Care Inc Method and apparatus for detecting false hypoglycemic conditions
US8386042B2 (en) * 2009-11-03 2013-02-26 Medtronic Minimed, Inc. Omnidirectional accelerometer device and medical device incorporating same
US8574201B2 (en) 2009-12-22 2013-11-05 Medtronic Minimed, Inc. Syringe piston with check valve seal
US8755269B2 (en) * 2009-12-23 2014-06-17 Medtronic Minimed, Inc. Ranking and switching of wireless channels in a body area network of medical devices
US20110152970A1 (en) * 2009-12-23 2011-06-23 Medtronic Minimed, Inc. Location-based ranking and switching of wireless channels in a body area network of medical devices
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US10092229B2 (en) 2010-06-29 2018-10-09 Abbott Diabetes Care Inc. Calibration of analyte measurement system
US8562565B2 (en) 2010-10-15 2013-10-22 Medtronic Minimed, Inc. Battery shock absorber for a portable medical device
US8603033B2 (en) 2010-10-15 2013-12-10 Medtronic Minimed, Inc. Medical device and related assembly having an offset element for a piezoelectric speaker
US8603032B2 (en) 2010-10-15 2013-12-10 Medtronic Minimed, Inc. Medical device with membrane keypad sealing element, and related manufacturing method
US8474332B2 (en) 2010-10-20 2013-07-02 Medtronic Minimed, Inc. Sensor assembly and medical device incorporating same
US8479595B2 (en) 2010-10-20 2013-07-09 Medtronic Minimed, Inc. Sensor assembly and medical device incorporating same
US8495918B2 (en) 2010-10-20 2013-07-30 Medtronic Minimed, Inc. Sensor assembly and medical device incorporating same
US8197444B1 (en) 2010-12-22 2012-06-12 Medtronic Minimed, Inc. Monitoring the seating status of a fluid reservoir in a fluid infusion device
US8628510B2 (en) 2010-12-22 2014-01-14 Medtronic Minimed, Inc. Monitoring the operating health of a force sensor in a fluid infusion device
US8469942B2 (en) 2010-12-22 2013-06-25 Medtronic Minimed, Inc. Occlusion detection for a fluid infusion device
US8690855B2 (en) * 2010-12-22 2014-04-08 Medtronic Minimed, Inc. Fluid reservoir seating procedure for a fluid infusion device
US9463309B2 (en) 2011-02-22 2016-10-11 Medtronic Minimed, Inc. Sealing assembly and structure for a fluid infusion device having a needled fluid reservoir
US8900206B2 (en) 2011-02-22 2014-12-02 Medtronic Minimed, Inc. Pressure vented fluid reservoir for a fluid infusion device
US9393399B2 (en) 2011-02-22 2016-07-19 Medtronic Minimed, Inc. Sealing assembly for a fluid reservoir of a fluid infusion device
US9283318B2 (en) 2011-02-22 2016-03-15 Medtronic Minimed, Inc. Flanged sealing element and needle guide pin assembly for a fluid infusion device having a needled fluid reservoir
US8614596B2 (en) 2011-02-28 2013-12-24 Medtronic Minimed, Inc. Systems and methods for initializing a voltage bus and medical devices incorporating same
US9101305B2 (en) 2011-03-09 2015-08-11 Medtronic Minimed, Inc. Glucose sensor product and related manufacturing and packaging methods
US8564447B2 (en) 2011-03-18 2013-10-22 Medtronic Minimed, Inc. Battery life indication techniques for an electronic device
US9018893B2 (en) 2011-03-18 2015-04-28 Medtronic Minimed, Inc. Power control techniques for an electronic device
WO2012142502A2 (en) 2011-04-15 2012-10-18 Dexcom Inc. Advanced analyte sensor calibration and error detection
US10092688B2 (en) * 2011-05-13 2018-10-09 Laura Jean Robinson Medicament kit and method of use
US8745572B2 (en) 2011-06-22 2014-06-03 Microsoft Corporation Software development automated analytics
US9622691B2 (en) 2011-10-31 2017-04-18 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9610401B2 (en) 2012-01-13 2017-04-04 Medtronic Minimed, Inc. Infusion set component with modular fluid channel element
US8603027B2 (en) 2012-03-20 2013-12-10 Medtronic Minimed, Inc. Occlusion detection using pulse-width modulation and medical device incorporating same
US8523803B1 (en) 2012-03-20 2013-09-03 Medtronic Minimed, Inc. Motor health monitoring and medical device incorporating same
US8603026B2 (en) 2012-03-20 2013-12-10 Medtronic Minimed, Inc. Dynamic pulse-width modulation motor control and medical device incorporating same
WO2013173541A1 (en) 2012-05-18 2013-11-21 Rebellion Photonics, Inc. Divided-aperture infra-red spectral imaging system for chemical detection
US9599508B2 (en) 2012-05-18 2017-03-21 Rebellion Photonics, Inc. Divided-aperture infra-red spectral imaging system
US8461589B1 (en) * 2012-06-05 2013-06-11 Texas Instruments Incorporated Circuit having integrated heating structure for parametric trimming
US20130338629A1 (en) 2012-06-07 2013-12-19 Medtronic Minimed, Inc. Diabetes therapy management system for recommending basal pattern adjustments
US9333292B2 (en) 2012-06-26 2016-05-10 Medtronic Minimed, Inc. Mechanically actuated fluid infusion device
US8808269B2 (en) 2012-08-21 2014-08-19 Medtronic Minimed, Inc. Reservoir plunger position monitoring and medical device incorporating same
US9878096B2 (en) 2012-08-30 2018-01-30 Medtronic Minimed, Inc. Generation of target glucose values for a closed-loop operating mode of an insulin infusion system
US10130767B2 (en) 2012-08-30 2018-11-20 Medtronic Minimed, Inc. Sensor model supervisor for a closed-loop insulin infusion system
US9623179B2 (en) 2012-08-30 2017-04-18 Medtronic Minimed, Inc. Safeguarding techniques for a closed-loop insulin infusion system
US9364609B2 (en) 2012-08-30 2016-06-14 Medtronic Minimed, Inc. Insulin on board compensation for a closed-loop insulin infusion system
US10496797B2 (en) 2012-08-30 2019-12-03 Medtronic Minimed, Inc. Blood glucose validation for a closed-loop operating mode of an insulin infusion system
US9662445B2 (en) 2012-08-30 2017-05-30 Medtronic Minimed, Inc. Regulating entry into a closed-loop operating mode of an insulin infusion system
US9849239B2 (en) 2012-08-30 2017-12-26 Medtronic Minimed, Inc. Generation and application of an insulin limit for a closed-loop operating mode of an insulin infusion system
EP2901153A4 (en) 2012-09-26 2016-04-27 Abbott Diabetes Care Inc Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US8870818B2 (en) 2012-11-15 2014-10-28 Medtronic Minimed, Inc. Systems and methods for alignment and detection of a consumable component
US9522223B2 (en) 2013-01-18 2016-12-20 Medtronic Minimed, Inc. Systems for fluid reservoir retention
US9107994B2 (en) 2013-01-18 2015-08-18 Medtronic Minimed, Inc. Systems for fluid reservoir retention
US9033924B2 (en) 2013-01-18 2015-05-19 Medtronic Minimed, Inc. Systems for fluid reservoir retention
US9308321B2 (en) 2013-02-18 2016-04-12 Medtronic Minimed, Inc. Infusion device having gear assembly initialization
US9445445B2 (en) 2013-03-14 2016-09-13 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
US10433773B1 (en) 2013-03-15 2019-10-08 Abbott Diabetes Care Inc. Noise rejection methods and apparatus for sparsely sampled analyte sensor data
US9474475B1 (en) 2013-03-15 2016-10-25 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
US10076285B2 (en) 2013-03-15 2018-09-18 Abbott Diabetes Care Inc. Sensor fault detection using analyte sensor data pattern comparison
US8920381B2 (en) 2013-04-12 2014-12-30 Medtronic Minimed, Inc. Infusion set with improved bore configuration
US9433731B2 (en) 2013-07-19 2016-09-06 Medtronic Minimed, Inc. Detecting unintentional motor motion and infusion device incorporating same
US9402949B2 (en) 2013-08-13 2016-08-02 Medtronic Minimed, Inc. Detecting conditions associated with medical device operations using matched filters
US9889257B2 (en) 2013-08-21 2018-02-13 Medtronic Minimed, Inc. Systems and methods for updating medical devices
US9880528B2 (en) 2013-08-21 2018-01-30 Medtronic Minimed, Inc. Medical devices and related updating methods and systems
US9259528B2 (en) 2013-08-22 2016-02-16 Medtronic Minimed, Inc. Fluid infusion device with safety coupling
EP2871452B1 (en) 2013-11-12 2019-05-01 Rebellion Photonics, Inc. Divided-aperture infra-red spectral imaging system
US9750877B2 (en) 2013-12-11 2017-09-05 Medtronic Minimed, Inc. Predicted time to assess and/or control a glycemic state
US9750878B2 (en) 2013-12-11 2017-09-05 Medtronic Minimed, Inc. Closed-loop control of glucose according to a predicted blood glucose trajectory
US10105488B2 (en) 2013-12-12 2018-10-23 Medtronic Minimed, Inc. Predictive infusion device operations and related methods and systems
US9849240B2 (en) 2013-12-12 2017-12-26 Medtronic Minimed, Inc. Data modification for predictive operations and devices incorporating same
US9694132B2 (en) 2013-12-19 2017-07-04 Medtronic Minimed, Inc. Insertion device for insertion set
GB2523989B (en) 2014-01-30 2020-07-29 Insulet Netherlands B V Therapeutic product delivery system and method of pairing
US9399096B2 (en) 2014-02-06 2016-07-26 Medtronic Minimed, Inc. Automatic closed-loop control adjustments and infusion systems incorporating same
US9861748B2 (en) 2014-02-06 2018-01-09 Medtronic Minimed, Inc. User-configurable closed-loop notifications and infusion systems incorporating same
US9610402B2 (en) 2014-03-24 2017-04-04 Medtronic Minimed, Inc. Transcutaneous conduit insertion mechanism with a living hinge for use with a fluid infusion patch pump device
US20170185748A1 (en) 2014-03-30 2017-06-29 Abbott Diabetes Care Inc. Method and Apparatus for Determining Meal Start and Peak Events in Analyte Monitoring Systems
US10001450B2 (en) 2014-04-18 2018-06-19 Medtronic Minimed, Inc. Nonlinear mapping technique for a physiological characteristic sensor
US10232113B2 (en) 2014-04-24 2019-03-19 Medtronic Minimed, Inc. Infusion devices and related methods and systems for regulating insulin on board
US20170026588A1 (en) 2014-05-01 2017-01-26 Rebellion Photonics, Inc. Dual-band divided-aperture infra-red spectral imaging system
US9681828B2 (en) 2014-05-01 2017-06-20 Medtronic Minimed, Inc. Physiological characteristic sensors and methods for forming such sensors
US11290662B2 (en) 2014-05-01 2022-03-29 Rebellion Photonics, Inc. Mobile gas and chemical imaging camera
US10275572B2 (en) 2014-05-01 2019-04-30 Medtronic Minimed, Inc. Detecting blockage of a reservoir cavity during a seating operation of a fluid infusion device
US10007765B2 (en) 2014-05-19 2018-06-26 Medtronic Minimed, Inc. Adaptive signal processing for infusion devices and related methods and systems
US10274349B2 (en) 2014-05-19 2019-04-30 Medtronic Minimed, Inc. Calibration factor adjustments for infusion devices and related methods and systems
US10152049B2 (en) 2014-05-19 2018-12-11 Medtronic Minimed, Inc. Glucose sensor health monitoring and related methods and systems
US10458905B2 (en) 2014-07-07 2019-10-29 Rebellion Photonics, Inc. Gas leak emission quantification with a gas cloud imager
US9833563B2 (en) 2014-09-26 2017-12-05 Medtronic Minimed, Inc. Systems for managing reservoir chamber pressure
US9839753B2 (en) 2014-09-26 2017-12-12 Medtronic Minimed, Inc. Systems for managing reservoir chamber pressure
US10279126B2 (en) 2014-10-07 2019-05-07 Medtronic Minimed, Inc. Fluid conduit assembly with gas trapping filter in the fluid flow path
US9833564B2 (en) 2014-11-25 2017-12-05 Medtronic Minimed, Inc. Fluid conduit assembly with air venting features
US10195341B2 (en) 2014-11-26 2019-02-05 Medtronic Minimed, Inc. Systems and methods for fluid infusion device with automatic reservoir fill
US9987420B2 (en) 2014-11-26 2018-06-05 Medtronic Minimed, Inc. Systems and methods for fluid infusion device with automatic reservoir fill
US9636453B2 (en) 2014-12-04 2017-05-02 Medtronic Minimed, Inc. Advance diagnosis of infusion device operating mode viability
US9943645B2 (en) 2014-12-04 2018-04-17 Medtronic Minimed, Inc. Methods for operating mode transitions and related infusion devices and systems
US9937292B2 (en) 2014-12-09 2018-04-10 Medtronic Minimed, Inc. Systems for filling a fluid infusion device reservoir
US10265031B2 (en) 2014-12-19 2019-04-23 Medtronic Minimed, Inc. Infusion devices and related methods and systems for automatic alert clearing
US10307535B2 (en) 2014-12-19 2019-06-04 Medtronic Minimed, Inc. Infusion devices and related methods and systems for preemptive alerting
EP3258991B1 (en) 2015-02-18 2020-10-21 Insulet Corporation Fluid delivery and infusion devices, and methods of use thereof
US10307528B2 (en) 2015-03-09 2019-06-04 Medtronic Minimed, Inc. Extensible infusion devices and related methods
US10449298B2 (en) 2015-03-26 2019-10-22 Medtronic Minimed, Inc. Fluid injection devices and related methods
US10137243B2 (en) 2015-05-26 2018-11-27 Medtronic Minimed, Inc. Infusion devices with distributed motor control and related operating methods
US9999721B2 (en) 2015-05-26 2018-06-19 Medtronic Minimed, Inc. Error handling in infusion devices with distributed motor control and related operating methods
US10575767B2 (en) 2015-05-29 2020-03-03 Medtronic Minimed, Inc. Method for monitoring an analyte, analyte sensor and analyte monitoring apparatus
US10648960B2 (en) 2015-05-29 2020-05-12 Rebellion Photonics, Inc. Hydrogen sulfide imaging system
US9987425B2 (en) 2015-06-22 2018-06-05 Medtronic Minimed, Inc. Occlusion detection techniques for a fluid infusion device having a rotary pump mechanism and sensor contact elements
US9879668B2 (en) 2015-06-22 2018-01-30 Medtronic Minimed, Inc. Occlusion detection techniques for a fluid infusion device having a rotary pump mechanism and an optical sensor
US10010668B2 (en) 2015-06-22 2018-07-03 Medtronic Minimed, Inc. Occlusion detection techniques for a fluid infusion device having a rotary pump mechanism and a force sensor
US9878095B2 (en) 2015-06-22 2018-01-30 Medtronic Minimed, Inc. Occlusion detection techniques for a fluid infusion device having a rotary pump mechanism and multiple sensor contact elements
US9993594B2 (en) 2015-06-22 2018-06-12 Medtronic Minimed, Inc. Occlusion detection techniques for a fluid infusion device having a rotary pump mechanism and rotor position sensors
US10463297B2 (en) 2015-08-21 2019-11-05 Medtronic Minimed, Inc. Personalized event detection methods and related devices and systems
US10478557B2 (en) 2015-08-21 2019-11-19 Medtronic Minimed, Inc. Personalized parameter modeling methods and related devices and systems
US10293108B2 (en) 2015-08-21 2019-05-21 Medtronic Minimed, Inc. Infusion devices and related patient ratio adjustment methods
US10867012B2 (en) 2015-08-21 2020-12-15 Medtronic Minimed, Inc. Data analytics and insight delivery for the management and control of diabetes
US10201657B2 (en) 2015-08-21 2019-02-12 Medtronic Minimed, Inc. Methods for providing sensor site rotation feedback and related infusion devices and systems
US10117992B2 (en) 2015-09-29 2018-11-06 Medtronic Minimed, Inc. Infusion devices and related rescue detection methods
US11666702B2 (en) 2015-10-19 2023-06-06 Medtronic Minimed, Inc. Medical devices and related event pattern treatment recommendation methods
US11501867B2 (en) 2015-10-19 2022-11-15 Medtronic Minimed, Inc. Medical devices and related event pattern presentation methods
US10146911B2 (en) 2015-10-23 2018-12-04 Medtronic Minimed, Inc. Medical devices and related methods and systems for data transfer
US10037722B2 (en) 2015-11-03 2018-07-31 Medtronic Minimed, Inc. Detecting breakage in a display element
US10449306B2 (en) 2015-11-25 2019-10-22 Medtronics Minimed, Inc. Systems for fluid delivery with wicking membrane
US10275573B2 (en) 2016-01-13 2019-04-30 Bigfoot Biomedical, Inc. User interface for diabetes management system
US10780223B2 (en) 2016-01-14 2020-09-22 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
US10589038B2 (en) 2016-04-27 2020-03-17 Medtronic Minimed, Inc. Set connector systems for venting a fluid reservoir
EP3515535A1 (en) 2016-09-23 2019-07-31 Insulet Corporation Fluid delivery device with sensor
WO2018075964A1 (en) * 2016-10-21 2018-04-26 Rebellion Photonics, Inc. Mobile gas and chemical imaging camera
US10948404B2 (en) 2016-10-21 2021-03-16 Rebellion Photonics, Inc. Gas imaging system
US11097051B2 (en) 2016-11-04 2021-08-24 Medtronic Minimed, Inc. Methods and apparatus for detecting and reacting to insufficient hypoglycemia response
US10238030B2 (en) 2016-12-06 2019-03-26 Medtronic Minimed, Inc. Wireless medical device with a complementary split ring resonator arrangement for suppression of electromagnetic interference
US10272201B2 (en) 2016-12-22 2019-04-30 Medtronic Minimed, Inc. Insertion site monitoring methods and related infusion devices and systems
US10532165B2 (en) 2017-01-30 2020-01-14 Medtronic Minimed, Inc. Fluid reservoir and systems for filling a fluid reservoir of a fluid infusion device
US10500135B2 (en) 2017-01-30 2019-12-10 Medtronic Minimed, Inc. Fluid reservoir and systems for filling a fluid reservoir of a fluid infusion device
US10552580B2 (en) 2017-02-07 2020-02-04 Medtronic Minimed, Inc. Infusion system consumables and related calibration methods
US10363365B2 (en) 2017-02-07 2019-07-30 Medtronic Minimed, Inc. Infusion devices and related consumable calibration methods
US11207463B2 (en) 2017-02-21 2021-12-28 Medtronic Minimed, Inc. Apparatuses, systems, and methods for identifying an infusate in a reservoir of an infusion device
US10646649B2 (en) 2017-02-21 2020-05-12 Medtronic Minimed, Inc. Infusion devices and fluid identification apparatuses and methods
WO2018156795A1 (en) 2017-02-22 2018-08-30 Rebellion Photonics, Inc. Systems and methods for monitoring remote installations
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
CA3077720A1 (en) 2017-10-24 2019-05-02 Dexcom, Inc. Pre-connected analyte sensors
WO2019094639A1 (en) 2017-11-09 2019-05-16 Rebellion Photonics, Inc. Window obscuration sensors for mobile gas and chemical imaging cameras
WO2019213493A1 (en) 2018-05-04 2019-11-07 Insulet Corporation Safety constraints for a control algorithm-based drug delivery system
CN112789070A (en) 2018-09-28 2021-05-11 英赛罗公司 Mode of activity of the artificial pancreas System
EP3864668A1 (en) 2018-10-11 2021-08-18 Insulet Corporation Event detection for drug delivery system
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
US11738144B2 (en) 2021-09-27 2023-08-29 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery

Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4387956A (en) * 1981-06-09 1983-06-14 Rockwell International Corporation Fiber optic interlock
US4731726A (en) * 1986-05-19 1988-03-15 Healthware Corporation Patient-operated glucose monitor and diabetes management system
US4797398A (en) * 1985-12-19 1989-01-10 Imperial Chemical Industries Plc Morpholine compounds, compositions and use
US5019974A (en) * 1987-05-01 1991-05-28 Diva Medical Systems Bv Diabetes management system and apparatus
US5049487A (en) * 1986-08-13 1991-09-17 Lifescan, Inc. Automated initiation of timing of reflectance readings
US5558638A (en) * 1993-04-30 1996-09-24 Healthdyne, Inc. Patient monitor and support system
US5615672A (en) * 1993-01-28 1997-04-01 Optiscan, Inc. Self-emission noninvasive infrared spectrophotometer with body temperature compensation
US5772586A (en) * 1996-02-12 1998-06-30 Nokia Mobile Phones, Ltd. Method for monitoring the health of a patient
US5840020A (en) * 1996-02-12 1998-11-24 Nokia Mobile Phones, Ltd. Monitoring method and a monitoring equipment
US5876675A (en) * 1997-08-05 1999-03-02 Caliper Technologies Corp. Microfluidic devices and systems
US5966654A (en) * 1996-11-01 1999-10-12 Ericsson Inc. Recyclable cellular telephone and method and apparatus for supporting the use of a recyclable cellular telephone within a cellular telephone network acting as a theme park communicator/scheduler
US5967975A (en) * 1997-11-13 1999-10-19 Ridgeway; Donald G. Home health parameter monitoring system
US6134504A (en) * 1997-10-31 2000-10-17 Mercury Diagnostics, Incorporated Analyte concentration information collection and communication system
US6196046B1 (en) * 1999-08-25 2001-03-06 Optiscan Biomedical Corporation Devices and methods for calibration of a thermal gradient spectrometer
US6248067B1 (en) * 1999-02-05 2001-06-19 Minimed Inc. Analyte sensor and holter-type monitor system and method of using the same
US6295506B1 (en) * 1997-10-27 2001-09-25 Nokia Mobile Phones Limited Measurement apparatus
US20010027331A1 (en) * 2000-03-31 2001-10-04 Medtronic, Inc. Variable encryption scheme for data transfer between medical devices and related data management systems
US20010031913A1 (en) * 2000-04-17 2001-10-18 Nec Corporation Method of providing a home health care service and system for providing a home health care service
US6327617B1 (en) * 1995-11-27 2001-12-04 Microsoft Corporation Method and system for identifying and obtaining computer software from a remote computer
US6347396B1 (en) * 1998-03-12 2002-02-12 Telefonaktiebolaget Lm Ericsson (Publ) Disturbance free update of data
US20020019586A1 (en) * 2000-06-16 2002-02-14 Eric Teller Apparatus for monitoring health, wellness and fitness
US6364834B1 (en) * 1996-11-13 2002-04-02 Criticare Systems, Inc. Method and system for remotely monitoring multiple medical parameters in an integrated medical monitoring system
US20020045808A1 (en) * 2000-08-18 2002-04-18 Russell Ford Formulation and manipulation of databases of analyte and associated values
US6377894B1 (en) * 1998-11-30 2002-04-23 Abbott Laboratories Analyte test instrument having improved calibration and communication processes
US6379301B1 (en) * 1997-01-10 2002-04-30 Health Hero Network, Inc. Diabetes management system and method for controlling blood glucose
US20020059030A1 (en) * 2000-07-17 2002-05-16 Otworth Michael J. Method and apparatus for the processing of remotely collected electronic information characterizing properties of biological entities
US6413213B1 (en) * 2000-04-18 2002-07-02 Roche Diagnostics Corporation Subscription based monitoring system and method
US20020123673A1 (en) * 1999-12-17 2002-09-05 Webb James D. Method and apparatus for remotely programming implantable medical devices
US20020183646A1 (en) * 2001-03-30 2002-12-05 Stivoric John M. System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow
US20020199094A1 (en) * 2000-10-06 2002-12-26 Protasis Corporation Fluid separate conduit cartridge with encryption capability
US20030100040A1 (en) * 1997-12-05 2003-05-29 Therasense Inc. Blood analyte monitoring through subcutaneous measurement
US20030118015A1 (en) * 2001-12-20 2003-06-26 Magnus Gunnarsson Location based notification of wlan availability via wireless communication network
US6645142B2 (en) * 2000-12-01 2003-11-11 Optiscan Biomedical Corporation Glucose monitoring instrument having network connectivity
US20040097796A1 (en) * 2001-04-27 2004-05-20 Medoptix Method and system of monitoring a patient
US6771993B2 (en) * 2001-08-16 2004-08-03 Optiscan Biomedical Corporation Sample adapter
US20050038674A1 (en) * 2003-04-15 2005-02-17 Braig James R. System and method for managing a chronic medical condition
US6958809B2 (en) * 2001-11-08 2005-10-25 Optiscan Biomedical Corporation Reagent-less whole-blood glucose meter

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4397956A (en) 1981-12-10 1983-08-09 Maggio Edward T Means for monitoring the status of control of ketoacidosis-prone diabetics
US4787398A (en) 1985-04-08 1988-11-29 Garid, Inc. Glucose medical monitoring system
ES2124186B1 (en) 1997-01-20 1999-08-01 Carpe Diem Salud S L SECTION AND TELEMATIC CONTROL SYSTEM OF PHYSIOLOGICAL PARAMETERS OF PATIENTS.
DE69841872D1 (en) 1997-11-12 2010-10-14 I Flow Corp METHOD AND DEVICE FOR MONITORING A PATIENT
AU2023100A (en) 1998-11-09 2000-05-29 Lifestream Technologies, Inc. Health monitoring and diagnostic device and network-based health assessment and medical records maintenance system
KR100627990B1 (en) 1998-11-30 2006-09-26 노보 노르디스크 에이/에스 A method and a system for assisting a user in a medical self treatment, said self treatment comprising a plurality of actions
CA2365609A1 (en) 1999-02-12 2000-08-17 Cygnus, Inc. Devices and methods for frequent measurement of an analyte present in a biological system
US6198949B1 (en) 1999-03-10 2001-03-06 Optiscan Biomedical Corporation Solid-state non-invasive infrared absorption spectrometer for the generation and capture of thermal gradient spectra from living tissue
CA2388689A1 (en) 1999-06-17 2000-12-28 Medtronic Minimed, Inc. Characteristic monitor system for use with analyte sensor
US6574490B2 (en) 2001-04-11 2003-06-03 Rio Grande Medical Technologies, Inc. System for non-invasive measurement of glucose in humans

Patent Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4387956A (en) * 1981-06-09 1983-06-14 Rockwell International Corporation Fiber optic interlock
US4797398A (en) * 1985-12-19 1989-01-10 Imperial Chemical Industries Plc Morpholine compounds, compositions and use
US4731726A (en) * 1986-05-19 1988-03-15 Healthware Corporation Patient-operated glucose monitor and diabetes management system
US5049487A (en) * 1986-08-13 1991-09-17 Lifescan, Inc. Automated initiation of timing of reflectance readings
US5019974A (en) * 1987-05-01 1991-05-28 Diva Medical Systems Bv Diabetes management system and apparatus
US5615672A (en) * 1993-01-28 1997-04-01 Optiscan, Inc. Self-emission noninvasive infrared spectrophotometer with body temperature compensation
US5558638A (en) * 1993-04-30 1996-09-24 Healthdyne, Inc. Patient monitor and support system
US6327617B1 (en) * 1995-11-27 2001-12-04 Microsoft Corporation Method and system for identifying and obtaining computer software from a remote computer
US5772586A (en) * 1996-02-12 1998-06-30 Nokia Mobile Phones, Ltd. Method for monitoring the health of a patient
US5840020A (en) * 1996-02-12 1998-11-24 Nokia Mobile Phones, Ltd. Monitoring method and a monitoring equipment
US5966654A (en) * 1996-11-01 1999-10-12 Ericsson Inc. Recyclable cellular telephone and method and apparatus for supporting the use of a recyclable cellular telephone within a cellular telephone network acting as a theme park communicator/scheduler
US6364834B1 (en) * 1996-11-13 2002-04-02 Criticare Systems, Inc. Method and system for remotely monitoring multiple medical parameters in an integrated medical monitoring system
US6379301B1 (en) * 1997-01-10 2002-04-30 Health Hero Network, Inc. Diabetes management system and method for controlling blood glucose
US5876675A (en) * 1997-08-05 1999-03-02 Caliper Technologies Corp. Microfluidic devices and systems
US6295506B1 (en) * 1997-10-27 2001-09-25 Nokia Mobile Phones Limited Measurement apparatus
US6134504A (en) * 1997-10-31 2000-10-17 Mercury Diagnostics, Incorporated Analyte concentration information collection and communication system
US5967975A (en) * 1997-11-13 1999-10-19 Ridgeway; Donald G. Home health parameter monitoring system
US20030100040A1 (en) * 1997-12-05 2003-05-29 Therasense Inc. Blood analyte monitoring through subcutaneous measurement
US6347396B1 (en) * 1998-03-12 2002-02-12 Telefonaktiebolaget Lm Ericsson (Publ) Disturbance free update of data
US20020082797A1 (en) * 1998-11-30 2002-06-27 Deweese Marshall D. Analyte test instrument having improved calibration and communication processes
US6377894B1 (en) * 1998-11-30 2002-04-23 Abbott Laboratories Analyte test instrument having improved calibration and communication processes
US6248067B1 (en) * 1999-02-05 2001-06-19 Minimed Inc. Analyte sensor and holter-type monitor system and method of using the same
US6196046B1 (en) * 1999-08-25 2001-03-06 Optiscan Biomedical Corporation Devices and methods for calibration of a thermal gradient spectrometer
US20020123673A1 (en) * 1999-12-17 2002-09-05 Webb James D. Method and apparatus for remotely programming implantable medical devices
US20010027331A1 (en) * 2000-03-31 2001-10-04 Medtronic, Inc. Variable encryption scheme for data transfer between medical devices and related data management systems
US20010031913A1 (en) * 2000-04-17 2001-10-18 Nec Corporation Method of providing a home health care service and system for providing a home health care service
US6413213B1 (en) * 2000-04-18 2002-07-02 Roche Diagnostics Corporation Subscription based monitoring system and method
US20020019586A1 (en) * 2000-06-16 2002-02-14 Eric Teller Apparatus for monitoring health, wellness and fitness
US20020059030A1 (en) * 2000-07-17 2002-05-16 Otworth Michael J. Method and apparatus for the processing of remotely collected electronic information characterizing properties of biological entities
US20020045808A1 (en) * 2000-08-18 2002-04-18 Russell Ford Formulation and manipulation of databases of analyte and associated values
US20020199094A1 (en) * 2000-10-06 2002-12-26 Protasis Corporation Fluid separate conduit cartridge with encryption capability
US6645142B2 (en) * 2000-12-01 2003-11-11 Optiscan Biomedical Corporation Glucose monitoring instrument having network connectivity
US20020183646A1 (en) * 2001-03-30 2002-12-05 Stivoric John M. System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow
US20040097796A1 (en) * 2001-04-27 2004-05-20 Medoptix Method and system of monitoring a patient
US6771993B2 (en) * 2001-08-16 2004-08-03 Optiscan Biomedical Corporation Sample adapter
US6958809B2 (en) * 2001-11-08 2005-10-25 Optiscan Biomedical Corporation Reagent-less whole-blood glucose meter
US20030118015A1 (en) * 2001-12-20 2003-06-26 Magnus Gunnarsson Location based notification of wlan availability via wireless communication network
US20050038674A1 (en) * 2003-04-15 2005-02-17 Braig James R. System and method for managing a chronic medical condition

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060047455A1 (en) * 2004-08-25 2006-03-02 Catelani Mark P Method and apparatus for management of calibration data
US7593825B2 (en) * 2004-08-25 2009-09-22 Agilent Technologies, Inc. Method and apparatus for management of calibration data
US20060200071A1 (en) * 2005-02-14 2006-09-07 Sterling Bernhard B Method and apparatus for detection of multiple analytes
US7722537B2 (en) 2005-02-14 2010-05-25 Optiscan Biomedical Corp. Method and apparatus for detection of multiple analytes
US20090295910A1 (en) * 2005-03-24 2009-12-03 Jose Mir Hyperspectral Imaging System and Methods Thereof
US7445389B2 (en) 2006-04-10 2008-11-04 Finisar Corporation Active optical cable with integrated eye safety
US8425444B2 (en) 2006-04-11 2013-04-23 Optiscan Biomedical Corporation Anti-clotting apparatus and methods for fluid handling system
US8597190B2 (en) 2007-05-18 2013-12-03 Optiscan Biomedical Corporation Monitoring systems and methods with fast initialization
US8487822B1 (en) * 2007-09-13 2013-07-16 Rockwell Collins, Inc. Adaptible antenna using liquid metal structures
US8333717B1 (en) 2011-06-21 2012-12-18 Yofimeter, Llc Test unit cartridge for analyte testing device
US8333716B1 (en) 2011-06-21 2012-12-18 Yofimeter, Llc Methods for using an analyte testing device
US8292826B1 (en) 2011-06-21 2012-10-23 YofiMETER, Inc. Cocking and advancing mechanism for analyte testing device
US8961432B2 (en) 2011-06-21 2015-02-24 Yofimeter, Llc Analyte testing devices

Also Published As

Publication number Publication date
US20040093167A1 (en) 2004-05-13
CA2505185A1 (en) 2004-05-27
AU2003290619A1 (en) 2004-06-03
AU2003290619A2 (en) 2004-06-03
US6931328B2 (en) 2005-08-16
WO2004043250A9 (en) 2004-07-08
EP1565103A1 (en) 2005-08-24
JP2006508713A (en) 2006-03-16
WO2004043250A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
US6931328B2 (en) Analyte detection system with software download capabilities
US7009180B2 (en) Pathlength-independent methods for optically determining material composition
US6771993B2 (en) Sample adapter
US6825044B2 (en) Method for adjusting a blood analyte measurement
US7050157B2 (en) Reagent-less whole-blood glucose meter
US6958809B2 (en) Reagent-less whole-blood glucose meter
US7999927B2 (en) In vitro determination of analyte levels within body fluids
US20030108976A1 (en) Method and apparatus for improving clinical accuracy of analyte measurements
US20030175806A1 (en) Method and apparatus for improving the accuracy of alternative site analyte concentration measurements
US20040132171A1 (en) Wearable device for measuring analyte concentration
US20040132168A1 (en) Sample element for reagentless whole blood glucose meter
US6917038B2 (en) Method and apparatus for adjusting signal variation of an electronically controlled infrared transmissive window
US20030122081A1 (en) Window assembly
AU2002359713B2 (en) Spectroscopic method of determining an analyte concentration in a sample
EP1850114A1 (en) Spectroscopic method of determining an analyte concentration in a sample
US20030215939A1 (en) Active sample collection system for analyte detection apparatus

Legal Events

Date Code Title Description
AS Assignment

Owner name: HERCULES TECHNOLOGY II, L.P., CALIFORNIA

Free format text: SECURITY AGREEMENT;ASSIGNOR:OPTISCAN BIOMEDICAL CORPORATION;REEL/FRAME:020995/0202

Effective date: 20080522

Owner name: HERCULES TECHNOLOGY II, L.P.,CALIFORNIA

Free format text: SECURITY AGREEMENT;ASSIGNOR:OPTISCAN BIOMEDICAL CORPORATION;REEL/FRAME:020995/0202

Effective date: 20080522

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: OPTISCAN BIOMEDICAL CORPORATION, CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:HERCULES TECHNOLOGY II, L.P.;REEL/FRAME:041344/0534

Effective date: 20170111